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When, namely, the anatomists of the last century applied the name of atheroma to a definite 
change in the coats of arteries, they of course had in their minds a condition similar to that 
of the skin, to which ever since the days of ancient Greece, the name of atheroma, grit-
follicle (Grützbalg) has been assigned… 
At all times there have moreover been observers who regarded the ossification of vessels as 
a change belonging to the same category as atheroma. Haller and Crell believed that the 
ossification proceeded from the atheromatous matter, and that this was a juice which like 
that exuding under the periosteum of bone, was capable of generating plates of bone out of 
itself. 
 
Rudolf Virchow, Lecture XVI - A more precise account of fatty metamorphosis. Cellular 
Pathology as based upon physiological and pathological histology. 1858  
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Coronary atherosclerosis is a chronic inflammatory disease which progresses to luminal 
stenosis and plaque rupture events. Recent developments in non-invasive cardiovascular 
imaging have enabled the identification of coronary plaques with an increased propensity to 
rupture. Coronary computed tomography angiography allows visualisation of the arterial 
wall to discern regions of high-risk plaque in patients with non-obstructive and obstructive 
coronary artery disease. The anatomical assessment afforded by coronary computed 
tomography angiography can be combined with hybrid positron emission tomography 
computed tomography to provide a measure of disease activity. Using novel radiotracers 
targeted at specific cellular pathways in atherosclerosis, it is now possible to observe plaque 
activity with 18F-sodium fluoride in vivo.  
 
The principal aims of this thesis were to evaluate the prognostic impact of adverse plaque 
features using standard coronary computed tomography angiography, to perform 
reproducibility and histological validation studies of a novel non-invasive imaging technique 
for detecting high-risk plaque with coronary 18F-fluoride imaging and assess whether 
coronary 18F-fluoride could be used to select high-risk individuals as part a phase 3 clinical 
trial of an investigational medicinal product. 
 
ADVERSE CORONARY ARTERY PLAQUE CHARACTERISTICS IN PATIENTS 
WITH CORONARY ARTERY DISEASE 
In a prognostic substudy of the SCOT-HEART trial, adverse plaque features were associated 
with a three-fold increase in coronary heart disease death or non-fatal myocardial infarction 
(hazard ratio 3.01 [95% confidence intervals 1.61 to 5.63]; p=0.001). Patients with both 
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obstructive disease and adverse plaque had the highest event rate with a greater than 10-fold 
increase in events (hazard ratio 11.50 [95% confidence interval 3.39 to 39.04]; p<0.001). 
However, these associations were dependent coronary artery calcium score, a surrogate 
measure of coronary plaque burden. 
 
MOLECULAR CORONARY PLAQUE IMAGING USING 18F-FLUORIDE 
To explore whether a novel non-invasive imaging technique could accurately detect regions 
of coronary microcalcification in patients with coronary artery disease, a scan-rescan 
reproducibility study of 30 patients was undertaken. Using a standardised metric (coronary 
to atrial blood pool ratio, TBRMAX), 18F-fluoride activity could be precisely and 
reproducibly measured within the coronary vasculature. The analytical performance of 
coronary 18F-fluoride activity was sufficient to determine whether this radiotracer could be 
used as a non-invasive imaging marker of plaque vulnerability in clinical trials. 
 
EX VIVO 18F-FLUORIDE UPTAKE IN HUMAN CORONARY 
ATHEROSCLEROSIS 
Ex vivo validation of coronary artery specimens using 18F-fluoride demonstrated highly 
selectivity for hydroxyapatite deposition in atherosclerotic coronary plaque. Specifically, 
coronary 18F-fluoride binding has a high signal to noise ratio compared with surrounding 
myocardium that makes it feasible to identify coronary mineralisation activity. Areas of 18F-
fluoride binding are associated with osteopontin, an inflammatory-stimulated 
glycophosphoprotein that increases tissue mineralisation. These results suggest that 18F-
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TICAGRELOR TO REDUCE MYOCARDIAL INJURY IN PATIENTS WITH 
HIGH-RISK CORONARY ARTERY PLAQUE 
In a double-blind randomised placebo-controlled trial, 191 patients with multivessel 
coronary artery disease underwent 18F-fluoride positron emission tomography and 
computed tomography coronary angiography. In patients with high-risk plaque defined by 
18F-fluoride uptake in at least one coronary plaque (n=120/191), there was no evidence that 
dual antiplatelet therapy with ticagrelor affected 30-day plasma troponin concentrations 
(ratio of geometric means 1.11 [95% confidence interval 0.90-1.36], p=0.32). 
 
CONCLUSION 
These observations suggest that high-risk plaque detection identifies individuals at increased 
risk of cardiovascular events. Coronary 18F-fluoride can be utilised in the setting of 
randomised controlled trials as a precise biomarker of plaque activity. Further projects to 
assess whether coronary 18F-fluoride can predict plaque rupture events are ongoing. 
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LAY SUMMARY OF THESIS 
 
Coronary artery disease is a leading cause of global mortality and morbidity due to the 
consequences that stem from a heart attack. The cellular processes that underlie coronary 
artery disease may be noted as early as the second decade of life, however these processes 
often remain silent until a patient presents with symptoms in middle age or later in life. 
Trying to identify patients at the highest risk of heart attacks from amongst the general 
population remains an ongoing challenge, especially as over half of patients presenting with 
their first heart attack lack prior warning symptoms. To provide a more ‘personalised’ 
approach to the treatment of coronary artery disease, new medical imaging scanners have 
been developed to assess different disease states. These medical advances allow researchers 
to detect the cellular processes in the wall of heart arteries that may determine whether a 
patient is at risk of a heart attack. This thesis set out to investigate how these new medical 
imaging scanners can be used in patients to provide a more detailed understanding of 
coronary artery disease activity and whether these imaging tests can help direct doctors to 
use different types of treatment. 
 
Coronary computed tomography angiography is an imaging test that can assess the 
narrowing of blood vessels coronary arteries and the composition of the wall of the artery. 
To identify whether different components in the wall of the artery contribute to the risk of a 
future heart attack, CT scans obtained from the SCOT-HEART study were analysed and 
classified according to whether the heart arteries contained high-risk features or not. If high-
risk features were present in the wall of the artery, these patients were three times more 
likely to have a heart attack compared to those who did not. However, patients with high-risk 
features also had a higher burden of coronary artery disease which may have accounted for 
this finding. 
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A new type of imaging test using a radioactive tracer, 18F-sodium fluoride, was investigated 
to see whether it provided accurate measurements of disease activity in heart arteries. Thirty 
patients, including patients with stable heart artery disease and patients with a recent heart 
attack, were scanned using this new imaging test and results were compared to assess 
whether there were any major differences between them. 18F-Sodium fluoride imaging of 
the heart arteries had good repeatability when performed within a two-week window. This is 
an important finding as an imaging test should be assessed in this way before it can be used 
in clinical practice. In order to establish which specific cellular processes are detected using 
18F-sodium fluoride imaging, a study using samples of human heart arteries was performed. 
In regions that had a high signal of 18F-sodium fluoride, cellular processes that control how 
tissue retains calcium were present. The cellular processes in arteries with 18F-sodium 
fluoride binding are similar to the mineralisation processes found in bone metabolism. 
 
Finally, a ‘gold standard’ research trial (double-blind randomised placebo-controlled trial) 
was performed to assess whether this imaging test could guide the use of additional anti-
platelet therapy in patients with high-risk features identified using a high signal of 18F-
sodium fluoride. Measures of a sensitive heart enzyme did not change at one month or one 
year when using this imaging test to guide treatment. This suggests that further research is 
needed before this imaging test should be used in a clinical setting. 
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1.1 Coronary computed tomography angiography 
Despite decades of investment in the delivery of effective treatment, cardiovascular 
disease remains responsible for the vast majority of deaths worldwide. Even prior to 
the recent fluctuations in the global financial climate, many modern healthcare 
economies had sharpened their focus on delivering healthcare that is both clinically 
and cost effective. Ensuring cost-effective and efficacious treatment is central to 
maintaining sustainable healthcare programmes as populations increase in age and 
access healthcare in greater numbers. In the United Kingdom (UK), the National 
Institute for Health and Care Excellence (NICE) routinely reviews clinical evidence 
and publishes advice and recommendations based on the combination of clinical 
efficacy and cost effectiveness of both therapies and technologies. Established in 
1997 it is now enshrined in UK law to ensure patients cared for in the English 
National Health Service (NHS) gain benefits from cost effective measures, and that 
NHS resources are optimised. It is in this context of a finite healthcare resource that 
the provision of non-invasive imaging of coronary artery disease will be reviewed. 
 
Guidelines on the investigation and management of coronary artery disease have 
evolved significantly over the past two decades. In the early 1990’s Braunwald’s 
Quick Reference Guide for Clinicians recommended patients were offered treatment 
based on their pre-test probability of angina and a clear history of anginal chest pain 
was a pre-requisite for stratifying which patients required downstream investigation 
(Braunwald, Jones et al. 1994). Non-invasive testing (predominantly exercise-ECG) 
was reserved for identifying high-risk patient groups that may benefit from additional 
medical therapy and coronary revascularisation. Since Braunwald’s early 
publication, the expansion of multi-modality cardiac imaging has generated a 
number of different testing strategies with improved sensitivity for diagnosing 
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coronary artery disease that have been incorporated into national and international 
guidelines (Knuuti, Wijns et al. 2019). 
 
1.1.1 Non-invasive stress testing in coronary artery disease 
There are a number of well-established stress testing modalities that are used 
across the world. When used to diagnose coronary artery disease, stress testing 
does have limitations, and all modalities have substantial false positive and negative 
rates  (Table 1.1). It is also important to acknowledge that the identification of non-
obstructive coronary artery disease is important and associated with substantial 
future cardiovascular risk (Nakazato, Arsanjani et al. 2014, Cho, Chang et al. 2012) 
that may be reduced by preventative therapy (Chow, Small et al. 2015).  
 
There is heterogeneity in the response to both physical and pharmacological stress 
that can limit the identification of areas of reduced myocardial perfusion. Myocardial 
perfusion abnormalities may appear in the absence of symptoms demonstrating 
silent ischaemia and may also be evident in the absence of epicardial coronary 
artery disease (such as microvascular angina). The advantage of stress testing is 
that it provides an objective assessment of whether myocardial ischemia is 
responsible for the symptoms of angina, irrespective of aetiology. It also provides an 
objective measure of response to therapy, such as improved time to ischaemia with 
anti-anginal drugs. In addition, defining the areas of myocardial hypoperfusion can 
be used to guide coronary revascularisation strategies especially where there are 
intermediate severity stenoses or multiple potential territories of ischaemia.  
 
Ultimately, stress testing is associated with both a false negative and false positive 
rate of one in six for the diagnosis of angina pectoris due to obstructive coronary 
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artery disease although the false negative rate is higher for exercise 
electrocardiography (Table 1.1) (Montalescot, Sechtem et al. 2013). As such, stress 
testing has limitations in those with a high (>85%) or low (<15%) pre-test probability 
of obstructive coronary artery disease. The pre-test probability of obstructive 
coronary artery disease can be determined from risk tables contained in both the 
European and American Guidelines, and can be used to assist in the selection of 
non-invasive investigations. However, these estimates are based on historical data, 
such as Diamond and Forrester’s post-mortem study from over 40 years ago 
(Diamond and Forrester 1979), which markedly overestimate the probability of 
obstructive coronary artery disease and consequently this tends to lead to the over 
investigation of patients (Cheng, Berman et al. 2011). 






Table 1.1 Comparison and performance of stress testing modalities. 
(Moss and Newby 2015)
 Diagnostic Performance Markers of Risk Limitations 
 Sensitivity Specificity   
Exercise Stress    Immobility, 
Deconditioning 
Electrocardiogram 45-50% 85-90% ≥1 mm ST 
depression during 
first 2 stages of 
Bruce Protocol 
≥2 mm ST 
depression at any 
time 
Fall or no rise in 
blood pressure 
Unable to complete 
stage 2 of Bruce 
Protocol 
Bundle Branch 





Echocardiography 80-85% 80-88% ≥3 Dysfunctional 
segments  
Suboptimal Imaging 






73-92% 63-87% Area of ischemia 
>10% 
Multiple territories of 
ischemia 




   Variability in 
Responsiveness 
Echocardiography 72-92% 82-95% ≥3 Dysfunctional 
segments 
Suboptimal Imaging 
















90-91% 75-84% Area of ischemia 
>10% 
Multiple territories of 
ischemia 




81-97% 74-91% Area of ischemia 
>10% 
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1.1.2 The ideal non-invasive investigation for coronary artery 
disease 
Whilst there has been much research comparing different stress imaging modalities 
to detect obstructive coronary artery disease (Greenwood, Maredia et al. 2012), 
there is a no definitive evidence to recommend the superiority of one diagnostic test 
over another. To achieve a reduction in cardiac death and non-fatal myocardial 
infarction, the diagnostic test needs to influence downstream clinical decision-
making through the avoidance of unnecessary invasive coronary angiography and 
the appropriate initiation of treatments that will ultimately reduce coronary events. 
The test should have a high level of diagnostic accuracy, the ability to better risk 
stratify individuals and be integrated into a cost-effective clinical pathway. Service 
provision should be tailored towards the needs of the population to optimise cost-
efficacy and a testing strategy that is applicable to the low-intermediate pre-test 
probability group of patients would cover the majority of patients presenting to chest 
pain clinics (Skinner, Smeeth et al. 2010). However, consideration should also be 
given to the application of guideline driven care which may lead to avoiding 
investigation in presumed low-risk groups, but do so at the expense of 
misdiagnosing significant coronary artery disease in up to 10% of patients 
(Patterson, Nair et al. 2015). Thus a test with a high negative predictive value has 
great merit in patients with suspected angina due to coronary artery disease. 
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1.1.3 Diagnostic accuracy of coronary computed tomography 
angiography  
The evolution of computed tomography (CT) platforms over the past 17 years has 
led to a substantial improvement in diagnostic performance. Modern scanners can 
now offer single-heartbeat angiograms with sub-millimetre sub-second spatial and 
temporal resolution (Table 1.2). The diagnostic accuracy of coronary CT 
angiography has been predominantly demonstrated with 64-slice scanners and has 
highlighted the high negative predictive value of coronary CT angiography to 
exclude the presence of obstructive and non-obstructive coronary artery disease 
when compared with invasive coronary angiography (Budoff, Dowe et al. 2008, 
Meijboom, Meijs et al. 2008, Miller, Rochitte et al. 2008). One potential limitation of 
anatomical assessment with coronary CT angiography is that it does not reliably 
predict the presence of myocardial ischaemia (Meijboom, Van Mieghem et al. 2008). 
However, CT perfusion imaging or CT fraction flow reserve are two approaches that 
can address this deficiency (Douglas, Pontone et al. 2015, Williams and Newby 
2012, Williams, Reid et al. 2011). 
  









    Scan Duration 
    Spatial Resolution 







10-20 minutes  
Millimeter 
Less than 60 milliseconds 
Radiation exposure 1 – 10 milliSieverts 
(depending on protocol) 
No radiation exposure 
Advantages Shorter total scan time,  
   - favoured by patients 
   - improved scanner efficiency 
 
 
Better spatial resolution for visualising 
coronary anatomy 
 
Single breath hold of only 5-10 
seconds 
Radiation free imaging  
      - serial scans 
      - young patients 
      - early disease 
 
Soft tissue characterisation 
 
 
Myocardial scar imaging 
 
Limitations Requirement for adequate rate control 
 
Contrast media reactions (Iodine) 
 
 









Contrast media reactions 
(Gadolinium) 
 
Risk of nephrogenic systemic 
fibrosis if glomerular filtration 
rate <30 mL/min/1.73 m2 
 
Metallic implants (including 
pacemakers) 
 




Table 1.2 Technical Comparison between CT and MRI in the evaluation of coronary artery 
disease. 
(Dweck, Williams et al. 2016) 
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Is this anatomical-guided strategy supported by the evidence?  Historically, invasive 
coronary angiography has been the definitive test to confirm of the presence of 
coronary artery disease against which all other non-invasive tests have been 
validated. However, invasive coronary angiography is the most expensive diagnostic 
investigation and, importantly, exposes individuals to the highest risk of procedural 
complications (NICE 2016). In the 2016 update, NICE determined the clinical 
effectiveness of the non-invasive modalities against a “gold-standard” of 50% 
stenosis on invasive coronary angiography, the same methodology that was used in 
the previous guidelines issued in 2010. Confirming the presence of a coronary 
artery luminal stenosis of 50% or greater is only part of the diagnostic assessment. 
Confirmation of inducible myocardial ischemia has been the principal goal prior to 
the initiation of appropriate of secondary prevention treatment and coronary 
revascularisation. In the NICE guidelines functional imaging is still recommended for 
those who have significant coronary artery disease or equivocal findings on CT 
coronary angiography. It should also be noted however that whilst non-invasive 
testing can assess multiple levels of the ischemia cascade, it is ultimately the 
confirmation of the anatomical burden of coronary artery disease which determines 
an individual’s future risk of cardiac events (Maddox, Stanislawski et al. 2014).  
 
1.1.4 Improving clinical outcomes with CT coronary 
angiography  
The publication of two large multicentre randomised control trials (Douglas, Hoffman 
et al. 2015, SCOT-HEART investigators 2015) has provided insight into whether 
coronary CT angiography can be incorporated into chest pain care pathways to 
improve diagnostic accuracy and risk stratification of coronary artery disease.  The 
PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) 
On the detection of vulnerable plaques in human coronary atherosclerosis 
 
 10 
trial conducted a head-to-head comparison of coronary CT angiography with stress 
imaging in the assessment of low-risk patients with intermediate probability of 
coronary artery disease whereas the Scottish COmputed Tomography of the 
HEART (SCOT-HEART) trial assessed the addition of coronary CT angiography to 
standard care across all patients (low, medium and high risk) presenting for 
assessment of suspected stable angina pectoris due to coronary artery disease 
(Table 1.3).  
 
The PROMISE trial 
The PROMISE trial recruited 10,003 patients aged 61±8 years from 193 centres 
across the United States of America and Canada to determine whether the use of 
coronary CT angiography (CCTA) or stress testing would reduce the long-term 
composite endpoint of major adverse cardiovascular and procedural events 
(Douglas, Hoffman et al. 2015). The study population was specifically selected to 
have an intermediate risk having excluded patients with a previous diagnosis of 
coronary artery disease and few patients (11%) having typical angina. The study 
population was therefore focused on a lower risk patient group and excluded 
patients with planned invasive coronary angiography. The functional testing 
performed differed significantly across the trial centres with 68% undergoing 
myocardial scintigraphy, 22% stress echocardiography and 10% exercise 
electrocardiography. This illustrates the diversity and lack of consensus surrounding 
the investigations for patients presenting with chest pain and the poor adherence to 
current North American guidelines (Fihn, Blankenship et al. 2014). In PROMISE, the 
number of invasive coronary angiograms increased (12.2% [CCTA] versus 8.1% 
[functional testing]) although the proportion of patients with normal coronary 
angiograms was reduced (3.4% [CCTA] versus 4.3% [functional testing]). Coronary 
CT angiography led to more coronary revascularisation procedures (6.2% [CCTA] 
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vs. 3.2% [functional testing]). Unfortunately there is little information regarding 
alterations in the clinician’s diagnosis and management plan, or changes in the 
patients’ drug therapies. Overall the two groups had similar rates of the composite 
primary end-point of death, myocardial infarction, hospitalisation for unstable angina 
or major procedural complication. 
  




Study SCOT-HEART PROMISE 
Population 4,146 patients 
Chest pain 100% 
Typical Angina 35% 
Previous CAD 9% 
10,003 patients 
Chest pain 73% 
Typical Angina 12% 
No previous CAD 
Randomisation 1:1 1:1 
Intervention CCTA in addition to Standard 
Care 
CCTA versus Functional Test 
Control Standard Care 
Nuclear Stress imaging (9%) 
Stress Echocardiography (1%) 
Exercise ECG (85%) 
Functional Test 
Nuclear Stress imaging (67.3%) 
Stress Echocardiography 
(22.5%) 
Exercise ECG (10.2%) 
Primary Outcome Certainty of diagnosis of angina 
due to coronary heart disease 
at 6 weeks 
All cause mortality, non-fatal MI, 
hospitalisation for unstable 




13.1% (cardiac death & non-
fatal MI) over 5 years 
9% (all-cause death, non-fatal 
MI, hospitalisation for unstable 










Positive test result 25% - 10.7% 11.7% 
Event rates (<2 years follow-up)* 
All-cause death/non-
fatal MI 
1.9% 2.7% 2.1% 2.2% 
Cardiac Death/non-
fatal MI¶ 
1.3% 2.0% - - 
Non-fatal MI (n) 1.1% (22) 1.7% (35) 0.6% (30) 0.8% (40) 
Revascularisation (n) 11.2% (233) 9.7% (201) 6.2% (311) 3.2% (158) 
Event rate (4.8 year follow-up) 
Cardiac Death/non-
fatal MI§ 
2.3% (48) 3.9% (81) - - 
Non-fatal MI 2.1% (44) 3.5% (73) - - 
Revascularisation 13.5% (279) 12.9% (267) - - 
 
 
Table 1.3 SCOT-HEART and PROMISE trials. 
 
* SCOT-HEART median follow-up 1.7 years, PROMISE median follow-up 2 years. 
¶ Hazard ratio 0.62, 95% confidence interval 0.38 – 1.01, p=0.0527 
§ Hazard ratio 0.59, 95% confidence interval 0.41 – 0.84, p=0.004  
 
CAD coronary artery disease, CCTA coronary computed tomography angiography, MI 
myocardial infarction 
(adapted from Moss, Williams et al. 2017)  
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The SCOT-HEART Trial 
The SCOT-HEART trial recruited 4,146 patients aged 18-75 years referred from 
primary care to a cardiology clinic with suspected angina pectoris due to coronary 
artery disease (SCOT-HEART investigators 2015). Only a small number of 
exclusion criteria (inability to undergo CT scanning, renal failure (eGFR <30mL/min), 
acute coronary syndrome within 3 months) ensured that the trial population was 
inclusive and recruited 47% of all eligible patients presenting to the clinic, making 
the application of the findings broadly applicable and highly generalisable. 
Participants were more likely to have typical angina (35%) and a small proportion 
(9%) had a history of prior coronary artery disease. Importantly the vast majority of 
patients (85%) underwent exercise electrocardiography during clinic assessment 
and prior to 1:1 randomisation to standard care alone (including cardiovascular risk 
assessment) or standard care with coronary CT angiography. The majority of 
patients had either normal (38%) or non-obstructive (37%) coronary artery disease 
reflecting the modest prevalence of coronary artery disease seen in patients 
attending UK rapid access chest pain clinics (Sekhri, Feder et al. 2007, Skinner, 
Smeeth et al. 2010). Of those who underwent standard care alone, a minority (11%) 
underwent further stress testing usually in the form of myocardial scintigraphy.  
 
Despite the use of stress testing in the clinic and wider spectrum of patient 
presentation, coronary CT angiography doubled the clinician’s certainty of the 
diagnosis of coronary artery disease (relative risk 2.56 [95% CI, 2.33-2.79]) and 
angina pectoris due to coronary artery disease (relative risk 1.79 [95% CI, 1.62-
1.96]; the primary end-point). Coronary CT angiography  also led to substantial 
cancellation of unnecessary investigations and changed pharmacological therapy in 
approximately 25% of participants. These alterations were associated with 
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improvements in the selection of patients for invasive coronary angiography with 
rates of normal coronary angiography more than halved. Rates of detection of 
obstructive coronary artery disease were also increased and led to a trend to an 
increase in coronary revascularisation (Hazard Ratio 1·20 [95% CI 0·99-1·45], 
P=0·061) despite similar overall rates of invasive coronary angiography. 
 
For patients being assessed for angina pectoris due to coronary artery disease, the 
most appropriate clinical outcome is coronary artery disease death or non-fatal 
myocardial infarction. At 5 years, there was a reduction in this combined endpoint  
(coronary heart disease death or non-fatal myocardial infarction) in the coronary CT 
angiography arm  (2.3% vs. 3.9%, Hazard Ratio 0.59, 95% CI 0.41–0.84), principally 
driven by a reduction in non-fatal myocardial infarction (2.1% versus 3.5%, Hazard 
Ratio 0.60, 95% CI 0.41-0.87) (SCOT-HEART investigators 2018) (Table 1.3). To 
date, this is the only randomised controlled trial of non-invasive cardiac imaging that 
has demonstrated improved outcomes in this setting. 
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1.2 Coronary positron emission tomography imaging 
Advances in cardiovascular molecular imaging offer the potential to unravel the 
complex in vivo cellular pathophysiology of a variety of cardiovascular disorders. 
Through a greater understanding of the pathogenesis of cardiovascular disease, 
molecular imaging may highlight novel risk factors and key targets for future 
treatments. Whereas traditional structural imaging modalities yield a generic 
approach to patient care, molecular imaging modalities give complementary 
information at the cellular level, informing about disease activity with the potential to 
facilitate personalised disease monitoring and direct targeted therapy. 
 
Atherosclerosis is a chronic inflammatory disease characterised by the formation of 
lipid-rich plaques. As early as the mid-19th Century, Rudolf Virchow advocated the 
role inflammation plays in the formation of Grützbalg (grit-follicles) within the 
coronary vasculature, namely that ‘inflammation of the inner arterial coat be the 
starting point of atheromatous degeneration’ (Virchow 1860).  Our understanding of 
the pro-inflammatory mechanisms associated with atherosclerotic events 
subsequently expanded through pathological studies of autopsy specimens and pre-
clinical models  (Narula, Nakano et al. 2013, Davies and Thomas 1984, Lendon, 
Davies et al. 1991, Burke, Farb et al. 1997). These demonstrated inflammation to be 
a central process at almost every stage of atherosclerosis but particularly important 
in the precipitation of acute plaque rupture, with macrophages secreting matrix 
metalloproteinases that serve to weaken the fibrous cap. Inflammation is therefore a 
key feature of plaques at risk of rupture in addition to other related characteristics 
such as a large necrotic core, a thin fibrous cap, angiogenesis and 
microcalcification. Each represents a potential imaging target, with molecular 
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imaging well placed to measure non-invasively the in vivo activity of these key 
processes. 
 
The emergence of hybrid coronary positron-emission tomography in conjunction 
with computed tomography or magnetic resonance offers the opportunity to 
investigate pathophysiological processes on a molecular scale. Potentially any 
pathological feature can be targeted depending on the availability of an appropriate 
radiopharmaceutical. Current approaches have made use of established 
radiotracers developed for oncological imaging. However, the potential exists to 
create bespoke tracers targeted specifically at high-risk atherosclerotic plaque 
features, thereby providing even more accurate imaging.  I will here review current 
and emerging PET tracers that hold promise in resolving the activity of these key 
processes underlying the progression of atherosclerosis in humans. I will also 
examine some of the technological challenges that will need to be met in order to 
translate these approaches in to the coronary arteries.  
 
1.2.1 18F-Fluorodeoxyglucose and macrophage metabolism 
2-[18F]-Fluoro-2-deoxy-D-glucose (18F-FDG) is a glucose analogue that enters cells 
expressing glucose transporters (known as solute carrier family 2, facilitated glucose 
transport member [GLUT] 1 and 3) by facilitated diffusion. It accumulates in the 
cytosol following phosphorylation by hexokinase to 18F-FDG-6-phosphate. The 
stoichiometry of 18F-FDG-6-phosphate prohibits further breakdown via the glycolytic 
pathway leading to a rise in concentration of 18F-FDG-6-phosphate that is 
proportional to the metabolic demand of the cell (Gallagher, Fowler et al. 1978).  
Macrophages are the key cellular constituent of active, inflamed atheroma and have 
increased metabolic demands compared to surrounding cells in the vasculature. Ex 
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vivo studies have demonstrated a close histological correlation between 18F-FDG 
uptake and macrophage density (Tawakol, Migrino et al. 2006). Macrophage density 
correlates with plaque progression and the size of the necrotic core (Moreno, Falk et 
al. 1994, Swirksi, Pittet et al. 2006). Pre-clinical mouse models suggest that 18F-
FDG may signal inflammation during the early phase of atherogenesis at the point of 
foam cell formation, whilst clinical studies have suggested uptake is less evident 
once macroscopic calcium has formed within the plaque (Ogawa, Nakamura et al. 
2012, Tarkin, Joshi et al. 2014). Satomi et al reported that the polarisation of 
macrophages towards a pro-inflammatory M1 subtype results in increased tritiated 
fluorodeoxyglucose (3H-FDG) uptake through the upregulation of glucose 
transporters compared with a reparative M2 subtype (Satomi, Ogawa et al. 2013). A 
two-fold increase in 3H-FDG was associated with an increase in GLUT-1 and 3 and 
hexokinase gene expression in M1 macrophages. Additionally, there was 
downregulation of glucose-6-phosphorylase, the reverse reaction of hexokinase. 
The same was not observed in M2 macrophages, which instead appear to decrease 
their dependence on glycolysis, perhaps in order to gain a survival advantage in the 
hostile inflammatory environment (Tavakoli, Zamora et al. 2013). More recently, 
18F-FDG accumulation in a Yucatan minipig model has raised questions of whether 
18F-FDG uptake is an accurate measure of vascular macrophage activity (Libby, 
Bhatt et al, 2019). There was considerable accumulation of 18F-FDG in all arteries 
without atherosclerotic plaque with activity localised to metabolically active medial 
smooth muscle cells (Al-Mashhadi, Tolbod et al 2019). Discriminating increased 
18F-FDG uptake activity in regions of macrophage-driven inflammation remains an 
ongoing challenge as the non-macrophage uptake accounts for the majority of 
signal intensity (Al-Mashhadi, Tolbod et al 2019). 
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The pivotal work of Rudd et al demonstrated that 18F-FDG uptake can be visualised 
in the atheromatous walls of the carotid artery (Rudd, Warburton et al. 2002). In 
eight patients with symptomatic carotid lesions, there were higher estimated 18F-
FDG accumulation rates compared with asymptomatic lesions and no significant 
uptake in angiographically normal arteries.  The carotids are especially well suited to 
vascular PET imaging because of their relatively large caliber, stationary nature and 
because vascular tissue is readily available for histological validation following 
endarterectomy. Optimisation of scanning protocols to determine the appropriate 
injected dose, circulation time and pre-scan fasting glucose have been conducted 
allowing quantification of carotid 18F-FDG with excellent scan-rescan reproducibility 
(Bucerius, Mani et al. 2014, Rudd, Myers et al. 2007, Rudd, Myers et al. 2007, 
Izquierdo-Garcia, Davies et al. 2009). This means that relatively few patients are 
required for clinical trials testing the anti-inflammatory effects of novel medication. 
This has facilitated the use of 18F-FDG–PET as a surrogate end point in phase 2 
clinical trials of novel pharmaceuticals, with the results closely tracking with the 
outcomes of subsequent studies focusing on clinical end-points (Fayad, Mani et al. 
2011, Fayad, Mani et al. 2011, Schwartz, Olsson et al. 2012). Phase 2 18F-FDG-
PET clinical trials have demonstrated good agreement between modification of 
plaque activity and subsequent larger phase 3 clinical outcome studies (Table 1.4). 
 
Translating 18F-FDG PET in to the coronary arteries is more challenging owing to 
the limited spatial resolution of clinical PET platforms and the impact of coronary 
motion. Assessment of the proximal coronary arteries and aortic root appears 
feasible with increased uptake observed in patients with recent acute coronary 
syndrome (Rogers, Nasir et al. 2010). However more detailed analysis of the mid 
and distal coronary vasculature is limited by spillover of signal from the myocardium, 
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such that even with optimal myocardial suppression protocols, half of all coronary 
territories cannot be interpreted (Joshi, Vesey et al. 2014, Dweck, Chow et al 2012). 
Clinical studies examining alternative methods for reducing physiological 18F-FDG 
uptake in the myocardium are under investigation in the hope that they will improve 
visualisation of coronary activity. Combined with the multitude of factors that may 
account for increased 18F-FDG uptake, these limitations have shifted attention to 
find more specific radiotracers that target inflammatory pathways, however none of 
these have made it through to clinical application to date. 
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 18F-FDG study (+) 18F-FDG study (-) 
Clinical outcome (+) Atorvastatin 
(Tawakol, Fayad et al, 
2013, 
Singh, Emami et al, 2016) 
Pioglitazone 
(Nitta, Tahara et al, 2013) 
 
Clinical outcome (-)  Dalceptrapib  
(Fayad, Mani et al, 2011) 
5-lipooxygenase inhibitor 
(Gaztanaga, Farkouh et al, 2015) 
Losmapimod 
(Elkhawa, Rudd et al, 2012) 
Oxidised low density lipoprotein 
antibody 
(Lehrer-Graiwer, Singh et al, 2015) 
 
 
Table 1.4 Use of 18F-fluoro-2-deoxyglucose positron emission tomography imaging to guide 
inflammatory response to treatment. 
 
Phase 2 clinical trials demonstrating cardiovascular 18F-fluoro-2-deoxyglucose activity 
response to therapy compared with subsequent phase 3 clinical outcome trials. 
Study references in brackets. 18F-FDG, 18F-fluoro-2-deoxyglucose. 
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1.2.1.1 18F-Fluorodeoxyglucose and biomarkers of inflammation 
 
The association between 18F-FDG uptake and other biomarkers of inflammation 
offers insight into the complex processes governing atherosclerotic progression. 
Following the publication of the JUPITER trial, interest in evaluating the 
inflammatory state of atherosclerotic plaques continues to grow (Ridker, Danielson 
et al. 2008). The use of high sensitivity C-reactive protein (hsCRP) provides a 
snapshot of inflammatory activation within the body, however it cannot localise this 
activity to the vasculature let alone specific vascular territories or plaques. By 
contrast, co-localisation of 18F-FDG to the arterial wall gives a clearer signal of focal 
atherosclerotic inflammation. Unraveling the complex relationship between systemic 
inflammation and 18F-FDG uptake is challenging, especially as plaque rupture 
events following myocardial infarction may exacerbate atherosclerotic inflammation 
at remote sites (Rudd, Myers et al 2009, Joshi, Toor et al. 2015). Importantly, 18F-
FDG plaque imaging appears more sensitive in detecting the anti-inflammatory 
effects of novel atherosclerosis therapies making it a useful end-point for phase 2 
clinical trials (Fayad, Mani et al. 2011, Mani, Woodward et al. 2014). From a clinical 
standpoint, identifying 18F-FDG uptake within carotid arteries improves 
cardiovascular risk stratification independent of hsCRP suggesting that 18F-FDG 
offers incremental information to the assessment of atherosclerotic inflammation 
(Noh, Moon et al. 2013).  
 
Pre-clinical 18F-FDG imaging has provided a deeper understanding of plaque 
pathophysiology and temporal fluctuations in plaque activity. Murine models using 
ApoE-/- mice fed on a high-fat Western diet exhibit higher 18F-FDG uptake within the 
descending aorta at 16 weeks. Lipid rich plaques that display focal regions of 18F-
FDG uptake recruit macrophages through the expression of vascular cell adhesion 
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molecule (VCAM-1). Associations between plaque inflammation and subsequent 
calcification have also been observed using 18F-FDG. 18F-FDG highlights regions 
of the vasculature associated with osteopontin, a marker of early vascular 
calcification, which has prognostic significance in human coronary atherosclerosis 
(Hay, Pedersen et al. 2012). High osteopontin levels are associated with increased 
major adverse cardiovascular events following myocardial infarction, stable coronary 
artery disease and in patients undergoing coronary intervention (Bjerre, Pedersen et 
al. 2013, Georgiadou, Iliodromitis et al. 2010, Kato, Momiyama et al. 2009). Over 5 
years of follow-up, focal 18F-FDG uptake identified locations of subsequent calcium 
deposition and calcium progression in the thoracic aorta. Whilst plaques with novel 
calcification were associated with increased arterial inflammation, regions of dense 
calcification were associated with a decreased level of inflammatory activity 
(Abdelbaky, Corsini et al. 2013, Joshi, Ranjani et al. 2016). Understanding the exact 
link between inflammation and calcification in atherosclerosis is a key topic of 
investigation, which may be aided by 18F-sodium fluoride PET imaging and is 
discussed in greater detail below. 
 
1.2.1.2 Link Between Inflammation and Calcification 
Vascular calcification is a key process in atherosclerosis although its exact role 
remains incompletely understood. Large macroscopic calcific deposits can be 
visualised on computed tomography and are usually associated with advanced 
stable atherosclerotic plaque. Nevertheless, CT-determined calcium predicts future 
adverse events presumably on the basis that patients with high calcium scores will 
also have more non-calcific plaques at risk of rupture and causing an event. By 
contrast, the early stages of calcification appear to be associated with plaque 
instability and increased risk of rupture and events. Ruptured and culprit plaques 
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often demonstrate regions of microcalcification on histopathology. In keeping with 
this hypothesis, low-density calcium deposition on CT is associated with an 
increased risk of events compared to high-density calcium (Criqui, Denenberg et al. 
2014). Similarly, the early stages of ‘spotty’ macrocalcification on CT appear to mark 
out a higher risk stage of the disease than the larger macroscopic deposits found in 
stable plaques (Motoyama, Kondo et al. 2007). CT imaging however, is unable to 
resolve true microcalcification, prompting investigation of alternative approaches 
with the capacity to detect this early form of calcium.  
 
The association between plaque inflammation and subsequent calcification has 
been studied using molecular imaging in pre-clinical models of atherosclerosis. 
High-resolution molecular imaging with a bisphosphonate-derived near-infrared 
imaging agent (OsteoSense) identifies distinct regions of calcification activity in the 
vasculature that can be compared with macrophage staining (Aikawa, Nahrendorf et 
al. 2007). Indeed, OsteoSense binds preferentially to nascent, nanocrystalline 
deposits of hydroxyapatite that coalesce to form spheres of microcalcification of <50 
μm. Microscopic analysis of these particles reveals a range in size from 5 μm down 
to individual matrix vesicles that are only 100 nm (Bertazzo, Gentleman et al 2013). 
Cell-derived matrix vesicles containing nanocrystals of hydroxyapatite are 
exocytosed from the cell membranes of macrophages and vascular smooth muscle 
cells. These are then released into the extracellular space where they form a nidus 
for microcalcification which then aggregate to form larger macroscopic deposits 
(New, Goesttsch et al. 2013, Hutcheson, Goettsch et al. 2016). This process is most 
evident in the necrotic core where nucleation and calcification growth occur in 
regions of collagen degradation (Hutcheson, Goettsch et al. 2016). Interestingly, 
hydroxyapatite may also be a contributor to the inflammatory process, rather than 
On the detection of vulnerable plaques in human coronary atherosclerosis 
 
 24 
merely an end product. Ectopic needle-shaped hydroxyapatite crystals stimulate IL-
1β /IL-18-dependent inflammatory pathways (Jin, Frayssinet et al. 2011). 
Additionally, if pairs of microcalcified spheres migrate into the fibrous cap, increases 
in local mechanical stresses due to interfacial debonding can lead to plaque rupture 
(Maldonado, Kelly-Arnold et al. 2012). 
 
1.2.2 18F-Sodium fluoride and microcalcification 
[18F]-Sodium fluoride (18F-fluoride) has been used as an oncological radiotracer for 
the past forty years. 18F-Fluoride binds to hydroxyapatite by substitution with a 
hydroxyl group on the surface of the hydroxyapatite matrix to form fluoroapatite 
(Ca10(PO4)6F2) (Hawkins, Choi et al. 1992). As hydroxyapatite is the dominant in 
vivo form of crystalline calcium, 18F-fluoride has been used to define areas of 
increased bone activity with greater accuracy in detecting bone metastases than 
other conventional imaging techniques (Schirrmeister, Gulmann et al. 1999).  
 
Hydroxyapatite is also the major component of vascular calcification leading to 
interest in using 18F-fluoride as a marker of vascular calcification activity. Early 
studies demonstrated areas of increased PET uptake in the aorta, the valves of 
patients with aortic stenosis and the coronary arteries (Dweck, Chow et al. 2012, 
Dweck, Khaw et al. 2013, Dweck, Jones et al. 2012, Dweck, Jenkins et al. 2014, 
Jenkins, Vesey et al. 2015). The latter is of particular interest with 18F-fluoride 
localising to individual plaques with excellent signal-to-noise and very low uptake in 
the surrounding myocardium. 
 
18F-Fluoride appears to provide different information to CT calcium scoring. 
Detailed electron microscopic analysis of carotid endarterectomy specimens has 
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shown that fluoride, like OsteoSense, binds preferentially to regions of 
microcalcification compared to the macroscopic deposits observed using computed 
tomography (Irkle, Vesey et al. 2015). This perhaps reflects the greater exposed 
surface area of hydroxyapatite in these nanocrystalline areas (Irkle, Vesey et al. 
2015). Indeed, 41% of patients with coronary artery calcium scores >1,000 do not 
have any evidence of increased 18F-fluoride uptake (Dweck, Chow et al. 2012). As 
previously discussed, microcalcification is a key component of high-risk 
atherosclerotic plaques and consistent with this, plaques with increased 18F-fluoride 
uptake have been shown to have multiple high-risk characteristics on histology and 
intravascular ultrasound including inflammation, positive remodelling, 
microcalcification and a large necrotic core (Figure 1.1). Moreover, in patients with 
recent myocardial infarction increased 18F-fluoride uptake has been observed in 
>90% of the culprit plaques responsible for that event (Joshi, Vesey et al. 2014). 
The clinical challenge is to now determine whether identification of microcalcification 
in the coronary arteries using 18F-fluoride PET can improve risk stratification in 



















































































































































































On the detection of vulnerable plaques in human coronary atherosclerosis 
 
 27 
1.3 Novel tracers 
1.3.1 Developments in coronary artery positron emission 
tomography 
The development and expansion of positron emission tomography will depend on 
the development of novel tracers targeting a range of different pathological 
processes (Figure 1.2). A number of tracers are in development with many centered 
on providing more specific imaging of inflammation, whilst others have been 
targeted to related processes associated with active atheroma, disease progression 
and plaque rupture (Table 1.5). In addition, improvements in spatial resolution and 
techniques for correcting cardiac motion will be required if these new tracers are to 
prove of use in the small and highly mobile coronary arteries.







Figure 1.2 Radiotracer accumulation in atherosclerotic plaques as markers of inflammation, 
hypoxia, apoptosis and microcalcification activity. 
 
Inflammatory pathways can be visualised in vivo using specific radiolabelled PET ligands. 
18F-FDG accumulates in activated macrophages, but can also be influenced by local 
hypoxia. Other radiotracers such as 68Ga-DOTATATE and 11C-PK11195 may be more 
specific markers of macrophage activity than 18F-FDG. An imbalance in metabolic 
substrates reduces the oxygen tension in the plaque promoting necrosis and apoptosis of 
macrophages and smooth muscle cells. Generation of reactive oxygen species, 
externalization of phosphatidylserine and the extrusion of microcrystalline hydroxyapatite 
can be detected by 18F-FMISO, 68Ga-Annexin V and 18F-fluoride respectively. 
 
DOTATATE, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-octreotate; 
FDG, fluorodeoxyglucose; FDG-P, fluorodexoyglucose-6-phosphate; FMISO, 
fluoromisonadazole; GLUT, facilitated glucose transporter member; NaF, sodium fluoride; 
SSTR2, somatostatin receptor type 2; TSPO, translocator protein. 
(Moss, Adamson et al. 2015) 




Target Ligand Radiotracer Application to date 
Macrophage 
activation 
GLUT (1&3) and conversion 
by hexokinase to 18F-FDG-
6-phosphate 
18F-FDG  Prospective in vivo 
studies in extra-cardiac 
atherosclerosis 
Myocardial suppression 
required to evaluate 
coronary arteries 
 Somatostatin receptor 
subtype 2 
68Ga-DOTATATE  Prospective in vivo 
studies in coronary 
artery disease 
 Translocator protein 18-kDa 11C-PK11195 Prospective in vivo 
study in carotid 
stenosis 
 Translocator protein 18-kDa 11C-PBR28 Clinical studies in 
healthy controls and 
multiple sclerosis 
 Mannose receptor 18F-FDM Preclinical cell culture 
model 
 Choline kinase 
phosphorylated to 
Phosphatidylcholine 
18F-choline  Preclinical murine 
model 
Apoptosis Phosphatidylserine 68Ga-Annexin A5 Preclinical murine 
model 
Hypoxia Reduction to amine 
derivative in low O2 
environment 
18F-FMISO  Preclinical murine 
model 
 Reduction to amine 
derivative in low O2 
environment 
18F-HX4 Proof of concept in 
carotid atherosclerosis 
Microcalcification Hydroxyapatite 18F-Fluoride Prospective in vivo 
studies in coronary and 
extra-cardiac 
atherosclerosis 
Angiogenesis αVβ3 & αVβ5 integrin 18F-Fluciclatide  Proof of concept in 
aortic atherosclerosis 




Table 1.5 PET radiotracers for coronary atherosclerosis. 
(Moss, Adamson et al. 2015)
On the detection of vulnerable plaques in human coronary atherosclerosis 
 
 30 
1.3.2 68Ga-DOTATATE and macrophage somatostatin 
receptors 
Somatostatin receptors are G-protein-coupled receptors that are expressed in a 
wide variety of tissues. 68Ga-DOTATATE binds to somatostatin receptor subtype 2 
(SSRT2) which are expressed by the lipopolysaccharide-activated macrophages 
associated with plaque vulnerability (Armani, Catalani et al. 2007). Whereas 18F-
FDG is hampered by diffuse myocardial uptake that often obscures coronary 
activity, 68Ga-DOTATATE permits clearer detection of macrophage accumulation in 
coronary plaques (Figure 1.3). In a retrospective analysis of 70 patients with 
neuroendocrine tumours, 44% had co-localisation of 68Ga-DOTATATE to 
atheromatous plaques in the proximal coronary arteries (Rominger, Saam, et al. 
2010). Whilst in another retrospective study of 44 cancer patients 68Ga-DOTATATE 
again accumulated in individual coronary lesions suggesting that it may ultimately 
prove a better marker of inflammation activity in these vessels that 18F-FDG 
(Mojiahedi, Alavi et al. 2015). The Vascular Inflammation imaging using 
SomatostatiN receptor positron emission tomography study (NCT02021188) 
demonstrated improved specificity for carotid and coronary atherosclerotic 
macrophage imaging using 68Ga-DOTATATE compared with 18F-FDG (Tarkin, 
Joshi et al, 2017). RNA sequencing of the different macrophage phenotypes 
revealed SSRT2 expression to be highly specific for pro-inflammatory M1 
macrophages, whilst there were very low levels of SSRT2 mRNA expression in 
unstimulated M0 or activated M2 subtypes (Tarkin, Joshi et al, 2017). Longitudinal 
studies exploring coronary plaque progression identified by 68Ga-DOTATATE are 
ongoing (NCT04043377). 
 












Figure 1.3 Coronary radiotracer uptake in calcified proximal left anterior descending arteries. 
 
Comparison of different radiotracers in the proximal left anterior descending artery of three 
different patients. The relatively low diffuse 18F-FDG signal (A) contrasts with enhanced 
focal uptake of 68Ga-DOTATATE (B) and 18F-fluoride (C).   Individual radiotracers can 
discriminate between the upregulation of different molecular pathways in macroscopically 
similar plaques. 
(Moss, Adamson et al. 2015). 
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1.3.3 11C-PK11195 and translocator protein/peripheral 
benzodiazepine receptors 
[11C]-PK11195 is an isoquinoline-derived ligand of the translocator protein (TSPO), 
previously known as the peripheral benzodiazepine receptor that is found on the 
outer mitochondrial membrane. TSPO is involved in cholesterol transport across the 
mitochondrial intermembrane space and regulation of the mitochondrial respiratory 
chain. This critical role means that TSPO is widely expressed in cardiac tissues, 
however the highest density of receptors are found in activated macrophages 
undergoing bursts of oxidative stress (Carayon, Portier, et al. 1996, Canat, Carayon 
et al. 1993). In a proof of concept study, Pugliese et al visualised 11C-PK11195 
uptake in 6 patients with large vessel vasculitis in the aortic arch and carotid arteries 
(Pugliese, Gaemperli et al. 2010). Symptomatic patients with active disease had 
higher signals in the vascular wall compared with asymptomatic patients with 
quiescent vasculitis. The same group performed 11C-PK11195 imaging in patients 
with carotid atherosclerosis demonstrating increased tracer uptake in the ipsilateral 
culprit carotid plaque of patients post stroke/TIA (Gaemperli, Shalhoub et al. 2012). 
In 8 patients undergoing carotid endarterectomy, ex vivo autoradiography using 3H-
PK11195 confirmed radiotracer co-localisation with CD68+ macrophages. Novel 
fluoride-labelled 18 kDa translocator protein radiotracers are in development 
(MacAskill, Walton et al, 2019).  
 
1.3.4 18F- Fluoro-D-mannose and M2 macrophages 
Mannose, an isomer of glucose, also serves as a substrate for glycolysis in 
metabolically active macrophages. Similar to glucose, it is incorporated into cells 
through glucose transporters, but also binds to mannose receptors expressed on 
M2 macrophages (Finn, Nakano et al. 2012). As such, radiolabeled 2-deoxy-2-[18F]-
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fluoro-D-mannose (18F-FDM) has been explored as a viable alternative to 18F-FDG 
for imaging inflammation in atherosclerosis (Tahara, Mukerjee et al. 2014). This pre-
clinical study highlighted an improved pharmacokinetic profile using 18F-FDM 
compared with 18F-FDG, which resulted in higher levels of 18F-FDM uptake in 
macrophages, predominantly due to less inhibition of hexokinase activity than is 
observed with 18F-FDG. Clinical translation of these results is now awaited. 
 
Detection of M2 macrophages may serve as an indirect measure of plaque 
haemorrhage, since macrophage clearance of intracellular iron and haemoglobin 
generates an M2 subtype characterised by high mannose receptor expression 
(Finn, Nakano et al. 2014). Intraplaque haemorrhage results in rapid expansion of 
the necrotic core following the sudden release of cholesterol-rich erythrocyte 
membranes. It is therefore an important contributor to episodic plaque growth and 
may account for the sudden transformation of stable coronary artery disease to 
active disease state at increased risk of rupture (Kolodgie, Gold et al. 2003).  
 
1.3.5 18F-Fluoromisonidazole and hypoxia 
Hypoxia is a key feature of both the expanding necrotic core and atherosclerotic 
plaque growth. In early plaques oxygen freely diffuses across the initima and the 
adventitial vasa vasorum. However with plaque expansion, this oxygen diffusion 
falls (Zemplenyi, Crawford et al. 1989). Combined with the increasing metabolic 
demand from activated macrophages, an oxygen debt builds up that renders these 
advanced atherosclerotic plaques severely hypoxic. 18F-FDG may provide an 
indirect measure of oxygen sufficiency as expression of reactive oxygen species 
and hypoxia inducible factors stimulate 18F-FDG uptake (Folco, Sheikine et al. 
2011, Lee, Quach et al. 2014). However radiolabelled  nitroimidazoles offer greater 
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specificity as they accumulate in tissues that lack oxygen, acting as an electron 
carrier in the mitochondrial respiratory chain. Uptake of nitroimidazoles is inversely 
proportional to the oxygen tension, such that 3H-fluoromisonidazole uptake 
increases by twenty-fold at low partial pressures of oxygen (Krohn, Link et al. 2008). 
18F-Fluoromisonidazole (18F-FMISO) has been used extensively in tumour imaging 
and is now under investigation in atherosclerosis (Mateo, Izquierdo-Garcia et al. 
2014). In a pre-clinical study, 18F-FMISO uptake co-localised with pimonidazole 
defined regions of hypoxia that were nestled in deep in macrophage-dense cores. In 
contrast, superficial macrophages in a subintimal location were not hypoxic and less 
inflamed. Clinical studies with a similar nitroimidazole analogue ([18F]-2-(4-((2-nitro-
1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol) have been reported 
demonstrating increased uptake in patients with carotid stenoses (van der Valk, 
Sluimer et al. 2015). 
 
1.3.6 18F-Fluciclatide and αVβ3 integrin receptors 
Angiogenesis occurs in response to atherosclerotic plaque hypoxia, with fragile 
microvessels sprouting from the advential vasa vasorum to provide the necrotic core 
with a new blood supply. These thin-walled vessels have poor structural integrity 
and are prone to leakage, rupture, and ultimately haemorrhage in to the plaque 
(Sluimer, Kolodgie, et al. 2009). The vascular endothelial cells responsible for 
establishing this microvasculature express αVβ3 integrin, part of the integrin 
superfamily of heterodimeric receptors responsible for cell adhesion and signaling. 
The αVβ3 receptor is upregulated in immature endothelial cells as a response to 
angiogenic guidance molecules. The arginine-glycine-aspartate (RGD) motif has 
allowed investigators to target the αVβ3 binding site to inhibit atherosclerotic 
progression (Maile, Busby et al. 2010). 18F-Fluciclatide successfully visualises 
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tumour angiogenesis and can detect treatment responses to chemotherapy (Battle, 
Goggi et al. 2011, Mena, Owenius et al. 2014). Pre-clinical experiments with a 
similar analogue, 18F-RGD-K5, demonstrated a moderate correlation between PET 
uptake and endothelial cell staining of ex vivo carotid plaques (Golestani, Mirfeizi et 
al. 2015). Our group has recently performed the first prospective clinical study 
(NCT01813045) using 18F-Fluciclatide to assess aortic atherosclerotic uptake 
(Jenkins, Vesey et al. 2017, Jenkins, Vesey et al. 2019). The expression of αVβ3 
integrin quantified using 18F-Fluciclatide is associated with aortic plaque burden 
and higher signal intensity was found in patients with recent myocardial infarction 
suggesting it may hold potential to quantify plaque angiogenesis and inflammation in 
high-risk individuals (Jenkins, Vesey et al. 2017, Jenkins, Vesey et al. 2019). 
 
1.3.7 68Ga-Annexin A5 and macrophage apoptosis 
The lipid-rich necrotic core is a key feature of the vulnerable plaque and is derived 
from the death of macrophages and smooth muscle cells within the plaque due to a 
combination of apoptosis and necrosis. Externalisation of phosphatidylserine onto 
the extracellular surface of the plasma membrane is an almost universal feature of 
apoptosis. This makes it a useful target for detection using Annexin based 
radiotracers (Kolodgie, Petro et al. 2003).  
 
Clinical SPECT imaging of atherosclerotic apoptosis using 99mTc-Annexin A5 was 
first performed by Kietselaer et al in four patients prior to carotid endarterectomy. In 
two patients who had suffered a recent transient ischaemic attack (TIA), the 
ipsilateral carotid artery showed Annexin A5 uptake (Kietselaer, Reutelingsperger et 
al. 2004). Interestingly, the other two patients with remote transient ischaemic 
attacks (3-4 months) had no observable Annexin A5 uptake. Histology 
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demonstrated a correlation between Annexin A5 binding and both macrophage 
staining and intraplaque haemorrhage. Development of the PET tracer 68Ga-
Annexin A5 has demonstrated promise in murine models of myocardial infarction. 
However, translation into clinical studies has been delayed because of suboptimal 
pharmacokinetics with accumulation in the liver and kidneys (Lehner, Todica et al. 
2014). Interestingly Annexin A5 also co-localises with matrix vesicles containing 
hydroxyapatite in atherosclerosis, indicating that cell death may be an important 
trigger to microcalcification (New, Goettsch et al. 2013).  
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1.4 Improving PET image quality 
 
1.4.1 Technical aspects of coronary PET imaging 
Clinical application of PET imaging to coronary atherosclerosis will require technical 
improvement with respect to spatial resolution and motion correction. Clinical 
positron emission tomography has a fundamental limit of spatial resolution in the 
range of 4–5 mm for 18F-radiotracers. This means assessment of the coronary 
arteries with a luminal diameter of 2–5 mm is at the very limit of the capabilities of 
current clinical PET systems. This is a particular problem because of the complex 
motion of the coronary vessels, which can displace the right coronary artery by as 
much as 20 mm (Schecter, Resar et al. 2006). Visualising and quantifying 
radiotracer uptake on this scale is additionally confounded by partial volume effects. 
Namely, the signal increases when surrounded by areas of high activity (e.g. 
myocardium with 18F-FDG) and attenuates when surrounded by areas of low 
activity (e.g. the lung with most tracers) (Soret, Bacharach et al. 2007). This 
combination of image blurring (limited spatial resolution) and partial voluming 
(distribution of signal across voxels) can result in discrepancy between fused PET 
and CT data sets, requiring careful co-alignment to delineate coronary artery 
segments with increased radiotracer uptake. ECG gating of the PET data can help 
substantially, but necessitates discarding much of the data resulting in reduced 
counts and noise. Cardiac motion correction algorithms that make use of all of the 
data are emerging and appear to improve the accuracy of co-registration (Le 
Meunier, Slomka et al. 2011, Slomka, Diaz-Zamudio et al. 2015). A recent feasibility 
study has found that these algorithms can improve signal detection in the coronary 
arteries by a third, with particular reductions in the blurring of the PET image and 
background noise (Rubeaux, Joshi et al. 2016). 




1.4.2 Positron Emission Tomography Magnetic Resonance 
Hybrid positron emission tomography is now being explored in conjunction with 
magnetic resonance (MR) platforms. Given that radiotracer uptake resides in the 
vessel wall rather than the coronary lumen, PET-MR can potentially provide 
additional information on soft tissue characterisation, of particular use in assessing 
carotid plaque characteristics (Vesey, Dweck et al. 2016). Ripa et al performed the 
first feasibility study of carotid atherosclerotic imaging using 18F-FDG PET-MR in 
six patients without flow-limiting luminal stenosis (Ripa, Knudsen et al. 2013). There 
was a strong correlation between PET-MR and PET-CT measurements in the 
absence of significant disease. Whilst the attenuation corrected computed 
tomography and magnetic resonance maps differ across the two platforms, 
quantification of radiotracer uptake appears to be comparable (Bini, Robson et al. 
2015). Enthusiasm for extending the use of PET-MR to assessment of the coronary 
vasculature in high-risk groups is tempered by the temporal and spatial resolution 
required for coronary imaging and compounded by artefact from coronary stenting. 
However reliable imaging of the proximal vessels using magnetic resonance 
angiography is now possible and one major potential advantage is the ability to 
continuously monitor cardiac motion using magnetic resonance, which can then be 
used to correct the PET data. In addition, radiation exposure can potentially be 
reduced by more than half. Studies are currently underway to further explore the 
utility of cardiac PET-MR imaging  (NCT01418313).   
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1.5 Future perspective 
Whilst an increasing number of radiotracers are in development to specifically 
evaluate coronary atherosclerosis, what steps are required to take PET imaging in 
to the primetime of non-invasive coronary imaging? For aspirations to become a 
clinical reality, the next decade of coronary artery PET research should focus on 
addressing three key objectives. Firstly, can PET imaging identify individuals at risk 
of future cardiovascular events? Following the model established by other non-
invasive imaging modalities, clinical outcome studies should evaluate whether PET 
imaging can stratify individuals at the greatest risk of myocardial infarction or 
cardiovascular death in primary and secondary disease settings. Secondly, can PET 
imaging assess an individual’s response to therapy? Identifying whether individuals 
are responders or non-responders to treatment is a perceived strength of molecular 
imaging and this may allow clinicians to ‘bridge the gap’ towards the delivery of 
personalised medicine, particularly when integrated with genetic profiling. Finally 
and possibly the highest bar for any imaging test to attain, can PET imaging assist 
in the selection of appropriate therapy to improve cardiovascular outcomes and 
save lives? This is likely to require randomised controlled trials testing whether the 
addition of molecular imaging can improve current paradigms. Ultimately if PET 
imaging is to have a clinical role this is likely to be in refining risk stratification in 
those already felt to be at risk. 
 
Hybrid positron emission tomography provides insight into the pathophysiology of 
atherosclerosis that until recently has been available only through autopsy 
examinations. The rapidly expanding number of radiotracers for the assessment of 
atherosclerosis now allows us to measure directly disease activity and to evaluate 
the molecular mechanisms governing plaque progression and rupture. Translating 
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this information into the clinic may ultimately provide a more stratified approach to 
risk prediction, ensuring that effective treatment is directed appropriately to those 
with active atherosclerosis, who are most likely to gain benefit. However 
considerable work remains to test this important hypothesis.  
  
On the detection of vulnerable plaques in human coronary atherosclerosis 
 
 41 
1.6 Thesis aims and Hypotheses 
 
Whilst the unifying theme of this thesis is to explore novel non-invasive imaging 
approaches to identify vulnerable plaques in patients with coronary atherosclerosis, 
the aims can be divided into four component parts. The first aim, using coronary 
plaque analysis from the SCOT-HEART study, is to assess the utility of CT coronary 
angiography in stratifying patients at increased risk of cardiovascular events based 
adverse plaque characteristics. The second aim is to evaluate whether novel 
coronary positron emission tomography using 18F-fluoride can be used as a 
reproducible metric of disease activity to support the use of this technique in 
randomised clinical trials. The third aim is to determine whether coronary 18F-
fluoride uptake is a measure of atherosclerotic plaque activity using histological 
correlation with coronary artery specimens. The final aim is to test whether the use 
of coronary 18F-fluoride positron emission tomography can be used to guide 
intensification of antiplatelet therapy in a randomised clinical trial. 
 
The following hypotheses will be tested: 
i. The identification of adverse plaque characteristics using coronary CT 
angiography adds incremental information to luminal stenosis severity to 
stratify patients at increased risk of cardiovascular events (Chapter 3). 
ii. Coronary 18F-fluoride positron emission tomography is a reproducible 
imaging technique in patients with stable and unstable coronary artery 
disease (Chapter 4). 
iii. 18F-Fluoride uptake identifies hydroxyapatite deposition in coronary 
plaques in regions of active plaque mineralization (Chapter 5). 
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iv. Dual antiplatelet therapy using P2Y12 inhibition with ticagrelor reduces 
myocardial injury, as measured using high-sensitivity troponin I, in 
patients with coronary 18F-fluoride uptake (Chapter 6).  
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2.1 Summary  
The Scottish Computed Tomography of the HEART trial was an open-label, 
multicentre, randomised controlled trial investigating the addition of coronary 
computed tomography angiography to the rapid access chest pain standard of care 
pathway in 12 centres across Scotland. Post-hoc analyses of coronary computed 
tomography angiography scan acquisitions detailed plaque composition and 
associations with clinical outcomes are presented in chapter 3. The methodology for 
coronary plaque analysis using 18F-fluoride positron emission tomography was 
optimised with scan-rescan reproducibility testing in chapter 4 using nested cohorts 
from two clinical trials of an investigational medicinal product, the Dual antiplatelet 
therapy to Inhibit coronary Atherosclerosis and MyOcardial injury in patients with 
Necrotic high-risk coronary plaque Disease (DIAMOND) trial and Prediction of 
Recurrent Events with 18F-Fluoride to Identify Ruptured and High-risk Coronary 
Artery Plaques in Patients with Myocardial Infarction (PRE18FFIR). Histological 
examination of post-mortem coronary artery specimens was undertaken using 18F-
fluoride micro-positron emission tomography scanning and presented in chapter 5. 
Finally, the DIAMOND trial primary analysis, a controlled trial of an investigational 
medicinal product (Ticagrelor AZD6410, 90mg tablet, AstraZeneca, Södertälje, 
Sweden) is presented in chapter 6. Specific study design, methodology and 
statistical analysis relevant to each study are detailed in the respective chapters. 
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2.2 Patient Cohorts 
 
2.2.1 Scottish Computed Tomography of the HEART Trial 
sub-study population 
The study population of the Scottish Computed Tomography of the HEART (COT-
HEART) trial has been previously described (SCOT-HEART investigators, 2015). 
Briefly, the trial was a pragmatic, open-label, parallel-group, multicentre randomised 
control trial of 4,146 patients attending the rapid access chest pain clinic for the 
assessment of suspected cardiac chest pain. Participants were recruited from 12 
cardiology clinics across Scotland between November 2010 and September 2014. 
Inclusion criteria were necessarily broad and included participants aged 18-75 years 
who were between 18 and 75 years old and had been referred by their primary care 
physician to a dedicated cardiology chest pain clinic with stable chest pain due to 
suspected coronary artery disease. Of note, participants with acute chest pain were 
referred directly to the emergency department and were not included in this study 
population. Exclusion criteria included the inability to undergo coronary computed 
tomography angiography, renal impairment (serum creatinine >250 µmol/L or 
estimated glomerular filtration rate <30 mL/min/1.73 m2), previous recruitment to the 
trial, major allergy to iodinated contrast, inability to give informed consent, known 
pregnancy, and recent acute coronary syndrome within 3 months (SCOT-HEART 
investigators, 2015). Participants were randomised 1:1 to standard care (n=2,073) 
or standard care plus computed tomography calcium score and coronary computed 
tomography angiography (n=2,703), of whom 1,778 underwent coronary computed 
tomography angiography at one of the study sites. The Chief Investigator for this 
study was Professor David Newby. 
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The sub-study of adverse plaque characteristics of participants randomised to 
computed tomography angiography from the SCOT-HEART trial presented in 
Chapter 3 is a secondary post-hoc analysis. To perform a detailed analysis of 
plaque characteristic, all images were re-analysed by trained readers in coronary 
computed tomography angiography at Edinburgh Imaging facility, Royal Infirmary of 
Edinburgh, Edinburgh, United Kingdom. 
 
2.2.2 Dual antiplatelet therapy to Inhibit coronary 
Atherosclerosis and MyOcardial injury in patients with 
Necrotic high-risk coronary plaque Disease trial population 
The Dual antiplatelet therapy to Inhibit coronary Atherosclerosis and MyOcardial 
injury in patients with Necrotic high-risk coronary plaque Disease (DIAMOND) trial 
was an investigator-initiated, controlled trial of an investigational medicinal product 
(Ticagrelor AZD6410, 90mg tablet, AstraZeneca, Södertälje, Sweden) conducted at 
a single centre in Edinburgh, United Kingdom (Clinical Trials.gov Study Identification 
Number: NCT02110303). Participants were recruited between March 2015 and 
March 2017 and included individuals with stable coronary artery disease aged ≥40 
years and already receiving aspirin therapy with angiographically proven multivessel 
coronary artery disease defined as at least two major epicardial vessels with any 
combination of either (a) >50% luminal stenosis, or (b) previous revascularization 
(percutaneous coronary intervention or coronary artery bypass graft surgery). 
Participants were excluded if they had any of the following criteria: an acute 
coronary syndrome within the last 12 months, any ongoing indication for dual anti-
platelet therapy, or concurrent thienopyridine (clopidogrel or prasugrel) or oral 
anticoagulant therapy, or percutaneous coronary intervention or coronary artery 
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bypass graft surgery within the last 3 months. Full eligibility criteria are provided in 
the Table 2.1. 
 
Participants were recruited from a local registry at the Royal Infirmary of Edinburgh 
and underwent hybrid coronary positron emission tomography computed 
tomography angiography at the Edinburgh Imaging facility, Royal Infirmary of 
Edinburgh, Edinburgh, United Kingdom. The Chief Investigator for this study was 
Professor David Newby.  





For inclusion in the study subjects should fulfil the following criteria: 
1. Patients aged ≥40 years with angiographically proven multivessel 
coronary artery disease defined as at least two major epicardial 
vessels with any combination of either (a) >50% luminal stenosis, or 
(b) previous revascularization (percutaneous coronary intervention or 
coronary artery bypass graft surgery) 
2. Provision of informed consent prior to any study specific procedures 
3. Receiving aspirin 
Exclusion Criteria 
Subjects should not enter the study if any of the following exclusion criteria 
are fulfilled: 
1. An acute coronary syndrome within the last 12 months 
2. An indication for dual anti-platelet therapy, such as drug eluting stent 
3. Receiving thienopyridine therapy such as clopidogrel or prasugrel 
4. Percutaneous coronary intervention or coronary artery bypass graft 
surgery within the last 3 months 
5. Inability or unwilling to give informed consent 
6. Women who are pregnant, breastfeeding or of child-bearing potential 
(women who have experienced menarche, are pre-menopausal and 
have not been sterilised) will not be enrolled into the trial 
7. Known hypersensitivity to ticagrelor or one of its excipients 
8. Active pathological bleeding or bleeding diathesis 
9. Significant thrombocytopenia: platelets <100 x 109 /L 
10. History of intracranial hemorrhage 
11. Moderate to severe liver impairments (Child’s Grade B or C) 
12. Maintenance therapy with strong CYP3A4 inhibitors, such as 
ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or 
clarithromycin 
13. Major intercurrent illness of life expectancy <1 year 
14. Renal dysfunction (eGFR ≤30 mL/min/1.73m2) 
15. Contraindication to iodinated contrast agents 
16. Planned coronary revascularization or major non-cardiac surgery in 
the next 12 months 
17. Maintenance therapy with simvastatin or lovastatin at doses greater 
than 40mg daily 
18. Receiving oral anticoagulants including warfarin, rivaroxaban, 
dabigatran or apixaban 
 
Table 2.1. Inclusion and exclusion criteria for DIAMOND trial 
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2.2.2.1 18F-Fluoride Positron Emission Tomography Computed 
Tomography Angiography reproducibility population in patients with 
stable coronary artery disease 
A pre-specified sub-study of the DIAMOND population included 20 participants 
whom underwent repeat coronary positron emission tomography computed 
tomography angiography to assess scan-rescan reproducibility within 2 weeks using 
the same image acquisition protocol. The sub-study comprised of 10 participants 
with increased coronary 18F-fluoride uptake and 10 participants without increased 
coronary 18F-fluoride uptake. Inclusion and exclusion criteria were the same of 
those detailed in the DIAMOND trial (Table 2.1). 
 
2.2.3 18F-Fluoride Positron Emission Tomography Computed 
Tomography Angiography reproducibility population in 
patients with recent acute coronary syndrome 
This study is a single centre observational cohort study nested within the Prediction 
of Recurrent Events with 18F-Fluoride to Identify Ruptured and High-risk Coronary 
Artery Plaques in Patients with Myocardial Infarction (PRE18FFIR). PRE18FFIR is an 
international multicentre observational controlled trial of an investigational medicinal 
product ([18F] sodium fluoride 250 Megabecquerel) recruiting participants in the 
United Kingdom, Australia and United States of America (Clinical Trials.gov Study 
Identification Number: NCT02110303). To assess the scan-rescan reproducibility of 
18F-fluoride positron emission tomography computed tomography angiography, 10 
participants with recent myocardial infarction were recruited from a single centre in 
Edinburgh, United Kingdom to undergo serial coronary positron emission 
tomography computed tomography angiography within 2 weeks using the same 
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image acquisition protocol. Full eligibility criteria are provided in the Table 2.2. The 
Chief Investigator for this study was Professor David Newby. 
  





For inclusion in the study subjects should fulfil the following criteria: 
1. Patients aged ≥50 years with recent (<21 days) type 1 myocardial 
infarction and angiographically proven multi-vessel coronary artery 
disease defined as at least two major epicardial vessels with any 
combination of either (a) >50% luminal stenosis, or (b) previous 
revascularization (percutaneous coronary intervention or coronary 
artery bypass graft surgery). 
2. Provision of informed consent prior to any study specific procedures 
3. Already consented to the main PRE18FFIR study 
Exclusion Criteria 
Subjects should not enter the study if any of the following exclusion criteria 
are fulfilled: 
1. Inability or unwilling to give informed consent 
2. Women who are pregnant, breastfeeding or of child-bearing potential 
(women who have experienced menarche, are pre-menopausal and 
have not been sterilised) will not be enrolled into the trial 
3. Major intercurrent illness with life expectancy <2 years 
4. Renal dysfunction (eGFR ≤30 mL/min/1.73m2) 
5. Contraindication to iodinated contrast agents, positron emission 
tomography or computed tomography 
6. Permanent or persistent atrial fibrillation 
7. Previous screening as part of this sub-study 
 
Table 2.2. Inclusion and exclusion criteria for PRE18FFIR-Reproducibility study. 
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2.3 Coronary computed tomography angiography 
 
2.3.1 Scan acquisition 
Computed tomography calcium score and computed tomography coronary 
angiography were performed using 64, 128 or 320-multidetector scanner. Protocols 
were optimised in accordance with manufacturers recommendations and have been 
described previously (Newby, Williams et al. 2012). 
 
2.3.2 Coronary plaque analysis 
Coronary artery calcium score was assessed on non-contrast computed 
tomography using the Agatston scoring method as previously described (Agatston, 
Janowitz et al. 1990). Coronary artery calcium scores were classified into four 
categories (0, 1-99, 100-399 and ≥400 Agatston units).  
 
On coronary computed tomography angiography images, per-segment assessment 
of atherosclerotic plaque was performed using a 15-segment model by 6 trained 
observers, with complex cases classified by consensus (Austen, Edwards et al. 
1975). Normal coronary arteries were defined by the absence of obstructive or non-
obstructive atherosclerotic plaque. Non-obstructive coronary artery disease was 
defined by the presence of atherosclerotic plaque occupying a cross-sectional area 
stenosis of up to 70%. Obstructive coronary artery disease was defined as a 
stenosis of more than 70% in one or more major epicardial vessels or more than 
50% in the left main stem. Observer agreement for the identification of coronary 
artery disease on coronary computed tomography angiography and coronary artery 
calcium score in the SCOT-HEART study has previously been shown to be 
excellent (Williams, Golay et al. 2015).   




For each segment, the presence or absence of four coronary artery plaque 
characteristics was assessed (Figure 2.1), namely positive remodeling, low 
attenuation plaque, spotty calcification and the “napkin ring” sign. Positive 
remodeling was defined as an outer vessel diameter which was 10% greater than 
the mean of the diameter of the segments immediately proximal and distal to the 
plaque (Motoyama, Sarai et al. 2009). Low attenuation plaque was defined as a 
focal central area of plaque with an attenuation density of <30 Hounsfield Units 
(Motoyama, Kondo et al. 2007). Spotty calcification was defined as focal 
calcification within the coronary artery wall which measured <3 mm in maximum 
diameter (Motoyama, Sarai et al. 2009). The ‘napkin ring’ sign was defined as 
previously described as a central area of low attenuation plaque which had a 
peripheral rim of high attenuation (Maurovich-Horvat, Schlett et al. 2012). Observer 
agreement for the assessment of coronary artery plaque characteristics has overall 
been shown to be fair (Mauroles, Hamilton-Craig et al. 2018). 
 
An individual adverse plaque was defined as one with positive remodeling or low 
attenuation plaque, as described previously by Motoyama et al (Motoyama, Sarai et 
al. 2009). Participants with one or more adverse plaques were defined as having 
adverse plaque.  
  







Figure 2.1 Coronary plaque characteristics identified on computed tomography coronary 
angiography.  
 
Coronary atherosclerotic plaque features detected using computed tomography coronary 
angiography including (A) positive remodelling, (B) low attenuation plaque, (C) spotty 
calcification and (D) the ‘napkin ring’ sign. Positive remodelling (A) was defined as an outer 
vessel diameter (large yellow line) which was 10% greater than the mean diameter of the 
segments immediately proximal (small yellow line) and distal to the plaque. Low attenuation 
plaque (B) was defined as a focal central area of plaque with an attenuation density of <30 
Hounsfield Units (yellow arrow). Spotty calcification (C) was defined as focal calcification 
within the coronary artery wall which measured <3 mm in maximum diameter (yellow arrow).  
The ‘napkin ring’ sign (D) was defined as a central area of low attenuation plaque with a 
peripheral rim of high attenuation (yellow arrow).  
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2.4  18F-Fluoride Positron Emission Tomography 
 
2.4.1 Scan acquisition 
All participants underwent coronary 18F-fluoride positron emission tomography 
computed tomography angiography. Participants were administered 50-100 mg oral 
metoprolol if their resting heart rate was >65 beats/min prior to the intravenous 
administration of 250 MBq 18F-fluoride. After 60 min, patients were imaged with a 
hybrid positron emission tomography computed tomography scanner (64-
multidetector Biograph mCT, Siemens Medical Systems, Erlangen, Germany). 
Attenuation correction CT scans were performed in held expiration prior to the 
acquisition of electrocardiographic-gated (ECG-gated) list-mode PET data using a 
single 30-min bed position centred on the heart. Finally, an ECG-gated coronary 
computed tomography angiogram was performed in mid-diastole during held 
expiration. All participants received sublingual glyceryl trinitrate prior to coronary 
computed tomography angiogram.  
 
2.4.2 Scan analysis 
ECG-gated PET images were reconstructed in diastole (50-75% of the R-R interval, 
2 iterations, 21 subsets Siemens Ultra-HD algorithm) and fused with contrast 
enhanced CCTA. Analysis of the CT images was performed using dedicated 
software (Vitrea Advanced, Toshiba Systems) with multi-planar reformatting for 
plaque analysis used as necessary. Coronary arteries with a diameter ≥ 2 mm were 
assessed according to the 18-segment Society of Cardiac Computed Tomography 
model (Leipsic, Abbara et al. 2014). The analysis of coronary 18F-fluoride activity 
has been described previously (Dweck, Chow et al. 2012, Joshi, Vesey et al. 2014). 
The pre-specified coronary 18F-fluoride analysis protocol for the DIAMOND study is 
detailed below. Visual assessment for increased coronary 18F-fluoride activity was 
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performed on both a per-patient level and per-segment basis. For a signal to be co-
localised to the coronary artery, an atherosclerotic plaque had to be present on the 
CCTA and the increased pattern of radiotracer had to arise from the coronary artery 
and follow its course over >5 mm in three dimensions on orthogonal views. Semi-
quantitative PET analysis was undertaken for all proximal coronary segments in 
addition to any atherosclerotic segment with focal 18F-fluoride activity as described 
above. Maximum standardized uptake values (SUVMAX) were measured within 
regions of interest. Correction was made for uptake in a referent proximal coronary 
plaque with no evidence of increased 18F-fluoride activity. To calculate coronary 
target to background ratios (TBR), coronary SUVMAX was divided by these 
background measures providing TBRMAX. Coronary 18F-fluoride activity with TBRMAX 
>1.25 was classified a high-risk plaque. Further exploratory methods of 18F-fluoride 
analysis are discussed in Chapter 4. 
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2.5 Micro-Positron Emission Tomography 
2.5.1 Scan acquisition 
Micro-positron emission tomography was performed at the Pre-clinical Edinburgh 
Imaging facility, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.  Micro-
positron emission tomography acquisitions used 1:5 coincidence mode and 
computed tomography with semi-circular full trajectory, maximum field of view, 480 
projections, 50 kVp, 300 ms and 1:4 binning (Mediso nanoScan PET/CT, Mediso 
Medical Imaging Systems, Hungary) and total activity counts over 30 min were 
measured. PET data were reconstructed using Mediso’s iterative Tera-Tomo 3D 
reconstruction algorithm using 4 iterations, 6 subsets, full detector model, normal 
regularization, spike filter on, voxel size 0·6 mm and 400-600 keV energy window. 
Micro-PET-CT images were analysed on an OsiriX workstation (OsiriX version 
7.5.1, 64-bit, OsiriX Imaging Software, Geneva, Switzerland).  
 
2.5.2 Saturation binding assays to quantify 18F-fluoride binding 
kinetics and selectivity to hydroxyapatite 
Saturation radioligand binding experiments to determine the number of binding sites 
(Bmax) and the dissociation constant (Kd) of 18F-fluoride were undertaken using 
nanocrystalline hydroxyapatite phantoms prior to performing ex vivo imaging. Five-
milligram vials of hydroxyapatite were incubated with 18F-fluoride (110, 230, 470 or 
700 kBq/mL) for 20 min. The supernatant fraction was then removed and 
hydroxyapatite was twice washed in 10 mL 0.9% sodium chloride for 5 min to 
remove unbound 18F-fluoride. Hydroxyapatite phantoms were scanned using high-
resolution micro-PET (1:5 coincidence mode) and computed tomography. Regions 
of interest were drawn around contours of phantoms on the CT and mapped to 
corresponding fused 18F-fluoride positron emission tomographic images. Total 
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binding activity curves and Scatchard plots were generated to calculate Bmax and 
Kd of 18F-fluoride for subsequent ex vivo experiments. To ensure saturation of 
binding sites, 2x Kd was used to evaluate the selectivity of 18F-fluoride for 
hydroxyapatite compared with phantoms of calcium phosphate, calcium oxalate and 
calcium pyrophosphate using the method described above. 
 
 
2.5.3 Cadaveric coronary arteries and 18F-fluoride micro-positron 
emission tomography computed tomography 
Atherosclerotic sections of left coronary arteries were obtained from victims of 
sudden death (both cardiac and non-cardiac) with ethical approval and informed 
relative authorisation from the next of kin (National Health Service South East 
Scotland Research Ethics Committee 14/SS/1090). Tissue was independently 
obtained at time of autopsy by the performing pathologist. Legislation regarding the 
regulation of tissue in victims of sudden death meant that only left main and 
proximal left anterior descending coronary artery specimens could be obtained for 
detailed research analysis. These were obtained with the surrounding myocardium 
and did not necessarily include the specific culprit plaque for patients who had 
suffered acute myocardial infarction. Tissue was immediately fresh frozen at -80 
degrees Celsius. Thawed non-decalcified coronary artery specimens were 
incubated for 20 min in 18F-fluoride 100 kBq/mL solution (10.5 MBq 18F-fluoride in 
99.5 mL 0.9% sodium chloride). Specimens were twice washed in 10 mL 0.9% 
sodium chloride for 5 min to remove unbound 18F-fluoride. Specimens were 
scanned using the micro-PET-CT protocol described above. Regions of interest 
were drawn in background regions, myocardium, non-calcified and calcified 
segments in coronary artery plaques using micro-CT images and the maximum 18F-
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fluoride activity in each region was recorded on co-registered micro-PET images. 
Maximum activity recorded in a region equal to or above 100 kBq/mL was defined 
as high 18F-fluoride intensity (>5x myocardium activity), whereas values with a 
maximum activity of less than 100 kBq/mL was defined as low intensity. After whole 
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2.6 Sample preparation and histological examination 
Formalin-fixed coronary arteries were sectioned into 2-4 mm slices by a vascular 
biology/pathology lab. The resulting slices were embedded in paraffin which 
provided 1-8 tissue cross-sections analysed per sample depending on the size of 
tissue initially isolated. Paraffin sections (4 µm) were used for histology and 
immunohistochemistry as described below. In all cases, images were generated 
using an Aperio Slide Scanner using ImageScope software (Leica Biosystems, 
Germany). Histological examination was performed using haematoxylin and eosin 
staining for overall pathology, followed by Movat’s pentachrome and trichome 
staining to differentiate fibrosis and elastic fibres. Von Kossa and Alizarin-red 
staining were used to assess for the presence of calcification.  
 
2.6.1 Fluorescein-bisphosphonate immunofluorescence of 
cadaveric coronary arteries 
To determine whether the binding of 18F-fluoride in regions of Von Kossa and 
Alizarin-red S was specific for hydroxyapatite deposition, categorisation of these 
regions using a fluorescein-bisphosphonate probe was undertaken. Fluorescein-
bisphosphonate is a highly sensitive and specific probe for identifying regions of 
microcrystalline hydroxyapatite. Incubation and binding in tissue has previously 
been described in detail (Sim, Rashdan et al. 2018). Briefly, sections were de-
waxed in xylene and incubated with Fluorescein-bisphosphonate (1 µM) for 2 h, 
washed in water (2x) followed by incubation with 2% Alizarin Red S (250 µL) for 5 
min. Sections were washed in water (3x) and subsequently incubated with 4’, 6-
diamidino-2-phenylindole (500 nM) for 5 min. Sections were washed with water (1x) 
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and then mounted using ProLong Gold Antifade. Fluorescence signal was detected 
under a Leica DMRB fluorescence microscope. 
 
2.6.2 Raman Spectroscopy 
Coronary artery specimens were embedded in paraffin wax, sectioned and 
subsequently placed on calcium fluoride slides. Once dried, the slides were placed 
in xylene for 15 min followed by dehydration in ethanol. As soon as they were 
dehydrated, the sections were ready for imaging and did not require additional 
processing. Alizarin Red S staining was used to discriminate regions of calcification. 
Sections from tissue presenting no calcification, calcification with low fluoride 
intensity (<100 kBq/mL), and no calcification with high fluoride intensity (≥100 
kBq/mL) were selected in order to address whether there were any differences in 
the apatite crystal or molecular substitution in the structure. Raman imaging was 
carried out using an InVia Renishaw Microscope with a 785-nm laser excitation 
source which was used to excite the sample through a 50, N.A. 0.75 objective. The 
total data acquisition was performed during 60 s for spectra with a 100% laser 
power using the WiRE software (Renishaw, Gloucestershire, United Kingdom). All of 
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2.6.3 Immunohistochemical categorisation of osteogenic 
markers  
Immunohistochemistry was completed using osteopontin (OPN) (Sigma-Aldrich 
Catalog No: 07264, 1:100 dilution), runt-related transcription factor 2 (Runx2) 
(Abcam Catalog No: Ab76956, 1:50 dilution), transforming growth factor beta 1 
(TGFβ1) (Abcam Catalog No: Ab64715, 1:25 dilution), wingless/integrated 3a 
(Wnt3A) (Abcam Catalog No: Ab28472, 1:200 dilution) and Caspase 3 (Cell 
Signalling No: 9664, 1:100 dilution). Staining was performed via automated staining 
with a Leica Bond Rx system using Bond Epitope Retrieval Solution 1 (pH=6, 
Catalog No: AR9961) and Bond Polymer Refine Red Detection (Catalog No: 
DS9390). The omission of the primary antibody served as negative controls. Blinded 
qualitative categorization of staining intensity was performed by a pathologist using 
a 4-point classification: 0, no notable staining, 1, <20% of plaque or relevant cells 
are weakly positive, 2, <50% of plaque or some relevant cells are strongly positively, 
3, 50-100% of plaque or all relevant cells are strongly positive. For comparison of 
immunohistochemical analysis with 18F-fluoride activity, plaques with a 
classification 3 were defined as ‘positive’ and classification <3 was defined as 
‘negative’ for osteopontin, runt-related transcription factor 2, transforming growth 
factor beta 1 and wingless/integrated 3a. Plaques with classification 2 were defined 
as ‘positive’ and classification <2 were defined as ‘negative’ for Caspase 3.  
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2.7 DIAMOND Trial study procedures 
2.7.1 DIAMOND trial allocation and randomisation 
Patients were randomly assigned 1:1 to either ticagrelor 90 mg twice daily or 
matched placebo tablets (AstraZeneca, UK). Randomization was performed using a 
web-based system that ensured allocation concealment, with treatment allocation 
incorporating minimization based on age (<65, ≥65 years old), sex, baseline plasma 
high-sensitivity troponin I concentration (≤5.1, >5.1 ng/L) and the presence or 
absence of coronary 18F-fluoride uptake. A random element was included with a 1 
in 10 chance of the determined treatment allocation being switched to the other 
treatment arm. 
 
2.7.2 High-sensitivity cardiac troponin I 
Plasma high-sensitivity cardiac troponin I concentrations were measured using the 
ARCHITECTSTAT assay (Abbott Laboratories, Abbott Park, Illinois). The limit of 
detection is 1.0 ng/L with an inter-assay co-efficient of variation <10% at 4.7 ng/L (9) 
(Shah, Anand et al. 2015). The upper reference limit (99th centile) based on 4,590 
samples from healthy men and women is 34 ng/L for men and 16 ng/L for women 
(10) (Shah, Griffiths et al. 2015). Samples were collected at baseline, 30 days and 
3, 6, 9 and 12 months. A value of 0.5 ng/L was imputed for troponin values below 
the limit of detection.  
 
2.7.3 Platelet function analysis 
Platelet and monocyte activation in response to adenosine diphosphate (ADP) was 
determined by flow cytometry, as described previously (Harding, Din et al. 2007). 
These analyses were performed by a single technician blinded to study allocation 
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with the results of these investigations withheld from the study team until after trial 
database lock. Briefly, peripheral venous blood was obtained from all participants at 
the baseline and 1-month visits. Blood was drawn by clean venepuncture of a large 
antecubital vein using a 19-gauge needle, and care was taken to ensure a smooth 
blood draw without venous stasis. Blood was collected into tubes containing the 
direct thrombin inhibitor, D-Phenylalanine-L-prolyl-L-arginine chloromethyl ketone 
(PPACK, Cambridge Biosciences). Tubes were gently inverted to ensure mixing of 
whole blood with anticoagulant.  
 
Immunolabelling and flow cytometry were performed in whole blood to avoid 
centrifugation and washing steps which can lead to artefactual platelet activation. All 
chemicals were obtained from BD Biosciences. (Oxford, UK). Aliquots of whole 
blood (50 μL) were incubated with anti-CD14-Allophycocyanin (APC), anti-CD42a-
fluorescein isothiocyanate (FITC), anti-CD11b-PE-Cyanine(Cy)7, anti-CD62p-
Phycoerythrin (PE) and isotype matched controls for 20 min at room temperature in 
Eppendorfs with and without ADP (at final concentration of 20 µmol/L). Thereafter, 
samples were fixed with 1% paraformaldehyde (p-selectin) or FACS-Lyse (platelet-
monocyte aggregates). All samples were analysed within 24 hours using a 
FACSCalibur flow cytometer (Becton-Dickinson). Data analysis was performed 
using FlowJo v10 (Treestar, Oregon, USA). A medium flow setting was used to 
minimize leukocyte-platelet coincident events. Monocytes were identified based on 
their forward and side scatter characteristics and then by triggering on FL-4 to 
identify CD14-PE positive monocytes and exclude large granular lymphocytes. For 
each measurement a minimum of 2,500 monocytes were collected. Platelet-
monocyte aggregates were defined as monocytes positive for CD42a. All results are 
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expressed as geometric mean of fluorescence. P-selectin expression was defined 
as CD42a-FITC positive platelets that were also positive for CD62p-PE. 
 
2.7.4 Study Endpoints 
The pre-specified primary endpoint was high-sensitivity cardiac troponin I 
concentrations at 30 days in patients with increased coronary 18F-fluoride activity. 
Secondary endpoints were plasma high-sensitivity cardiac troponin I concentration 
at 30 days in patients without coronary 18F-fluoride activity, and plasma high-
sensitivity troponin I concentration over 1 year. Adverse events were recorded in all 
patients who received a single dose of study medication and included bleeding 
events categorized according to PLATO criteria as major life-threatening, other 
major, minor or minimal bleeding (Wallentin, Becker et al. 2009). 
 
2.7.5 Sample Size 
In patients with increased coronary 18F-fluoride uptake, we previously reported that 
mean troponin concentrations were more than double those in patients without 
increased coronary 18F-fluoride uptake (7.9 [SD 9.3] vs. 3.1 [SD 1.9] ng/L, p=0.047) 
(Joshi, Vesey et al. 2014). It was estimated that ticagrelor would reduce troponin 
concentration by half. Forty-eight patients per treatment arm were required to 
achieve 80% power at two-sided p<0.05. After allowing for 15% dropout, we 
estimated that fifty-five patients would be required per treatment arm. Previous 
studies had found that 45% of patients with advanced but stable coronary artery 
disease demonstrated increased coronary 18F-fluoride uptake, so a total sample 
size of 250 patients was estimated to be required to identify 110 patients with 
increased coronary 18F-fluoride activity. Termination of further recruitment could be 
authorized by the trial steering committee once a per-protocol population of 110 
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patients with increased coronary 18F-fluoride activity had been randomized and 
completed the primary endpoint at 30 days. 
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2.8 Ethical considerations 
All participants for whom data has been included in the results chapters provided 
written informed consent prior to any involvement in the respective study. Each 
study was approved by the local institutional review board, the Scottish Research 
Ethics Committee and in appropriate cases the Medicines and Healthcare products 
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2.9 Statistical analysis 
Full details of the statistical methods are provided in the respective results chapters. 
Pre-specified statistical analysis undertaken as part of a controlled trial of 
investigational medicinal product is included in this thesis. As stipulated by 
regulations governing clinical trial of investigational medicinal products, primary 
outcome statistical analyses were designed and performed by a clinical trial 
statistician at the Edinburgh Clinical Trial Units, Edinburgh, United Kingdom.  Post-
hoc analyses were performed by clinical investigators independent of a clinical trial 
statistician. 
  









Adverse coronary artery plaque characteristics 
in patients with coronary artery disease 
A SCOT-HEART sub-study 
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McCall JR, Roditi G, van Beek EJR, Newby DE, Nicol ED. 
Coronary artery plaque characteristics associated with adverse outcomes in 
the SCOT-HEART study. 









Unlike most non-invasive imaging modalities, coronary computed tomography 
angiography (CCTA) can characterise subtypes of atherosclerotic plaque. The 
objective of this study was to investigate the prognostic implications of adverse 
coronary plaque characteristics in patients with suspected coronary artery disease. 
 
Methods 
In this post-hoc analysis of the SCOT-HEART trial, the presence of adverse plaque 
(positive remodelling or low attenuation plaque), obstructive disease and coronary 
artery calcification within 15 coronary segments was assessed on CCTA of 1,769 
patients who were followed up for 5 years.   
 
Results 
Among study participants (mean age 58±10 years; 56% male), 608 (34%) patients 
had one or more adverse plaque features. Coronary heart disease death or non-
fatal myocardial infarction was three-times more frequent in patients with adverse 
plaque (n=25/608 (4.1%) versus n=16/1161 (1.4%), p<0.001; hazard ratio 3.01 
(95% confidence interval 1.61 to 5.63); p=0.001) and was twice as frequent in those 
with obstructive disease (n=22/452 (4.9%) versus n=16/671 (2.4%), p=0.024; 
hazard ratio 1.99 (95% confidence interval 1.05 to 3.79); p=0.036). Patients with 
both obstructive disease and adverse plaque had the highest event rate with a 10-
fold increase in coronary heart disease death or non-fatal myocardial infarction 
compared to patients with normal coronary arteries (hazard ratio 11.50 (95% 
confidence interval 3.39 to 39.04); p<0.001). However, these associations were not 
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independent of coronary artery calcium score, a surrogate measure of coronary 
plaque burden.  
 
Conclusion  
Adverse coronary plaque characteristics and overall coronary plaque burden confer 
an increased risk of coronary heart disease death or non-fatal myocardial infarction. 
 
  




The investigation of patients with suspected coronary artery disease has previously 
focused on functional assessments that attempt to identify the presence of 
myocardial ischaemia as a downstream surrogate marker of proximal coronary 
artery stenoses. In contrast, non-invasive imaging with coronary computed 
tomography angiography (CCTA) has the ability to provide precise structural 
information of the coronary artery wall, and can assess for the presence and 
constituents of atherosclerotic plaque even in the absence of flow limiting disease.  
 
Pathological studies in patients with myocardial infarction have identified an 
association between plaque rupture and adverse plaque characteristics that include 
positive remodelling, a large necrotic core, microcalcification and a thin fibrous cap 
(Virmani, Burke et al, 2003). Correlates of these features have been described for 
non-invasive imaging with CCTA and include the presence of positive remodelling, 
low attenuation plaque, spotty calcification and the ‘napkin ring’ sign (Motoyama, Ito 
et al. 2015). These plaque characteristics are associated with an increased risk of 
subsequent acute coronary syndromes (Motoyma, Ito et al. 2015, Motoyama, Sarai 
et al, 2009, Thomsen, Abdulla et al, 2016). Recent data have suggested that 
positive remodelling and low attenuation plaque in particular provide the most useful 
prognostic information (Motoyama, Ito et al. 2015, Conte, Annoni et al. 2017), 
although it remains unclear whether this is of incremental value to traditional 
cardiovascular risk factors or coronary plaque burden. 
 
In the Scottish COmputed Tomography of the HEART (SCOT-HEART) prospective 
multi-centre randomised controlled trial of patients with stable chest pain, the 
addition of CCTA to routine care led to improved diagnostic certainty and patient 
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care that ultimately reduced the rate of coronary heart disease death or non-fatal 
myocardial infarction (SCOT-HEART investigators. 2015, SCOT-HEART 
investigators. 2018, Williams, Hunter et al, 2016). These benefits were largely 
attributable to subsequent changes in patient management and treatment which had 
been guided by the presence of obstructive or non-obstructive coronary artery 
disease as determined by CCTA. However, it may be that further risk stratification 
and targeted intensification of therapy in patients with adverse plaque 
characteristics could achieve additional benefits which go beyond the presence of 
obstructive or non-obstructive coronary artery disease. 
 
In this secondary analysis of the SCOT-HEART trial, we aimed to determine the 
extent of adverse coronary artery plaque characteristics on CCTA and their 
association with subsequent clinical outcomes. If confirmed, the identification of 
these coronary artery plaque characteristics may help risk stratification and guide 










3.3.1 Study design 
The SCOT-HEART trial was a multicentre randomised controlled trial of CCTA in 
out-patients with suspected angina pectoris due to coronary artery disease (Newby, 
Williams et al. 2012). The primary results have been reported previously (SCOT-
HEART investigators. 2015, SCOT-HEART investigators. 2018, Williams, Hunter et 
al, 2016). This is a secondary post-hoc analysis of the SCOT-HEART study.  
 
3.3.2 Participants 
In brief, 4,146 patients who attended the cardiology outpatient clinic were 
randomised to standard care alone or standard care plus CCTA, and were followed 
up for symptoms, management and outcomes. Of the 2,073 participants who were 
randomised to the intervention arm, 1,778 underwent CCTA. CCTA and non-
contrast imaging for calcium scoring was performed as described previously (SCOT-
HEART investigators 2015). Cardiovascular risk was assessed using the ASSIGN 
score. This score has been validated for the Scottish population and, in addition to 
traditional cardiovascular risk factors, incorporates social deprivation and family 
history of cardiovascular disease (Woodward, Brindle et al. 2007). 
 
3.3.3 Clinical Management and Outcomes 
Outcome information including invasive coronary angiography and coronary 
revascularisation (percutaneous coronary intervention or coronary artery bypass 
graft surgery) was obtained from the electronic Data Research and Innovation 
Service (eDRIS) of the National Health Service (NHS) Scotland, and where 
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appropriate, confirmed by review of the patient health records. Categorisation of 
outcomes was performed blinded to the CCTA or other study data. The primary 
clinical endpoint for this study was the occurrence of coronary heart disease death 
or non-fatal myocardial infarction. Outcome data were updated in March 2018 
(SCOT-HEART investigators. 2018).  
 
3.3.4 Statistical analysis 
Statistical analysis was performed using R version 3.5.0 (R Foundation for 
Statistical Computing, Vienna, Austria). Normally distributed quantitative variables 
are presented with mean and standard deviation. Non-normally distributed data are 
presented with median and interquartile range. Statistical significance was assessed 
using Pearson’s Chi-square test, Fisher’s exact test, Student’s t-test, Mann-Whitney 
U test, Kruskal-Wallis test or ANOVA as appropriate. Outcome data investigating 
whether the presence of adverse plaque characteristics predicted coronary heart 
disease death or non-fatal myocardial infarction in patients with non-obstructive 
disease were analysed using Cox proportional hazards regression and presented 
graphically using cumulative incidence plots. A time-to-event analysis was 
performed using coronary heart disease death or non-fatal myocardial infarction as 
the endpoint, with the primary independent variable being the presence or absence 
of adverse plaque on CT. Deaths not classified as coronary heart disease deaths 
were censored for both the Cox regression analysis and the cumulative incidence 
plots. Hazard ratios (HR) and 95% confidence intervals (CI) are presented. 
Coronary artery calcium score and cardiovascular risk score were log transformed 
for analysis (log base 2 of 1 plus the parameter). Variables were included in 
multivariable analysis if they were statistically significant on univariable analysis. 
The assumption of proportional hazards was checked using SPSS. A statistically 
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significant difference was defined as a two-sided P value <0.05.  
  




Of the 1,778 individuals who underwent a CCTA, 1,769 participants had images that 
were available and of suitable quality for analysis (Figure 3.1). Patients had a mean 
age of 58±10 years and 56% were male with a range of cardiovascular risk factors 
and symptoms (Table 3.1). Of these patients, 37% (n=646) had normal coronary 
arteries, 38% (n=671) had non-obstructive coronary artery disease, and 26% 
(n=452) had obstructive coronary artery disease. Coronary heart disease death or 
non-fatal myocardial infarction occurred in 41 patients (2.3%) over a median of 4.7 
years of follow up (interquartile range (IQR) 4.0 to 5.7 years).  
  





Figure 3.1 CONSORT diagram of SCOT-HEART sub-study. 
(Williams, Moss et al. 2019)  
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Male 997 (56%) 545 (47%) 452 (74%) <0.001 
Age 57.6 ± 9.5 55.9 ± 9.8 60.8 ± 7.8 <0.001 
Body mass index (kg/m2) 29.6 ± 5.5 30.0 ± 5.8 28.8 ± 4.8 <0.001 
Atrial fibrillation 34 (1.9%) 20 (1.7%) 14 (2.3%) 0.399 
Smoking status Current 
smoker 
330 (19%) 208 (18%) 122 (20%) <0.001 
Ex-smoker 593 (34%) 357 (31%) 236 (39%) 
Non-smoker 845 (48%) 595 (51%) 250 (41%) 
Hypertension 608 (35%) 373 (32%) 235 (39%) 0.005 
Diabetes 196 (11%) 128 (11%) 68 (11%) 0.919 
Family history 765 (43%) 507 (44%) 258 (42%) 0.552 





654 (37%) 347 (30%) 307 (51%) <0.001 
Atypical 
angina 
432 (24%) 293 (25%) 139 (23%) 
Non-anginal  683 (39%) 521 (45%) 162 (27%) 
ASSIGN 17.9 ± 11.0 16.1 ± 10.9 21.4 ± 10.6 <0.001 
Coronary artery calcium score 
(Agatston units) 
21 [0 - 230] 0 [0 - 34] 281 [89 - 775] <0.001 
 
Table 3.1 Characteristics of SCOT-HEART sub-study participants according to presence or 
absence of adverse plaque. 
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3.4.1 Plaque Characteristics 
CCTA characteristics of atherosclerotic plaque were assessed in 26,535 segments 
in 1,769 patients. This demonstrated positive remodelling in 1,163 segments (4.4%), 
low attenuation plaque in 213 segments (0.8%), spotty calcification in 472 segments 
(1.8%), and the napkin ring sign in 78 segments (0.3%). All plaque characteristics 
were more common in the proximal coronary artery segments, in particular the 
proximal left anterior descending coronary artery (Table 3.2, Table 3.3, Table 3.4, 
Table 3.5). Adverse plaques were present in 608 (34%) patients. Patients with 
adverse plaques were older, had a higher body-mass index, and were more likely to 
be male. They were also more likely to have a previous history of coronary heart 
disease or hypertension, to be a smoker, or to have typical angina (Table 3.1). 
Patients with adverse plaques had a higher cardiovascular risk score and higher 
calcium score. Coronary heart disease death or non-fatal myocardial infarction was 
three-times more frequent in patients with adverse plaque compared to those 
without (n=25/608 (4.1%) versus n=16/1161 (1.4%), p<0.001; hazard ratio (HR) 
3.01, 95% confidence interval (CI) 1.61 to 5.63; p=0.001; Figure 3.2). Most events 
occurred in patients with adverse plaques in the proximal segments rather than the 
mid and distal segments (n=23/489 (4.7%) versus n=2/119 (1.7%); p=0.197). 
Adverse plaque features appeared to have a greater prognostic value in women and 
those under the age of 60 years, with a body-mass index of greater than 30 kg/m2 or 
with a lower cardiovascular risk score, but these differences were not statistically 
significant (Table 3.6). The presence of one or more segments of spotty calcification 
or the napkin ring sign was not associated with a difference in coronary heart 
disease death or non-fatal myocardial infarction on per patient assessment (Table 
3.7).  








Figure 3.2 Coronary heart disease death or non-fatal myocardial infarction across the total 
cohort in patients with and without adverse plaque. 
 
The effect of the presence of one or more adverse plaques (defined by the presence of low 
attenuation or positive remodelling) on subsequent coronary heart disease death or non-fatal 
myocardial infarction. Cumulative incidence plot for patients with and without adverse plaque 
features. 
(Williams, Moss et al. 2019) 
 
  
























N % N % N % N % N % 
Left Main 
Stem 
60 3.4 59 3.3 12 0.7 13 0.7 5 0.3 
Prox LAD 388 21.9 385 21.8 78 4.4 117 6.6 33 1.9 
Mid LAD 234 13.2 224 12.7 50 2.8 84 4.7 13 0.7 
Dist LAD 21 1.2 19 1.1 5 0.3 14 0.8 1 0.1 
D1 19 1.1 19 1.1 1 0.1 20 1.1 1 0.1 
D2 5 0.3 5 0.3 0 0 8 0.5 0 0 
Prox Cx 109 6.2 106 6.0 18 1.0 39 2.2 6 0.3 
OM1 27 1.5 26 1.5 4 0.2 13 0.7 1 0.1 
AV Cx 11 0.6 11 0.6 1 0.1 4 0.2 1 0.1 
OM 2 1 0.1 1 0.1 0 0 2 0.1 0 0 
Mid Dist Cx 5 0.3 5 0.3 0 0 1 0.1 0 0 
Prox RCA 116 6.6 112 6.3 20 1.1 56 3.2 6 0.3 
Mid RCA 132 7.5 130 7.3 19 1.1 63 3.6 10 0.6 
Distal RCA 51 2.9 51 2.9 4 0.2 25 1.4 1 0.1 
RCA/CX PD 10 0.6 10 0.6 1 0.1 13 0.7 0 0 
 
Table 3.2 Frequency of plaque characteristics in each of the 15 coronary artery segments. 
 
* Positive remodelling or low attenuation plaque.  
Prox, proximal; RCA, right coronary artery; Cx, circumflex; PD, posterior descending; LM, left 
main; LAD, left anterior descending; D1, first diagonal; D2, second diagonal; OM1, obtuse 
marginal; AV, atrioventricular.  






Patients with non-obstructive 
disease 
N = 671 
Patients with obstructive 
disease 
N = 452 
N % N % 
Left Main Stem 19 2.8 41 9.1 
Prox LAD 170 25.3 218 48.2 
Mid LAD 81 12.1 153 33.8 
Dist LAD 4 0.6 17 3.8 
D1 4 0.6 15 3.3 
D2 1 0.1 4 0.9 
Prox Cx 28 4.2 81 17.9 
OM1 6 0.9 21 4.6 
AV Cx 2 0.3 9 2.0 
OM 2 0 0 1 0.2 
Mid Dist Cx 2 0.3 3 0.7 
Prox RCA 34 5.1 82 18.1 
Mid RCA 30 4.5 102 22.6 
Distal RCA 9 1.3 42 9.3 
RCA/CX PD 2 0.3 8 1.8 
  
Table 3.3 Frequency of adverse plaque in patients with non-obstructive and obstructive 
coronary artery disease in each of the 15 coronary artery segments. 
 
Prox, proximal; RCA, right coronary artery; Cx, circumflex; PD, posterior descending; LM, left 
main; LAD, left anterior descending; D1, first diagonal; D2, second diagonal; OM1, obtuse 
marginal; AV, atrioventricular. 
  












Left Main Stem 11 0.6 
Prox LAD 75 4.2 
Mid LAD 40 2.3 
Dist LAD 3 0.2 
D1 1 0.1 
D2 0 0.0 
Prox Cx 15 0.8 
OM1 3 0.2 
AV Cx 1 0.1 
OM 2 0 0 
Mid Dist Cx 0 0 
Prox RCA 16 0.9 
Mid RCA 17 1.0 
Distal RCA 4 0.2 
RCA/CX PD 1 0.1 
 
Table 3.4 Presence of positive remodelling and low attenuation plaque in different coronary 
artery segments. 
 
Prox, proximal; RCA, right coronary artery; Cx, circumflex; PD, posterior descending; LM, left 
main; LAD, left anterior descending; D1, first diagonal; D2, second diagonal; OM1, obtuse 
marginal; AV, atrioventricular.  
  






Fatal or non-fatal myocardial infarction  
n (%) Hazard ratio 
(95% confidence intervals) 
Positive 
remodeling 
Present 602 (34%) 25 (4.1%) 3.05 (1.63, 5.71) 




Present 168 (10%) 6 (3.6%) 1.60 (0.67, 3.80) 
p=0.289 Absent 1601 (91%) 35 (2.2%) 
Spotty 
calcification 
Present 299 (17%) 6 (2.0%) 0.83 (0.35, 1.97) 
p=0.669 Absent 1470 (83%) 35 (2.4%) 
Napkin ring Present 76 (4.3%) 2 (2.6%) 1.16 (0.28. 4.79) 
p=0.841 
 
Table 3.5 Per patient assessment of plaque characteristics and subsequent fatal or non-fatal 
myocardial infarction across the total population. 
  





 Age < 60 years Age ≥ 60 years 
Adverse plaque 
features on CCTA 
3.65 (1.54, 8.65) 
p=0.003 
2.44 (0.97, 6.13) 
p=0.057 
 
 Male Female 
Adverse plaque 
features on CCTA 
2.44 (1.14, 5.22) 
p=0.021 
3.27 (1.00, 10.71) 
p=0.051 
 
 BMI < 30 kg/m2 BMI ≥ 30 kg/m2 
Adverse plaque 
features on CCTA 
1.76 (0.83, 3.74) 
p=0.143 
9.06 (2.53, 32.50) 
p=0.001 
 
 Low cardiovascular risk 
score* 
High cardiovascular risk 
score* 
Adverse plaque 
features on CCTA 
3.12 (1.35, 7.21) 
p=0.008 
2.64 (1.00, 6.94) 
p=0.050 
 
Table 3.6 Univariable analysis for fatal or non-fatal myocardial infarction in patients with 
adverse plaque features on CCTA stratified by age, sex and body mass index.  
 
* High cardiovascular risk score defined as an ASSIGN score greater than or equal to 20.  
CCTA – Coronary Computed Tomography angiography; BMI – Body-mass index 
  

































179 (67%) <0.001 74 (66%) 273 (80%) 0.002 
Age 59.0 ± 
8.7 
59.7 ± 8.2 0.282 61.4 ± 8.7  61.6 ± 7.4 0.823 




28.4 ± 4.9 <0.001 29.9 ± 5.3 29.2 ± 4.6 0.210 















101 (38%) 48 (43%) 149 (44%) 
Hypertension 157 
(39%) 
86 (32%) 0.070 53 (48%) 149 (45%) 0.565 
Diabetes 56 (14%) 31 (12%) 0.379 20 (18%) 37 (11%) 0.054 
Family history 177 
(44%) 
111 (41%) 0.229 43 (38%) 147 (43%) 0.553 
Previous CHD 32 
(7.9%) 

















105 (39%) 23 (21%) 57 (17%) 


















Table 3.7 Characteristics of study participants with non-obstructive disease and obstructive 
disease with and without adverse plaque. 
 
N (%), mean ± standard deviation or median [interquartile range] 
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3.4.2 Coronary Artery Stenosis 
Patients with obstructive coronary artery disease were twice as likely to suffer 
coronary heart disease death or non-fatal myocardial infarction (n=22/452 (4.9%)) 
than patients with non-obstructive disease (n=16/671 (2.4%), Chi-squared p=0.024; 
HR 1.99, 95% CI 1.05 to 3.79; p=0.036). Patients with obstructive coronary artery 
disease were also more likely to undergo coronary revascularisation (n=215/452 
(48%) versus n=35/671 (5%); p<0.001) and be prescribed preventative medications 
at 6 weeks (n=427/452 (95%) versus n=538/671 (80%); p<0.001) than patients with 
non-obstructive disease. 
 
Adverse plaques were observed in 40% of patients with non-obstructive disease 
(n=268/671) and three quarters of patients with obstructive coronary artery disease 
(n=340/452). Patients with both obstructive disease and adverse plaque had the 
worst outcome during follow-up (Figure 3.3). Although the presence of adverse 
plaque is suggestive of a worse prognosis at 2 years in patients with non-obstructive 
disease, at 5 years the outcomes of patients with non-obstructive disease and 
obstructive disease without adverse plaque were similar (Figure 3.3).   Indeed, 
compared to patients with normal coronary arteries, patients with obstructive 
disease and adverse plaque had a greater than 10-fold increase in the rate of 










Figure 3.3 Coronary heart disease death and non-fatal myocardial infarction in patients with 
different stenosis severity and coronary artery plaque characteristics. 
 
Cumulative incidence plot for coronary heart disease death and non-fatal myocardial 
infarction in patients (top panel) with normal coronary arteries, non-obstructive disease and 
obstructive disease and (bottom panel) normal coronary arteries, non obstructive disease 
with and without adverse plaque characteristics and obstructive disease with and without 
adverse plaque features. AP, adverse plaque. 
(Williams, Moss et al. 2019) 
  




  Univariable analysis Multivariate analysis # 
Non-obstructive disease  
without adverse plaque * 
4.95 (1.34, 18.29) 
p=0.016 
2.79 (0.64, 12.18) 
p=0.172 
Non-obstructive disease  
with adverse plaque * 
5.81 (1.50, 22.46) 
p=0.011 
2.67 (0.53, 13.43) 
p=0.234 
Obstructive disease  
without adverse plaque * 
7.73 (1.73, 34.54) 
p=0.007 
3.20 (0.52, 19.61) 
p=0.208 
Obstructive disease  
with adverse plaque * 
11.50 (3.39, 39.04) 
p<0.001 
4.10 (0.76, 22.0) 
p=0.100 
Coronary Artery Calcium 
Score ** 
1.23 (1.13, 1.35) 
p <0.001 
1.12 (0.98, 1.28) 
p=0.107 
Cardiovascular Risk score $ 1.65 (1.13, 2.41) 
p=0.01 
1.10 (0.71, 1.70) 
p=0.673 
 
Table 3.8 Univariable and multivariable analysis for coronary heart disease death or non-
fatal myocardial infarction compared to patients with normal coronary arteries. 
 
Hazard ratios and 95% confidence intervals.  
* Adverse plaque defined as the presence of positive remodelling or low attenuation plaque.  
** Per doubling of coronary artery calcium score 
$ ASSIGN score, per doubling of cardiovascular risk score 
# Log rank statistic 27.29, p<0.001; Harrell’s C statistic 0.728 (standard error 0.046) 
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3.4.3 Coronary Artery Calcium Score 
Patients with a coronary artery calcium score ≥1000 AU had a thirteen-fold increase 
in coronary heart disease death or non-fatal myocardial infarction compared to 
patients without coronary artery calcification. There was a clear gradation of risk 
with calcification associated with increasing risk (Figure 3.4). Patients with 
obstructive coronary artery disease had an eight-fold higher coronary artery calcium 
score than patients with non-obstructive coronary artery disease (435 [IQR 138 to 
1127] versus 54 [IQR 12 to 190] Agatston units (AU); p<0.001). In multivariable 
analysis, the presence of both adverse plaque and obstructive plaque were 
dependent on coronary artery calcium score as a predictor of coronary heart 
disease death or non-fatal myocardial infarction (Table 3.9).  
 
  











Figure 3.4 Coronary heart disease death and non-fatal myocardial infarction in patients with 
different severity of coronary artery calcification. 
 
Cumulative incidence plots of the effect of different severity of coronary artery calcification 
on subsequent coronary heart disease death or non-fatal myocardial infarction. 
(Williams, Moss et al. 2019) 
 
  




  Univariable analysis Multivariable analysis # 
Adverse plaque * 3.01 (1.61, 5.63) 
p=0.001 
1.18 (0.55, 2.52) 
p=0.671 
Coronary Artery Calcium 
Score ** 
1.23 (1.13, 1.35) 
p <0.001 
1.17 (1.04, 1.33) 
p=0.011 
Obstructive coronary artery 
disease 
3.35 (1.81, 6.19) 
p <0.001 
1.36 (0.63, 2.93) 
p=0.439 
Cardiovascular Risk score $ 1.65 (1.13, 2.41) 
p=0.01 
1.14 (0.74, 1.75) 
0.563 
 
Table 3.9 Univariable and multivariable analysis for coronary heart disease death or non-
fatal myocardial infarction across the total population. 
 
Hazard ratios and 95% confidence intervals.  
* Compared to patients without adverse plaque in the total population.  Adverse plaque 
defined as the presence of positive remodelling or low attenuation plaque.  
** Per doubling of coronary artery calcium score 
$ ASSIGN score, per doubling of cardiovascular risk score 
# Log rank statistic 26.74 (p<0.001), Harrell’s C statistic 0.723 (standard error 0.046) 
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3.5 Discussion  
In a large multicentre prospective study of CCTA, we have demonstrated that 
adverse coronary plaque characteristics are associated with a tripling of the risk of 
coronary heart disease death or non-fatal myocardial infarction. The presence of 
obstructive disease was also a major predictor of risk, with the combination of 
adverse plaque with obstructive disease appearing to confer the greatest risk. 
However, overall the only independent predictor of risk was the coronary artery 
calcium score, a measure of overall plaque burden. These results suggest that 
whilst plaque composition and its haemodynamic consequences are associated with 
future myocardial infarction, the predominant factor governing patient outcomes is 
the burden of coronary atherosclerosis.  
 
Adverse coronary plaque is associated with subsequent cardiovascular events in 
patients with stable coronary artery disease (Motoyama, Ito et al. 2015, Thomsen, 
Abdulla et al. 2016, Conte, Annoni et al. 2017, Motoyama, Kondo et al, 2007). In 
keeping with previous work (Motoyama, Ito et al. 2015, Motoyama, Sarai et al. 2009, 
Motoyama, Kondo et al. 2007, Scheltt, Maurovich-Horvat et al. 2013, Narula, 
Nakano et al. 2013), we found that the plaque characteristics which were the most 
helpful in predicting future coronary events were positive remodelling and low 
attenuation plaque. These CT characteristics are markers of pathological 
vulnerability (Obaid, Calvert et al. 2017), and are potential culprit lesions for 
subsequent acute coronary events. Motoyama et al identified that the presence of 
adverse plaque was predictive of acute coronary syndrome at 4 years in a study of 
3,158 patients with 88 events (2.8%) (Motoyama, Ito et al. 2015). In the Prospective 
Multicentre Imaging Study for Evaluation of Chest Pain (PROMISE) trial, adverse 
plaques were present in 15% of patients and were associated with an increased risk 
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of the combined endpoint of death, myocardial infarction or unstable angina 
(Ferencik, Mayrhofer et al. 2018). However, overall adverse plaques have a low 
positive predictive value for the identification of subsequent coronary events. This is 
in keeping with the known theory of continuous plaque remodelling where adverse 
plaques may stabilise with or without sub-clinical rupture, rather than cause a 
clinically apparent acute coronary syndrome.  
 
Acute myocardial infarction occurs when there is rupture or erosion of a coronary 
atherosclerotic plaque and there is associated thrombus formation causing vessel 
occlusion (Davies. 2000). The presence of pre-existing flow limitation due to 
obstructive atheroma is not a pre-requisite for this process. Indeed, it should be 
remembered that the majority (~80%) of myocardial infarctions are attributable to 
non-obstructive coronary plaques on antecedent angiography (Maddox, 
Stanislawski et al. 2014). Moreover, the risk of future myocardial infarction is similar 
whether the coronary plaque causes 50-85% or >85% luminal stenosis (Van Lierde, 
De Geest et al. 1990). A nested-case control study of patients without known 
coronary artery disease within the Coronary CT Angiography Evaluation for Clinical 
Outcomes: An International Multicentre (CONFIRM) registry identified that >65% of 
patients who developed acute coronary syndromes had non-obstructive disease on 
their baseline CCTA (Chang, Lin et al. 2018). This reflects the important nature of 
the biology of the atherosclerotic plaque rather than the functional consequence of 
luminal stenosis (Mann, Davies. 1999). For the prediction of subsequent coronary 
events, the presence of atherosclerotic plaque is more important than the presence 
of coronary stenoses. Indeed, in our study, patients with a combination of both 
obstructive coronary artery disease and adverse plaque had the worst outcomes. 
Moreover, patients with non-obstructive disease and adverse plaque had similar 
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outcomes to patients with obstructive disease without adverse plaque. Thus, our 
study provides evidence that coronary artery disease should no longer be defined 
based on luminal severity, but by the volume and type of disease.  
 
When examined across the cohort as a whole, adverse plaques did not provide 
independent prognostic information when CT calcium scoring was included. CT 
calcium scoring is a surrogate marker of plaque burden and its prognostic utility has 
been established in large studies of symptomatic and asymptomatic patients (Shah, 
Bellam et al. 2014, McClelland, Chung et al. 2006). It is likely that patients with 
higher plaque burden are more likely to have adverse plaques and are more likely to 
have severe coronary artery stenoses. Few studies have assessed the clinical 
implications of this overlap. A small study of 339 patients with suspected coronary 
artery disease found that both adverse plaques and CT calcium score were 
independent predictors of cardiac events at 2 years (Takamura, Fujimoto et al. 
2017). Clearly the greater the burden of disease, the greater the risk of events. 
However, for the individual patient, the assessment of coronary artery calcium alone 
is not sufficient to guide management as the presence and volume of coronary 
artery calcification is not directly related to the degree of coronary artery stenosis 
and cannot inform on the pathophysiological status of the atherosclerotic plaque 
(Newby 2017). Indeed, in the PROMISE study, CCTA provided better prognostic 
discrimination compared to coronary artery calcium score (Budoff, Mayrhofer et al. 
2017).  
 
It is perhaps not surprising that the identification of plaque characteristics at a single 
time point by CCTA may not be sufficient to predict future events in long term follow-
up. Atherosclerotic plaque undergoes continuous remodelling driven by a variety of 
On the detection of vulnerable plaques in human coronary atherosclerosis 
 
 97 
genetic and environmental factors, and we know that medications, such as statins, 
alter the constituents of atherosclerotic plaque (Lee, Chang et al. 2018). Autopsy 
studies show that atherosclerosis is present in young people (Joseph, Ackerman et 
al. 1993) and normograms for CT calcium score (McClelland, Chung et al. 2006) 
and plaque burden (Naoum, Berman et al. 2017) are in clinical use. Concerns have 
been raised about over medicalising patients with the routine use of preventative 
therapies for patients with non-obstructive disease (Redberg, Katz et al. 2017). 
However, the event rate in patients with non-obstructive disease in our study 
highlights that atherosclerosis is not “normal”. Similarly in the PROMISE study 
CCTA identified patients with non-obstructive disease who were at risk of 
subsequent events (Hoffmann, Ferencik et al. 2017). Indeed, future studies should 
assess whether the identification of coronary artery disease per se can guide 
treatment changes and improve outcomes for the wider population.  
 
3.5.1 Limitations 
There are a number of study limitations that we should acknowledge. First, the 
relatively low number of events over 5 years of follow-up limits our power to assess 
multiple subgroups. This in part reflects our selection of the hard clinical end-point of 
coronary heart disease death or non-fatal myocardial infarction as well as the low to 
intermediate risk of the population recruited in the SCOT-HEART trial. Second, the 
SCOT-HEART study was not designed or powered for this secondary analysis, and 
our findings are exploratory. Third, we used a simple and pragmatic approach to the 
identification of adverse plaques that would not greatly add to the time spent 
analysing CT scans. Automated software that can identify plaque characteristics 
may further improve observer variability in the classification of adverse plaques and 
help standardisation. Finally, the trial did encourage the use of secondary 
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preventative therapies in patients found to have either obstructive or non-obstructive 
disease. This will have inevitably reduced the number of events as well as reduced 
our ability to identify associations between plaque characteristics and clinical events 
because they will have been modified by the initiation of antiplatelet and statin 
therapies.  




In conclusion, we have demonstrated that adverse plaque characteristics provide 
prognostic information out to 5 years, but that this is not independent of plaque 
burden assessed by coronary artery calcium score. Patients with obstructive 
disease and adverse plaques have the highest event rates throughout follow-up. 
This may aid the identification of a subgroup of patients who would benefit from 
more intensive medical therapy. 
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Coronary 18F-fluoride positron emission tomography (PET) identifies ruptured and 
high-risk atherosclerotic plaque. The optimal method to identify, to quantify and to 
categorize increased coronary 18F-fluoride uptake and determine its reproducibility 
has yet to be established. This study aimed to optimise the identification, 
quantification, categorisation and scan-rescan reproducibility of increased 18F-
fluoride activity in coronary atherosclerotic plaque. 
 
Methods 
In a prospective observational study, patients with multi-vessel coronary artery 
disease underwent serial 18F-fluoride PET. Coronary 18F-fluoride activity was 
visually assessed, quantified and categorised with reference to maximal tissue to 
background ratios (TBRMAX). Levels of agreement for both visual and quantitative 
methods were determined between scans and observers. 
 
Results  
Thirty patients (90% male, 20 patients with stable coronary artery disease, and 10 
with recent type 1 myocardial infarction) underwent paired serial PET-CCTA 
imaging within an interval of 12±5 days. A mean of 3.7±1.8 18F-fluoride positive 
plaques per patient were identified following recent acute coronary syndrome, 
compared with 2.4±2.3 positive plaques per patient in stable coronary artery 
disease. The bias in agreement in TBRMAX measurements in visually positive 
plaques was low between observers (mean difference -0.01, 95% limits of 
agreement -0.32 to 0.30) or between scans (mean difference 0.06, 95% limits of 
agreement -0.49 to 0.61). Good agreement in the categorisation of focal 18F-
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fluoride uptake was achieved using visual assessment alone (κ = 0.66) and further 
improved at higher TBRmax values. 
 
Conclusions 
Coronary 18F-fluoride activity is a precise and reproducible metric in the coronary 
vasculature. The analytical performance of 18F-fluoride is sufficient to assess the 
prognostic utility of this radiotracer as a non-invasive imaging biomarker of plaque 
vulnerability. 
 
Clinical Trial Registration Information 
Clinical Trials.gov Study ID: NCT02110303, NCT02278211 





Atherosclerotic plaque rupture is the commonest cause of acute coronary 
syndromes (Libby, 2013). Cardiovascular imaging modalities have focused on 
identifying the presence and severity of luminal stenoses to stratify the risk of plaque 
rupture events. However, luminal stenosis is a relatively late feature of coronary 
atherosclerosis and the majority of rupture events occur at sites of non-obstructive 
plaque on antecedent angiography (Van Lierde, De Geest et al. 1990, Chang, Lin et 
at. 2018, Ahmadi, Leipsic et al. 2015). As such, interest has grown in identifying 
adverse atherosclerotic plaque characteristics and regions of increased disease 
activity within the arterial wall that may better predict subsequent plaque rupture and 
clinical events. One promising approach has been to use combined positron 
emission tomography (PET) and computed tomography (CT) angiography that co-
registers the detailed anatomy of the arterial wall with the in vivo biological activity of 
disease (Dweck, Chow et al. 2012). 
 
To date, PET-CT has predominantly been used to evaluate the presence of 
inflammatory processes in large calibre arteries using the radiotracer 18F-
fluorodeoxyglucose (18F-FDG) (Rudd, Warburton et al. 2002). However, the 
application of this tracer to the coronary circulation is limited because background 
myocardial 18F-FDG uptake obscures and prevents assessment of coronary plaque 
activity (Joshi, Vesey et al. 2014). Recent studies have found that 18F-sodium 
fluoride (18F-fluoride) holds major promise in identifying culprit plaques in the 
coronary circulation following myocardial infarction (Dweck, Chow et al. 2012, Joshi, 
Vesey et al. 2014). Validation work in the carotid arteries indicates that 18F-fluoride 
also identifies culprit plaques following neurovascular events and preferentially 
binds to microcalcification, a key component of high-risk atherosclerotic plaque 
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(Irkle, Vesey et al. 2015, Vesey, Jenkins et al. 2017). Studies are now ongoing to 
assess the prospective prognostic capability of coronary 18F-fluoride PET and 
whether the signal can help guide the use of novel therapies (NCT02110303 and 
NCT02278211). However, coronary 18F-fluoride imaging is challenging due to the 
small calibre of the vessels and their near continuous motion throughout the cardiac 
cycle (Demer, Tintut et al. 2017, Alavi, Werner et al. 2016). Moreover, there is a lack 
of consensus regarding image analysis techniques with a number of differing 
approaches having been used. Hence, there is a need to optimise and to 
standardise coronary PET imaging methodology to facilitate the widespread 
application of coronary molecular imaging.  
 
To address these issues, we undertook a prospective observational clinical study in 
patients with stable and unstable coronary artery disease that aimed to establish a 
reproducible methodology for identifying, quantifying and characterising 18F-fluoride 
activity in the coronary arteries.  
 
  




4.3.1 Study Population 
Participants were recruited within pre-specified reproducibility substudies of the 
DIAMOND (Dual antiplatelet therapy to Inhibit coronary Atherosclerosis and 
MyOcardial injury in patients with Necrotic high-risk coronary plaque Disease) and 
PRE18FFIR (Prediction of Recurrent Events with 18F-Fluoride to Identify Ruptured 
and High-risk Coronary Artery Plaques in Patients with Myocardial Infarction) trials. 
Inclusion required the presence of multi-vessel coronary artery disease on invasive 
angiography, either following recent myocardial infarction (PRE18FFIR), or in the 
context of stable coronary artery disease (DIAMOND). Exclusion criteria included 
inability to receive iodinated contrast, renal impairment (estimated glomerular 
filtration rate ≤30 mL/min/1.73 m2) or women of child-bearing potential. The study 
was approved by the local institutional review board, the Scottish Research Ethics 
Committee (REC reference: 14/SS/0089 and 15/SS/0203), and the United Kingdom 
(UK) Administration of Radiation Substances Advisory Committee. It was performed 
in accordance with the Declaration of Helsinki. All patients provided written informed 
consent prior to any study procedures. 
 
4.3.2 18F-Fluoride Positron Emission Tomography And 
Coronary Computed Tomography Angiography  
All patients underwent 18F-fluoride PET-CT and coronary CT angiography scanning 
on two occasions two weeks apart using the same protocol. Patients were 
administered 50-100 mg oral metoprolol if their resting heart rate was >65 beats/min 
prior to the intravenous administration of 250 MBq 18F-fluoride. After 60 min, 
patients were imaged with a hybrid PET-CT scanner (64-multidetector Biograph 
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mCT, Siemens Medical Systems, Erlangen, Germany). Attenuation correction CT 
scans were performed in held expiration prior to the acquisition of 
electrocardiographic-gated (ECG-gated) list-mode PET data using a single 30-min 
bed position centred on the heart. Finally, an ECG-gated coronary CT angiogram 
(CCTA) was performed in mid-diastole during held expiration. All patients received 
sublingual glyceryl trinitrate prior to CCTA.  
 
4.3.3 Image Analysis 
ECG-gated PET images were reconstructed in diastole (50-75% of the R-R interval, 
2 iterations, 21 subsets Siemens Ultra-HD algorithm) and fused with contrast 
enhanced CCTA. Analysis of the CT images was performed using dedicated 
software (Vitrea Advanced, Toshiba Systems) with multi-planar reformatting for 
plaque analysis used as necessary. Coronary arteries with a diameter ≥ 2 mm were 
assessed according to the 18-segment Society of Cardiac Computed Tomography 
model (Leipsic, Abbara et al. 2014). Qualitative and semi-quantitative analysis of the 
PET images from all sixty scans was performed independently by trained observers 
using an OsiriX workstation (OsiriX version 3.5.1 64-bit; OsiriX Imaging Software, 
Geneva, Switzerland).  
 
4.3.4 Identification of Coronary 18F-Fluoride Uptake 
Co-registration of PET and CCTA images was undertaken to aid image 
interpretation in a two stage process. First, 18F-fluoride blood pool activity on the 
PET scan was aligned with contrast enhanced CCTA images of the cardiac 
chambers in three dimensions using axial, sagittal and coronal views of the heart. 
This approach is made possible by the increased blood pool activity of 18F-fluoride 
in comparison to the myocardium, allowing the contours of the cardiac chambers to 
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be determined on the PET images. Second, axial, coronal and sagittal views were 
again interrogated in three dimensions to ensure optimal alignment of any tracer 
uptake in the aortic valve, aortic root, and the inner curve of the ascending aorta 
with the contrast CCTA (Figure 4.1).  
 
Visual assessment for increased coronary 18F-fluoride activity was performed on 
both a per-patient level and per-segment basis. For a signal to be co-localised to the 
coronary artery, a coronary atherosclerotic plaque had to be present on the CCTA 
and the increased pattern of radiotracer had to arise from the coronary artery and 
follow its course over >5 mm in three dimensions on orthogonal views. Care was 
taken to exclude 18F-fluoride activity arising from adjacent structures such as the 
aortic valve, mitral valve annulus, left atrial appendage and the pulmonary artery.  
  








Figure 4.1 Co-registration of 18F-fluoride positron emission tomography with contrast-
enhanced computed tomography. 
 
Patient and cardiac motion between the acquisition of positron emission tomography (PET) 
and coronary computed tomography angiography (CCTA) datasets can be enhanced by co-
alignment of diastolic phase electrocardiogram-gated PET reconstructions (50-75% of 
cardiac cycle) with the diastolic phase of CCTA. 18F-Fluoride activity in cardiac chambers 
facilitates accurate 3-dimension co-alignment in axial and coronal views. At low levels of 
activity, 18F-fluoride is predominantly restricted to the intravascular compartment with 
minimal activity observed in the myocardium. 18F-Fluoride activity that co-localises to the 
inner and outer curvature of the ascending aorta and aortic valve can be used as markers for 
co-registration. 18F-Fluoride activity in coronary arteries is referenced to blood pool activity 
allowing coronary 18F-fluoride activity to be differentiated from the surrounding structures in 
multiplanar views. 
  
On the detection of vulnerable plaques in human coronary atherosclerosis 
 
 109 
4.3.5 Quantification of Coronary 18F-Fluoride Uptake 
Semi-quantitative PET analysis was undertaken for all proximal coronary segments 
in addition to any atherosclerotic segment with focal 18F-fluoride activity as 
described above. First, maximum standardised uptake values (SUVMAX) were 
measured within regions of interest drawn around these areas. Due to the difficulties 
of drawing reproducible regions of interest around the perimeter of coronary 
segments, mean SUV values were not recorded.   
 
SUVMAX values were corrected for background activity using several different 
methods. First, correction was made for uptake in a referent proximal coronary 
plaque with no evidence of increased 18F-fluoride activity (Dweck, Chow et al. 
2012, Joshi, Vesey et al. 2014). Second, correction was made for blood pool activity 
using elliptical regions of interest drawn within the brachiocephalic vein, superior 
vena cava, and all four cardiac chambers with mean standardized uptake values 
(SUVMEAN) recorded for each region. To calculate coronary target to background 
ratios (TBR), coronary SUVMAX was divided by these background measures 
providing TBRREFERENT and TBRMAX values respectively. 
 
4.3.6 Categorisation of Coronary 18F-Fluoride Uptake 
18F-Fluoride activity in plaques meeting visual criteria for positivity was quantified 
and use to categorise plaques into the following groups: uptake below (TBR <0.9), 
similar to (TBR 0.9-1.1), and above (TBR >1.1) blood pool activity. This 
categorisation was then applied to both patients with recent acute coronary 
syndromes and stable coronary artery disease to assess the frequency of 18F-
fluoride active lesions with the different thresholds. Discrepancies in reporting were 
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resolved by consensus adjudication (two out of three blinded observers) of the 
presence of focal coronary 18F-fluoride activity.  
 
4.3.7 Reproducibility of Coronary 18F-Fluoride Uptake 
Repeat anonymised scans for all 30 patients were presented to three experienced 
observers in random order. Each observer performed scan analysis independent of 
the other readers. First, they determined the presence of coronary plaques with 
increased visual activity using the criteria for visual identification described above. 
Second, they quantified activity in the coronary plaques which was referenced to 
background activity in the referent plaque, right atrium, left atrium, right ventricle, left 
ventricle, superior vena cava and brachiocephalic vein. Coefficients of variation for 
each of these background measurements were then calculated. Subsequently, 
coefficients of variation were calculated for each metric of coronary 18F-fluoride 
activity (e.g. SUVMAX, TBRMAX, TBRREFERRENT etc.). Finally, we assessed the 
agreement of these metrics across serial scans using visual categorisation in 
isolation, and in combination with a low semi-quantitative threshold (TBR >0.9) or a 
high semi-quantitative threshold (TBR >1.1). 
 
4.3.8 Statistical analysis 
Continuous variables are reported as mean ± standard deviation (SD) or median 
and interquartile range (IQR). Categorical variables are reported as absolute 
number and percentages. Paired t-tests were used to determine statistical 
significance for comparisons of means with normal distribution. Consensus observer 
agreement (two out of three observers) of coronary segment tracer localisation was 
used to adjudicate positive focal tracer uptake and the presence of a single positive 
segment was sufficient for a patient level diagnosis of 18F-fluoride positivity. Limits 
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of agreement analysis was conducted to assess scan-rescan and inter-observer 
repeatability for all coronary segments and visually positive coronary plaques using 
TBRMAX adjusted for the left atrial blood pool. Following the mixed effects limits of 
agreement methodology of Parker et al. (Parker, Weir et al. 2016), a mixed effects 
model was fitted to the TBRMAX between-scan paired differences with segment 
included as a random effect nested within patient, adjusting for study (DIAMOND or 
PRE18FFIR) and observer as fixed effects. The mixed model for the TBRMAX 
between-observer paired differences was similar but with scan number and 
observer comparison as fixed effects instead of observer. In both cases, the mean 
bias was separately estimated based on a model only including the nested random 
effects of segment within patient (Parker, Weir et al. 2016). Variance components 
concordance correlation coefficients (CCC) were computed as an additional 
measure of scan-rescan and inter-rater agreement using mixed effects methodology 
suitable for repeated measures data (Carrasco, Phillips et al. 2013). Specifically, we 
fitted a mixed effects model to the raw outcome data including nested random 
effects of segment within patient and adjusting for observer, study (DIAMOND or 
PRE18FFIR), scan (first or second), and the global mean as fixed effects. For 
assessment of scan-rescan agreement we included the scan re-scan variance in the 
denominator of the repeated measures CCC formula, whereas for inter-observer 
agreement we included the between-observer variance in the denominator instead. 
Note that the CCC is strongly dependent on the between-segment and between-
patient variability. Pan et al. (Pan, Rose et al. 2013) suggest that the CCC variance 
components method calculated using mixed effects modelling could also be applied 
to binary outcome data, and concludes that the method works well when the 
proportions are “not too extreme”. Therefore, the same CCC method was used to 
measure agreement of the binary visual uptake outcome to produce a kappa-type 
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statistic κ. The κ values were interpreted as follows: poor ≤0.20, fair 0.21 to 0.4, 
moderate 0.41 to 0.60, good 0.61 to 0.80, and very good ≥0.81. A non-parametric 
bootstrap method was used to compute 95% bias-corrected percentile confidence 
intervals for the CCC estimates. Statistical analysis was performed using R version 
3.5.3 (R Foundation for Statistical Computing, Vienna, Austria). Statistical 
significance was taken as P<0.05. 
 
  





Thirty patients (90% male, 20 patients with stable coronary artery disease, and 10 
with recent type 1 myocardial infarction) underwent serial PET-CCTA imaging within 
12±5 days. Cardiovascular risk factors were common and twenty-eight (93.3%) 
patients had undergone prior coronary revascularisation (22 percutaneous coronary 
intervention and 9 coronary artery bypass grafting) (Table 4.1). 
  









N 30 10 20 
Age, years 67.3±7.6 62.83±6.30 69.53±7.32 
Male  27 (90) 10 (100) 17 (85) 
Body Mass Index, kg/m2 28.3±4.2 29.8±4.40 27.51±3.97 
Medical history    
Previous Myocardial Infarction 23 (77) 10 (100) 13 (65) 
Coronary Revascularisation  28 (93.3) 9 (90) 16 (80) 
Percutaneous Coronary 
Intervention 
22 (63) 9 (90) 13 (50) 
Coronary Artery Bypass 
Grafting 
9 (20) 0 9 (30) 
Hypertension  17 (57) 3 (30) 14 (70.0) 
High Cholesterol  26 (87) 6 (60) 20 (100) 
Diabetes Mellitus  5 (17) 3 (30) 2 (10) 
Prior Stroke/Transient 
Ischemic Attack  
1 (3) 0 1 (5) 
Atrial Fibrillation  1 (3) 0 1 (5) 
Peripheral Vascular Disease  1 (3) 0 1 (5) 
Medications    
Aspirin  30 (100) 10 (100) 20 (100) 
P2Y12 Antagonist  10 (33) 10 (100) 0 
Statin  30 (100) 10 (100) 20 (100) 
Beta-Blocker  13 (43) 4 (40) 9 (45) 
Angiotensin Converting 
Enzyme Inhibitor/Angiotensin 
II Receptor Blocker  
25 (83) 8 (80) 17 (85) 
Creatinine, mg/dL 0.9±0.2 1.0±0.2 0.9±0.1 
Estimated Glomerular Filtration 
Rate, mL/min/1.73m2 
98.5±16.9 94.6±17.6 100.4±16.7 
Interscan Interval, days 12.3±5.1 13.9±6.1 11.5±4.5 
 
Table 4.1 Baseline characteristics of 18F-fluoride reproducibility population. 
Values are n (%) or mean ± standard deviation. 
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4.4.1 Blood Pool 18F-Fluoride Activity 
18F-Fluoride blood pool activity was consistently higher in all four cardiac chambers 
than in the myocardium  (blood pool SUVMEAN 1.14 versus interventricular septum 
SUVMEAN 0.80) (Figure 4.2, Figure 4.3, Figure 4.4). This facilitated accurate manual 
co-registration of the PET and CCTA data sets as described above (Figure 4.1). 
Background measurements in the referent plaque, brachiocephalic vein and the 
superior vena cava were consistently lower than cardiac blood pool with high 
coefficients of variation. The regions with the least variability in serial measurements 
of background activity (SUVMEAN) were the cardiac atria with coefficients of variation 
in the left and right atria of 5.9±2.8% and 6.5±2.5% respectively (Figure 4.2, Table 
4.2).  
  











Figure 4.2 Standardised Uptake Values of Blood Pool and Cardiac 18F-Fluoride activity. 
 
Box-plot of the median and the interquartile range of mean standardise uptake values for 
brachiocephalic, superior vena cava, right atrium, interventricular septum (black line, mean). 
Note the low myocardial and background coronary arterial 18F-fluoride uptake compared to 
blood pool in the right atrium. 
BCV, brachiocephalic vein, IVS, interventricular septum, LA, left atrium, LV, left ventricle, 
RA, right atrium, RV, right ventricle, SVC, superior vena cava. 
NS, non-significant; *, p≤0.05, †, p≤0.01, ‡, p≤0.001, §, p≤0.0001. 
 
  






Figure 4.3 Coefficients of variation of Blood Pool and Cardiac 18F-Fluoride Activity.  
 
The mean standardised uptake value (SUVMEAN) (g/mL) in each region was compared by 
three observers across two scans. (A) Box-plot of the median and the interquartile range of 
coefficients of variation for each region (black line, mean). There was no difference in the 
coefficients of variation of 18F-fluoride SUVMEAN within intra-cardiac chambers (red), but 
there were increased coefficients of variation using systemic venous blood pool 
measurement (p<0.001) and interventricular septal myocardium (p<0.001) compared with 
measurement of SUVMEAN 18F-fluoride activity in the left atrium. 
 
BCV, brachiocephalic vein, IVS, interventricular septum, LA, left atrium, LV, left ventricle, 
RA, right atrium, RV, right ventricle, SVC, superior vena cava. 











Figure 4.4 Background cardiac 18F-fluoride activity. 
The mean standardised uptake value SUVMEAN (g/mL) in each location in all patients with 
coronary artery disease. The horizontal bar inside each box is the median, the lower and 
upper hinges correspond to the first and third quartiles (the 25th and 75th percentiles). The 
upper and lower whiskers extend from the hinge to the largest or smallest value no further 
than 1.5 times the interquartile range from the hinge. The short black horizontal line 
corresponds to the mean value. 
BCV, brachiocephalic vein, IVS, interventricular septum, LA, left atrium, LV, left ventricle, 
RA, right atrium, RV, right ventricle, SVC, superior vena cava. 
  




 BLOOD POOL SUVMEAN 
LOCATION  DIFFERENCE  
 
OVERALL 
MEAN MEAN SD 
95% LIMITS OF 
AGREEMENT 
(A)     
BRACHIOCEPHALIC VEIN 0.903 -0.08 0.16 -0.394 to 0.233 
INTERVENTRICULAR 
SEPTUM 0.771 0.028 0.052 -0.074 to 0.131 
LEFT ATRIUM 1.159 -0.018 0.043 -0.103 to 0.067 
LEFT VENTRICLE 1.142 -0.016 0.064 -0.142 to 0.110 
RIGHT ATRIUM 1.13 -0.009 0.053 -0.112 to 0.095 
RIGHT VENTRICLE 1.124 -0.019 0.051 -0.118 to 0.080 
SUPERIOR VENA CAVA 1.084 -0.013 0.174 -0.355 to 0.328 
(B)     
BRACHIOCEPHALIC VEIN 0.863 -0.056 0.188 -0.423 to 0.312 
INTERVENTRICULAR 
SEPTUM 0.785 -0.038 0.098 -0.229 to 0.154 
LEFT ATRIUM 1.15 -0.024 0.114 -0.248 to 0.200 
LEFT VENTRICLE 1.134 -0.048 0.119 -0.282 to 0.185 
RIGHT ATRIUM 1.126 -0.029 0.131 -0.286 to 0.227 
RIGHT VENTRICLE 1.114 -0.022 0.134 -0.284 to 0.240 
SUPERIOR VENA CAVA 1.078 -0.049 0.17 -0.382 to 0.285 
 
 
Table 4.2  Bland-Altman analysis of background 18F-fluoride cardiac activity. 
Between observer (A) and between scan (B) reproducibility. 
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4.4.2 Identification of Coronary 18F-Fluoride Uptake 
Low myocardial 18F-fluoride uptake enabled visual separation between areas of 
focal 18F-fluoride binding in the coronary arteries and background blood pool 
activity in the cardiac chambers. After accurate co-registration, these factors 
facilitated the identification of radiotracer originating from the coronary arteries even 
at levels of intensity similar to background blood pool activity that would otherwise 
not be discernible (Figure 4.5). Using this method, focal coronary 18F-fluoride 
activity of variable intensity could be visually identified in all culprit plaques (n=10) in 
patients with recent type 1 myocardial infarction. 
  








Figure 4.5 Culprit plaque 18F-fluoride activity on positron emission tomography-coronary 
computed tomography angiography. 
 
Following acute myocardial infarction, culprit plaque 18F-fluoride activity can be measured in 
the right coronary artery (A-F), left anterior descending artery (G-I) and atrioventricular 
circumflex artery (J-L). 
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4.4.3 Quantification of Coronary 18F-Fluoride Uptake 
Quantification of coronary 18F-fluoride activity within the plaque of interest, 
standardised according to a proximal non-diseased coronary artery segment 
(TBRREFERENT) demonstrated a high degree of variability on repeated measurements. 
The coefficients of variation reduced in a stepwise manner when using the 
brachiocephalic vein and superior vena cava as the sites of measurement for blood 
pool activity and were lowest for target to background ratios determined after 
standardisation for intracardiac blood pool activity using either the left or right atria 
(p<0.05 for all comparisons, Figure 4.6). Therefore, subsequent analyses used 
TBRMAX values standardized according to the atrial blood pool, with 18F-fluoride 
originating in the coronary arteries categorised into levels below (TBRMAX <0.9), 
similar to (TBRMAX 0.9-1.1) and above (TBRMAX >1.1) atrial blood pool activity 
(Figure 4.7). 
  







Figure 4.6 Coefficients of variation of different measures of coronary 18F-fluoride activity. 
 
Variation of coronary 18F-fluoride measurements using different anatomical sites for 
measurement of background tracer activity.  
Paired t-tests used compared with TBRMAX (LA): *, p≤0.05, ****, p ≤0.0001. 
TBR, target-to-background ratio; BCV, brachiocephalic vein; SVC, superior vena cava; LA, 
left atrium. 
  





Figure 4.7 Quantification of coronary 18F-fluoride activity. 
Visual identification of coronary 18F-fluoride activity was present in all ruptured plaques and 
13.8% of stable coronary segments. The signal intensity of 18F-fluoride activity in coronary 
plaque was assessed both visually and semi-quantitatively by referencing to atrial blood pool 
activity (maximum target-to-background ratio [TBRMAX]). Activity in coronary plaques was 
categorised into activity above blood pool (TBRMAX >1.1), at or around blood pool (TBRMAX 
0.9-1.1), or below blood pool (TBRMAX <0.9). Higher intensity signals were observed in stable 
segments compared with ruptured plaques. 
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4.4.4 Categorisation of Coronary 18F-Fluoride Uptake 
Using atrial blood pool as a point of reference allowed comparison of coronary 18F-
fluoride TBRMAX between patients with recent acute coronary syndromes and stable 
coronary artery disease. At the patient level, there were 3.7±1.8 positive plaques in 
patients with recent acute coronary syndrome compared with 2.4±2.3 positive 
plaques in patients with stable disease. Amongst patients with recent myocardial 
infarction, 100% (n=10/10) of culprit plaque segments met the criteria for visual 
uptake compared with 13.7% (n=73/530) of all segments not associated with plaque 
rupture. Visual assessment of coronary segment positivity achieved good inter-
observer reliability (κ = 0.66, 95% confidence interval 0.63 to 0.70). Minor 
discrepancies between reporters occurred in regions adjacent to high background 
activity including the right atrial blood pool, pulmonary artery and mitral valve 
annulus that limited assessment in regions of the right, left anterior descending 
artery and atrioventricular circumflex arteries respectively. Agreement increased 
amongst coronary segments with higher TBRMAX values and the application of a 
semi-quantitative method of determining 18F-fluoride positivity, requiring both visual 
evidence of tracer localization to a coronary region of interest and TBRMAX above the 
pre-specified intensity thresholds achieved good scan-rescan agreement at both 
pre-defined cut points (TBRMAX >0.9, κ = 0.72, 95% confidence interval 0.67 to 0.77; 
TBRMAX >1.1 κ = 0.77, 95% confidence interval 0.71 to 0.83; Figure 4.7, Figure 
4.8). When applied to patients with recent myocardial infarction, the use of TBRMAX 
thresholds resulted in fewer culprit plaques being classified as positive for focal 18F-
fluoride uptake (n=7/10 (70%) at TBRMAX ≥0.9; n=2/10 (20%) at TBRMAX >1.1).   








Figure 4.8 Scan-rescan repeatability of coronary 18F-fluoride uptake.  
Examples of repeated 18F-fluoride positron emission tomography and computed 
tomography scans across different thresholds of uptake. There were high levels of 
agreement between scans using a TBRMAX >0.9 (93.0%, TBRMAX >0.9, 94.2%, TBRMAX >1.1). 
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4.4.5 Reproducibility of Coronary 18F-Fluoride Uptake 
There were no differences in scan variables between the serial scans (Table 4.3). 
Patients with stable coronary artery disease had an increased dose-length product 
than patients with recent myocardial infarction due to the wider field of view on 
coronary CT angiography required for assessing the origin of the left internal 
mammary artery in cases of previous coronary artery bypass grafting. In all 
measured coronary segments (n=519), there was a mean bias of -0.03 between 
observers (95% limits of agreement -0.39 to 0.33) and a mean bias of 0.04 between 
scans (95% limits of agreement -0.41 to 0.49) (Table 4.4, Figure 4.9). In visually 
positive plaques, mixed effects biases were low between observers (mean bias -
0.01, 95% limits of agreement -0.32 to 0.30) and between scans (mean bias 0.06, 
95% limits of agreement -0.49 to 0.61). (Table 4.4) There was very good 
concordance between observers (concordance correlation coefficient 0.88, 95% 
confidence interval 0.85 to 0.90) and between scans (concordance correlation 
coefficient 0.86, 95% confidence interval 0.83 to 0.89). At the level of the patient, 
there was 100% agreement between the repeat scans on whether a patient 
demonstrated any increased coronary 18F-fluoride activity in at least one plaque. At 
the per-segment level, there was excellent agreement  (92.4%) between scans 
using the visual assessment alone, although further improvements in agreement 
were achieved by applying the TBRMAX thresholds (93.0% agreement rate TBRMAX 
≥0.9; 94.2% agreement rate TBRMAX >1.1) (Figure 4.8). 
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(A) SCAN 1 SCAN 2 
NUMBER 10 10 
HEART RATE, /MIN 63.7±9.1 59.6±9.9 
DOSE LENGTH PRODUCT, MGY 278±103 336±112 
18F-FLUORIDE DOSE, MBQ 242±9 239±9 




(B) SCAN 1 SCAN 2 
NUMBER 20 20 
HEART RATE, /MIN 56.8±8.0 57.3±10.3 
DOSE LENGTH PRODUCT, MGY 448±259 394±226 
18F-FLUORIDE DOSE, MBQ 249±9 248±9 




Table 4.3 Scanning variables in patients with myocardial infarction and stable 
coronary artery disease. 
 
Patient with myocardial infarction (A) and stable coronary artery disease (B). 
Values are mean ± standard deviation. 
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  All segments Visually Positive Plaques 
   
Between scan 
CCC CCC 0.88, 95% CI 0.87 to 0.90 CCC 0.86, 95% CI 0.83 to 0.89 
Between 
observer CCC CCC 0.89, 95% CI 0.87 to 0.90 CCC 0.88, 95% CI 0.85 to 0.90 
   
Between scan 
Kappa VU CCC 0.69, 95% CI 0.65 to 0.72 
 Between 
observer kappa 
VU CCC 0.66, 95% CI 0.63 to 0.70 





Mean bias 0.04, 95% Limits of 
Agreement are from -0.41 to 0.50. 
Between segment SD 0.12, 
Between patient SD 0.12, 
Residual SD 0.15 
Mean bias 0.06, 95% Limits of 
Agreement are from -0.49 to 
0.61. Between segment SD 
0.16, Between patient SD 0.18, 





Mean bias -0.027, 95% Limits of 
Agreement are from -0.386 to 
0.332, Between segment SD 
0.065, Between patient SD 0.030, 
Residual SD 0.169 
Mean bias -0.0068, 95% Limits 
of Agreement are from -0.316 to 
0.303. Between segment SD 
0.040, Between patient SD 
0.023, Residual SD 0.151 
 
Table 4.4 Mixed effects limits of agreement analysis. 
Between scans and observers for all segments and visually positive plaques. CCC, 
concordance correlation coefficient, CI confidence interval, SD standard deviation. 
  








Figure 4.9 Bland-Altman plots of coronary 18F-fluoride activity. 
Correlation and Bland-Altman plots for scan-rescan reproducibility for coronary plaques at 
different levels of coronary 18F-fluoride activity (TBRMAX) (A, C respectively). Correlation and 
Bland-Altman plots for interobserver reproducibility between two observers at different levels 
of 18F-fluoride activity (TBRMAX) (B, D respectively). The shaded circles represent individual 
observations whilst the red and grey hatched lines represent the mean difference and 95% 
mixed effects limits of agreement respectively. 





This study describes an optimised methodology for assessing coronary 18F-fluoride 
activity in vivo. Using this approach there is good agreement in the identification of 
plaques with increased coronary 18F-fluoride uptake between observers and on 
different scans. The tissue (SUVMAX) to background (left atrial SUVMEAN) ratio 
(TBRMAX) has a low bias between observers and between scans. At TBRMAX 
thresholds >0.9, there is low sampling variability and high interobserver agreement 
in the adjudication of coronary 18F-fluoride activity. 18F-Fluoride demonstrates 
optimal characteristics for coronary plaque molecular imaging, namely, low 
myocardial and background coronary artery activity, which allows regions of 
increased coronary 18F-fluoride uptake to be more readily detected at low levels of 
intensity. This technique has direct application to ongoing clinical trials using the 
identification of atherosclerotic plaque mineralisation to predict coronary events and 
improve the stratification of emerging therapeutic interventions (NCT02278211 and 
NCT02110303).  
 
This study has a number of notable strengths. First, it is the largest prospective 
study to investigate the scan-rescan reproducibility of coronary imaging with 
repeated 18F-fluoride PET-CT scans. Second, the study population comprising 
thirty patients with established, multi-vessel coronary disease represents a high-risk 
cohort for whom imaging biomarkers have genuine potential to improve prognostic 
stratification and guide therapeutic interventions. Third, it directly compared several 
proposed methods for quantifying focal tracer activity within coronary atherosclerotic 
lesions and determined the interobserver and scan-rescan agreement for these 
metrics. Lastly, it derived a standardized semi-quantitative approach to image 
analysis that allows consistency in the reporting of diagnostic findings.  




For an imaging biomarker to have clinical utility, it should demonstrate precise and 
reproducible analytical performance (Vasan, 2006). Specifically, precision refers to 
the closeness of agreement between independent observations under stipulated 
conditions (free from random error) and reproducibility reflects to the differences 
observed over separate scan acquisitions. The methodology of coronary 18F-
fluoride assessment presented here has been optimised to define a precise 
measure of background activity (cardiac atria) that yields a precise measure of 
coronary activity (TBRMAX) across serial scan acquisitions. Demonstrating the 
reliability of this metric is an important step towards implementing coronary PET 
imaging in clinical practice and prospective research trials. Future studies should 
apply similar acquisition and image analysis protocols to that described here, and 
continue to explore the clinical significance of such measurements. 
 
To discriminate 18F-fluoride uptake from levels of background signal, focal coronary 
artery activity has previously been referenced to proximal non-diseased coronary 
artery segments (TBRREFERENT) (Dweck, Chow et al. 2012, Joshi, Vesey et al. 2014). 
Although this practice differs from non-coronary 18F-fluoride PET imaging, it has 
been considered more appropriate to reference to a similar sized structure rather 
than a large blood pool region to avoid artificially low TBR values related to partial 
volume effects. However, this metric was found to have a high degree of variability 
on serial testing, due to inconsistency in measurements in the referent plaque. This 
likely reflects the inherent difficulty in reproducibly measuring a coronary segment 
without visual 18F-fluoride activity compared with the much easier agreement 
between observers when drawing a region of interest around a focal site of tracer 
uptake. Of note, this study identified 18F-fluoride activity within distal and 
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sidebranch vessels that may be more susceptible to partial volume averaging 
effects. In these regions, activity may ‘spill out’ into surrounding structures, thereby 
decreasing counts in plaques which would otherwise have increased activity. 
Similarly, coronary segments in close proximity to calcified tissue in the aortic and 
mitral annulus may be subjected to ‘spill-in’ of 18F-fluoride activity in regions that 
would otherwise have low activity. These small changes in localisation of maximal 
activity explain the variation observed when measuring structures below the field-
width half maximum of 18F-fluoride (6mm). Future work using an increased delay 
between injection and acquisition (Kwiecinksi, Berman et al. 2019), optimising the 
reconstruction algorithm and motion-correcting the list mode data (Doris, Otaki et al. 
2018) may improve quantitative reproducibility. Thus, quantification of activity should 
only be undertaken in plaques that meet the visual criteria stipulated in the 
methodology. 
 
This optimised methodology for estimating background blood pool activity also 
differs from previous 18F-FDG cardiovascular PET studies. In 18F-FDG studies, 
background blood pool activity was measured within the large venous capacitance 
vessels, such as the superior vena cava (Rudd, Myers et al. 2007, Tarkin, Joshi et 
al. 2017). This is preferred over measurements from within the cardiac chambers 
because 18F-FDG is taken up by viable myocardium and blood pool activity can be 
contaminated by signal over spill from the myocardium. In contrast, there is very low 
myocardial uptake of 18F-fluoride and thus estimating atrial blood pool activity is not 
susceptible to this confounding issue. The superior vena cava can be a relatively 
small compressed structure sensitive to sampling error and partial volume effects 
whereas the atria present larger spherical volumes of activity that can be more 
readily and reliably sampled, providing a measurement with higher precision and 
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reproducibility. Thus for tracers with a low background myocardial uptake, 
background blood pool activity would appear to be best measured in the cardiac 
atria. Consequently, although standardisation of coronary activity with reference to 
the atrial blood pool (TBRMAX) resulted in numerically lower values than when 
standardised according to either a referent coronary segment or an extracardiac 
blood pool, the coefficients of variation were much reduced. Indeed, because the 
referent plaque uptake is lower (0.7-0.8 of that in the atrial blood pool), the previous 
TBRMAX threshold of 1.25 equates to a TBRMAX threshold 0.9-1.0 when using the 
atrial blood pool activity. This finding has important implications for future studies 
that seek to measure change in tracer signal over serial scans, either to explore the 
natural history of plaque vulnerability or in order to use this metric as a surrogate for 
therapeutic response.  
 
Whilst quantitative measurements of 18F-fluoride activity have particular relevance 
to serial imaging studies, it is not clear that the numeric value of the TBRMAX has 
direct correlation with plaque vulnerability. Indeed, this study found that amongst 
patients with acute myocardial infarction, the culprit plaques demonstrated 
proportionally lower TBRMAX values than visually positive plaques in patients with 
clinically stable disease. Although somewhat counterintuitive, this finding is 
consistent with previous observations (Joshi, Vesey et al. 2014) and the relationship 
between TBRMAX and risk of future clinical events remains to be determined in large-
scale prospective trials, such as the PRE18FFIR trial (NCT02278211). It should be 
remembered that 18F-fluoride uptake correlates with microcalcification and is a 
marker of calcification activity (Joshi, Vesey et al. 2014). While it identifies high-risk 
plaque with a necrotic core, the magnitude of uptake may reflect different stages of 
the calcification process and it may be the presence rather than the magnitude of 
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uptake that is most important. For example, high 18F-fluoride uptake may represent 
advanced calcification activity with rapidly developing macrocalcification which is 
stabilising the plaque and making it less prone to rupture. Conversely, relatively 
lower levels of 18F-fluoride uptake may represent the immediate response to a 
recently developed unstable plaque with a necrotic core that has yet to develop 
demonstrable macrocalcification and has only nascent calcification activity. 
 
This study has demonstrated good reliability for visual assessment alone in the 
identification of culprit plaques following recent acute coronary syndrome. Perhaps 
unsurprisingly, the inter-observer and scan-rescan agreement for the classification 
of 18F-fluoride positivity within a coronary segment increased inline with the TBRMAX 
and was greatest for coronary segments with maximum standardized uptake values 
>1.1 times the blood pool SUVMEAN. In this regard, a recent cohort study has 
demonstrated that coronary TBRMAX ≥1.28 stratified individuals at increased risk of 
plaque rupture (Kitagawa, Yamamoto et al. 2018). Whilst this higher patient-level 
threshold identified individuals at risk of late coronary revascularisation, at the 
plaque-level 45% of culprit plaques (n=5/11) did not meet this threshold (Kitagawa, 
Yamamoto et al. 2018). This observation is in keeping with the finding that culprit 
plaque 18F-fluoride activity, whilst readily identifiable, is often at a lower intensity 
than blood pool which future studies may need to account for. The identification of 
low intensity 18F-fluoride activity needs to be prospectively evaluated in future 
studies of repeated imaging following an acute coronary syndrome. 
 
4.5.1 Limitations 
This study has a number of limitations. It was undertaken in a single centre with 
extensive experience in cardiac 18F-fluoride PET-CCTA imaging and scans were 
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performed using a single PET-CCTA scanning system. It is important to 
acknowledge that many operator and system-dependent variables can influence 
final image quality and these will necessitate careful consideration when applying 
our findings in different settings. A number of limitations of our study are inherent to 
coronary PET imaging, and include the challenges of non-specific binding, cardiac 
motion, partial voluming and relatively low signal-to-noise ratios. We chose to use 
18F-fluoride as our PET tracer as there is low physiological activity within the 
myocardium reducing the chance for ‘spill-in’ activity. Furthermore, data from our 
group have previously established that the problem of cardiac motion can be 
overcome through ECG-gating in a similar manner to that employed in coronary 
computed tomography angiography (Pawade, Cartlidge et al. 2016). Although 
restricting the analysis of the PET signal to one quarter of the cardiac cycle reduces 
the signal-to-noise ratio, this can be compensated for by increasing tracer dose, 
increasing scan duration, and applying advanced image reconstruction algorithms 
including time-of-flight reconstruction with point spread function modelling. In 
combining these incremental gains, this study has derived a semi-quantitative 
measure of plaque pathophysiology that is highly reproducible on interval scanning 
and is well placed for observing dynamic changes in activity over time. 
  




In conclusion, 18F-fluoride PET-CCTA imaging is highly reproducible over repeated 
scans and between multiple observers. A semi-quantitative approach achieves 
repeatable metrics than can now be assessed to determine their clinical 
significance. This approach to image acquisition and analysis provides strong 
support for the ongoing clinical studies investigating the value of 18F-fluoride PET-
CCTA to inform cardiovascular prognostic assessment and guide novel therapeutic 
strategies. 
  






















18F-Fluoride positron emission tomography is a sensitive imaging biomarker that 
identifies microcalcification in atherosclerotic plaque. Coronary plaques with early 
microcalcification have an increased propensity to rupture and are associated with 
acute myocardial infarction. The objective of this study was to characterise and 
define 18F-fluoride uptake in human coronary atherosclerotic plaques. 
 
Methods 
Fresh frozen post-mortem human specimens of left coronary artery were imaged 
using 18F-fluoride micro-positron emission tomography-computed tomography prior 
to fixation in 10% buffered formalin. Histology, fluorescein-bisphosphonate 
immunofluorescence and Raman spectroscopy were performed to identify specific 
regions of hydroxyapatite deposition. Immunohistochemical analysis was 




Compared with low levels of non-specific binding in the myocardium, 18F-fluoride 
demonstrated a high signal to noise ratio in both calcified (median 149.8, 
interquartile range [IQR] 85.3 to 207.3 kBq/mL) and non-calcified (median 158.1, 
IQR 121.79 to 234.8 kBq/mL) coronary atherosclerotic plaque. High intensity 18F-
fluoride (157 kBq/mL) had a Raman signal at 963 cm-1 corresponding to 
hydroxyapatite. Areas of enhanced osteopontin and Runt-related transcription factor 
2 staining were associated with increased coronary 18F-fluoride uptake (increases 
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of 50.5 [95% confidence interval 28.1 to 72.9] kBq/mL (p<0.0001) and 37.2 [95% 
confidence interval 12.6 to 61.8] kBq/mL (p=0.0043) respectively). 
 
Conclusions 
18F-Fluoride uptake in human coronary atherosclerosis identifies early 
microcalcification in the form of hydroxyapatite. Coronary plaques with high 18F-
fluoride uptake are associated characteristic histologic markers of active 
mineralisation and atherosclerosis. 
  





Coronary atherosclerosis is an inflammatory disease that results in the formation of 
intimal plaque with an increased propensity to rupture. Microscopic calcification is a 
key feature of ruptured atherosclerotic plaques and the identification of coronary 
microcalcification is closely linked to coronary thrombotic events (Joshi, Vesey et al. 
2014). However, the in vivo mechanisms governing the accumulation of early 
microscopic calcification within the coronary vasculature are poorly understood. Pre-
clinical studies have proposed atherosclerotic inflammation to be an initiator of 
plaque calcification through the extrusion and response to calcifying extracellular 
vesicles (Hutcheson, Blaser et al. 2017, Hutcheson, Goettsch et al. 2016). 
Additionally, in vitro models of intimal plaque microcalcification have demonstrated 
that spherical or ellipsoidal micro-calcifying vesicles aggregate within plaques and 
coalesce to form larger plates of macrocalcification (Hutcheson, Goettsch et al. 
2016). Whilst the transition from microcalcification to macrocalcification in the vast 
majority of plaques is thought to confer stability, the presence of micro-calcifying 
vesicles in the tunica intima has the potential to reduce the structural integrity of 
thin-capped fibroatheroma, resulting in plaque rupture (Kelly-Arnold, Maldonado et 
al. 2013, Mori, Torii et al. 2018). 
 
Recently, studies have demonstrated that increased 18F-sodium fluoride (18F-
fluoride) positron emission tomography (PET) uptake is observed in culprit plaques 
following myocardial infarction and in plaques with multiple adverse features in 
patients with stable disease (Joshi, Vesey et al. 2014, Dweck, Chow et al. 2012, 
Kitagawa, Yamamoto et al. 2018). 18F-Fluoride preferentially binds to exposed 
hydroxyl groups on the surface of nanocystalline hydroxyapatite. We have 
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previously demonstrated that the signal intensity of 18F-fluoride in carotid 
endarterectomy specimens increases as the size of the calcifications decrease, 
such that 18F-fluoride is an imaging biomarker of unbound microscopic calcification 
(Creager, Hohl et al. 2019, Irkle, Vesey et al. 2015). However, there are important 
differences between carotid and coronary atherosclerotic plaque progression, 
predominantly attributed to plaque composition. Compared with carotid plaques, 
vulnerable coronary plaques are more prone to rupture owing to thinner fibrous caps 
(<65 µm versus <200 µm) and a reduction in smooth muscle cells in the tunica 
media. To address these differences in pathophysiology and to fully understand the 
mechanisms of 18F-fluoride binding in coronary atherosclerotic plaque, direct 
histological examination of coronary artery tissue is warranted (Salarian, Sadeghi et 
al. 2019). In this study, we performed an ex vivo histological validation of 18F-
fluoride binding to calcium derivatives and osteogenic proteins involved in human 
coronary atherosclerotic calcification.  
  






5.3.1 18F-Fluoride micro-positron emission tomography 
computed tomography 
Calcium derivative phantoms and coronary artery specimens underwent micro-
positron emission tomography computed tomography followed by specimen 
histology and Raman spectroscopy as described in Chapter 2.  
 
5.3.2 Statistical analysis 
Categorical variables are reported as number (%) and continuous variables as 
mean ± standard deviation for parametric or median and interquartile range for non-
parametric data. Normality was tested for using the D’Agostino and Pearson test. 
Continuous unpaired variables were compared using Student’s T-test with Welch’s 
correction when two samples had unequal variances and/or unequal sample sizes. 
Non-parametric data was compared between two categories using Mann-Witney U 
Test or using Kruskal-Wallis Test for multiple categories. Statistical analysis was 
undertaken using PRISM for OS X, version 8.1.1. (GraphPad Software, San Diego, 
California, USA). Statistical significance was considered as a two-sided p value 
<0.05.  





5.4.1 Selectivity of 18F-fluoride for hydroxyapatite 
18F-Fluoride had favourable equilibrium kinetics (Bmax 9.8 kBq/mL, Kd 58.14 kBq) 
for hydroxyapatite with binding equilibrium occurring within 20 min (Figure 5.1). To 
achieve target saturation, 100 kBq of 18F-fluoride was used for subsequent ex vivo 
experiments. There was high selectivity of 18F-fluoride for hydroxyapatite in 
comparison with other calcium-phosphate derivatives (calcium bisphosphate, 
p<0.01; calcium pyrophosphate p<0.001) (Figure 5.1). Very low activity was 
observed in calcium oxalate samples incubated with 18F-fluoride (p<0.001). 
 
5.4.2 Study population 
Between 2016 and 2017, coronary artery samples were obtained at autopsy from 13 
victims of sudden death. The majority were male (n=10, 76.9%) with a median age 
of 51 (range 40-71) years. Ten deaths (76.9%) were adjudicated as related to 
ischemic heart disease, one death was attributed to haemopericardium from 
thoracic aortic dissection and two deaths were related to non-cardiac causes 
(suffocation and alcohol toxicity) (Table 5.1). None of the coronary artery specimens 
represented culprit or ruptured plaque directly related to the sudden death.  
  








Figure 5.1 18F-Fluoride activity in calcium derivative phantoms. 
 
(A) Total activity of 18F-fluoride (MBq/mL) following 20 min incubation in hydroxyapatite 
plotted against dose of 18F-fluoride (kBq) per milligram of hydroxyapatite. Scatchard plot of 
bound/free versus bound 18F-fluoride (inset). (B) Hydroxyapatite and other calcium-derived 
minerals were incubated with 18F-fluoride for 20 minutes after which unbound supernatant 
was removed and the solid particles were analysed by micro positron emission tomography. 











Age Sex Cause of death Plaque type - Macro-
calcified/ Non-calcified 
(n = plaques) 
1  46 M Ischaemic heart disease Macro-calcified (6) 
2  57 M Ischaemic heart disease Macro-calcified (2) 
3 49 M Ischaemic heart disease Macro-calcified (1) 
4 49 F Complications of alcohol 
toxicity 
Non-calcified (1) 
5 71 F Ischaemic heart disease Macro-calcified (4) 
6  57 M Ischaemic heart disease Non-calcified (3) 
7 69 M Ischaemic heart disease Non-calcified (3) 
8 71 F Suffocation Macro-calcified (1) 
9 51 M Ischaemic heart disease Non-calcified (2) 
10 50 M Thoracic aortic dissection Macro-calcified (1) 
11 67 M Ischaemic heart disease Macro-calcified (2) 
12 48 M Ischaemic heart disease Macro-calcified (1) 
13 40 M Ischaemic heart disease Non-calcified (4), 
Macro-calcified (1) 
 
Table 5.1 Cause of death 
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5.4.3 18F-Fluoride co-localisation with hydroxyapatite  
Within tissue sections from the 13 patients, 32 plaques were identified. 18F-Fluoride 
binding was observed in plaques both with (n=19) and without (n=13) areas of 
macroscopic calcification as determined on micro-CT (Figure 5.2). Total plaque 
18F-fluoride binding (median 157.5 [IQR 103.9 to 216.9] kBq/mL) was more than 
10-fold greater than non-specific binding in the surrounding myocardium (median 
14.9 [IQR 9.6 to 27.4] kBq/mL, p<0.0001) and more than 500-fold greater than 
background regions (median 0.3 [IQR 0.09 to 1.3] kBq/mL, p<0.0001) (Figure 5.2). 
18F-fluoride activity in coronary plaques without macroscopic calcification (median 
158.1 [IQR 121.7 to 234.8] kBq/mL) was higher than plaque with macrocalcification 
(median 149.8 [IQR 85.3 to 207.3] kBq/mL; p=0.0469). Even in plaques with 
macrocalcification 18F-Fluoride occurred in distinct regions remote from larger 
macrocalcific deposits identified on micro-computed tomography (Figure 5.3). In 
these regions, 18F-fluoride colocalised with histological markers of microcalcification 
(von Kossa, Alizarin Red S). Moreover the microcalcification observed in areas of 
18F-fluoride binding was specifically classified as hydroxyapatite using a highly 
selective immunofluorescence probe, Fluorescein-bisphosphonate (Figure 5.3). 
  










Figure 5.2 18F-Fluoride binding in ex vivo coronary artery specimens. 
 
(A) Volume rendered images micro-positron emission tomography-computed tomography of 
left anterior descending artery segments were reconstructed to provide axial alignment of 
coronary arteries for quantitative analysis. Micro-computed tomography defined regions of 
myocardium, non-calcified plaque and calcification in coronary arteries with PET 
quantification on hybrid images. (B) Non-specific binding in the surrounding myocardium was 
higher than background activity (median 14.9 [interquartile range 9.6 to 27.4] versus 0.30 
[interquartile range, 0.09 to 1.3] kBq/mL respectively, p<0.0001). Signal in coronary artery 
segments was 10-fold higher (p<0.0001) than myocardium (non-calcified plaque median 
158.1 [interquartile range, 121.7 to 234.8] kBq/mL and calcified plaque median 149.8 
[interquartile range, 85.3 to 207.3] kBq/mL).  
CaPi, calcium bisphosphate, CaPyr, calcium pyrophosphate, CaOx, calcium oxalate, HAP, 
hydroxyapatite. 
  










Figure 5.3 18F-Fluoride, coronary microcalcification and hydroxyapatite deposition. 
 
Coronary artery specimens had focal (A), circumferential (F) or large regions (K) of 
macrocalcification on microcomputed tomography. 18F-Fluoride binding occurred in regions 
remote from macrocalcification in intimal fibroatheromatous plaque (B, G, L) and colocalised 
with histological markers of tissue mineralisation (Von Kossa, C, H, M), microcalcification 
(Alizarin Red, D, I, M) and a hydroxyapatite-specific bisphosphonate probe (Fluorescein-
Bisphosphonate [green], E, J, O). 
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5.4.4 Raman spectroscopy and 18F-fluoride intensity 
Raman spectroscopy imaging of selected regions with high and low intensity 18F-
fluoride binding was performed in eight samples (Figure 5.4). The characteristic cell 
Raman signal was observed in all these samples at 1004 cm-1 corresponding to 
phenylalanine. In a control sample, no Raman signal was observed in the range 
between 940 and 1000 cm-1 (Figure 5.4). Samples containing microcalcification 
identified by high intensity 18F-fluoride (157 kBq/mL) had a Raman signal at 963 
cm-1 corresponding to hydroxyapatite (Figure 5.4). In macrocalcified specimens with 
low 18F-fluoride intensity (30 kBq/mL), Raman signal with an asymmetrical v1 
stretching band appeared at 973 cm-1 corresponding to whitlockite (Figure 5.4). As 
there was an asymmetrical peak to signal in these macrocalcified specimens, further 
analysis of the area under the whitlockite peak revealed two overlapping peaks 
attributable to hydroxyapatite and whitlockite at a ratio of 30:70 (Figure 5.5). 
  





Figure 5.4 18F-Fluoride with Raman spectroscopy for hydroxyapatite and whitlockite. 
 
Coronary artery specimens with high 18F-fluoride binding and low 18F-fluoride binding 
underwent Raman spectroscopy analysis to differentiate mineral composition (n=8). Non-
macrocalcified specimens with low 18F-fluoride intensity (control, n=1) had a single spectra 
peak at 1004 cm-1 corresponding to phenylalanine (A-D). Focal regions with no 
macrocalcification and high 18F-fluoride intensity (n=3) had a Raman spectra peak at 963 
cm-1, hydroxyapatite (E-H). Macrocalcified regions with low 18F-fluoride intensity had a 
Raman spectra peaks at 975 cm-1, whitlockite (I-L). Raman Shift: Hydroxyapatite, 963cm-1, 
Whitlockite, 973 cm-1, Phenylalanine, 1004 cm-1. 
 
  







Figure 5.5 Raman spectra for macrocalcification with low 18F-fluoride intensity. 
 
Peak fitted analysis of Raman spectra in regions with macrocalcification and low 18F-fluoride 
intensity. Analysis of the area under the whitlockite peak reveals the merging of two peaks 
corresponding to hydroxyapatite and whitlockite in a 30:70 ratio. HAP, hydroxyapatite, WTK, 
Whitlockite. 
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5.4.5 18F-Fluoride co-localisation with markers of osteogenic 
activity in coronary arteries 
Detailed analysis of coronary artery specimens revealed that 18F-fluoride binding 
was predominantly observed within the tunica intima in areas of plaque formation 
(Figure 5.6). Little or no binding was observed in the tunica media. In coronary 
atherosclerotic plaques without macrocalcification, there was no intense staining for 
alkaline phosphatase (weakly positive) despite high 18F-fluoride activity (Figure 
5.6). However, these regions of high 18F-fluoride activity co-localised with the 
increased expression of osteopontin (Figure 5.6). Osteopontin-positive plaques had 
higher 18F-fluoride activity compared to those without (mean 145 versus 94.5 
kBq/mL respectively: difference in means 50.5 [95% confidence interval 28.1 to 
72.9] kBq/mL, p<0.0001) (Figure 5.7). Similarly, Runt-related transcription factor 2 
(Runx2) positive plaques had higher 18F-fluoride activity compared to those without 
(mean 139.8 versus 102.6 kBq/mL respectively; difference in means 37.2 [95% 
confidence interval 12.6 to 61.8] kBq/mL, p=0.0043) (Figure 5.7). Staining for 
transforming growth factor beta 1 and caspase 3 was evident in these plaques, 
particularly in regions of macrocalcification. However, 18F-fluoride activity did not 
correlate with increased staining for transforming growth factor beta 1 (TGFβ1, 
p=0.1042), wingless/integrated 3a (WNT3A, p=0.8732) or caspase 3 (p=0.5476). 
  






Figure 5.6 Intimal 18F-fluoride plaque intensity and markers of osteogenic activity. 
 
Fibroatheromatous plaques had an abundance of microcalcification (Alizarin Red S) in 
regions of high 18F-fluoride signal. The distribution of the biomineralisation 
glycophosphoprotein osteopontin colocalised with microcalcification in the intimal layer. 
  








Figure 5.7 18F-Fluoride and transcription factors associated with atherosclerotic 
mineralisation. 
 
High 18F-fluoride activity was associated with markers of inflammatory mediated 
mineralization (Osteopontin: positive 145.0 kBq/mL versus negative 94.5 kBq/mL, difference 
in means 50.5 [95% confidence interval 28.1 to 72.9] kBq/mL, p<0.0001; Runt-related 
transcription factor 2: positive 139.8 kBq/mL versus negative 102.6 kBq/mL, difference in 
means 37.2 [95% confidence interval 12.6 to 61.8] kBq/mL, p=0.0043). No difference in 18F-
fluoride activity was observed for TGFβ1 (p=0.1042) or Caspase 3 (p=0.5476).  
OPN, Osteopontin, RUNX-2, Runt-related transcription factor 2, TGFβ1, Transforming 
growth factor-beta1.  
  





In this ex vivo imaging study of coronary atherosclerosis, we have demonstrated for 
the first time that 18F-fluoride is a selective marker of intimal hydroxyapatite 
deposition in human coronary atherosclerotic plaques. Similar to other disease 
states it preferentially binds in areas of microcalcification rather than 
macrocalcification. 18F-Fluoride has a high affinity for hydroxyapatite, which is more 
abundant in regions of microcalcification compared with larger macrocalcified 
deposits. Importantly, high 18F-fluoride signal co-localises with the distribution of 
osteopontin and Runx 2, established markers of early calcification activity and 
adverse plaque formation. This histological validation supports the use of 18F-
fluoride positron emission tomography as a marker of developing microcalcification 
and plaque activity in patients with coronary artery disease. 
 
Whilst there has been histological confirmation of 18F-fluoride binding in carotid 
atheroma, studies demonstrating increased 18F-fluoride activity in the coronary 
arteries (Joshi, Vesey et al. 2014, Dweck, Chow et al. 2012) have been called into 
question due to the limited spatial resolution of clinical positron emission 
tomography, with some investigators questioning whether 18F-fluoride binding 
actually occurs in coronary arteries (Demer, Tintut et al. 2017). In this regard, the 
confirmation of high intensity 18F-fluoride binding in the intimal layer of coronary 
plaques compared to background and adjacent myocardium is of considerable 
importance. We have also confirmed that 18F-fluoride binding occurs in plaques 
both with and without macroscopic calcium observed on CT, and that binding 
appears to occur preferentially in regions of developing microcalcification. This 
strongly supports 18F-fluoride PET as a marker of calcification activity and 
developing microcalcification in the coronary arteries and is consistent with previous 
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observations in coronary artery disease as well the data in carotid atheroma and 
other cardiovascular disease states (Creager, Hohl et al. 2019, Irkle, Vesey et al. 
2015, Forsythe, Dweck et al. 2018, Dweck, Jenkins et al. 2014, Cartlidge, Doris et 
al. 2019).  
 
Of particular interest is the potential for 18F-fluoride to discriminate hydroxyapatite 
deposition above other calcium derivatives in regions of active mineralisation 
(Aikawa, Nahrendorf et al. 2007). Of the many calcium derivatives, nanocrystalline 
hydroxyapatite is the central component of microcalcification in atherosclerotic 
coronary plaques (Aikawa, Nahrendorf et al. 2007). We have here confirmed the 
preferential binding of 18F-fluoride for microcalcification and for hydroxyapatite 
based upon the binding of a specific optical probe and Raman spectroscopy. At later 
stages in the calcification process, other calcium derivatives, such as whitlockite, 
become more abundant in calcified vascular tissue, particularly within large vessel 
atherosclerosis where there is often a high whitlockite to hydroxyapatite ratio (You, 
Bergholt et al. 2017). The phase transformation of hydroxyapatite to whitlockite may 
occur in the hypoxic or acidic conditions within necrotic cores where magnesium 
ions are incorporated onto the surface and prevent further growth of hydroxyapatite 
crystals (Jang, Jin et al. 2014). Traditionally surface area effects have been used to 
explain the preferential binding of 18F-fluoride for microcalcification. However, the 
specificity of 18F-fluoride for hydroxyapatite provides an additional explanation for 
why high 18F-fluoride activity is not observed in areas macrocalcification and why it 
provides different information to CT (Creager, Hohl et al. 2019). 
 
We also observed a close relationship between the coronary 18F-fluoride signal and 
both osteopontin and Runx-2 expression, established markers of early calcification 
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activity and adverse coronary plaque. High concentrations of osteopontin 
accumulate in coronary atheroma exposed to hypoxia and endothelial injury 
(O’Brien, Garvin et al. 1994). Of note, inflammatory signalling within metabolically 
active coronary plaques stimulates macrophage-derived foam cells to express high 
levels of osteopontin (Shanahan, Cary et al. 1994). In comparison, low levels of 
osteopontin mRNA are found in vascular smooth muscle cells often regarded as the 
cell type responsible for initiating plaque calcification (Newman, Bruun et al. 1995). 
Importantly, from a clinical perspective, high plasma osteopontin levels are 
associated with adverse clinical events in patients with both stable and unstable 
coronary artery disease (Minoretti, Falcone et al. 2006, Bjerre, Pedersen et al. 
2013). Combined with high-sensitivity C reactive protein, osteopontin had a two-fold 
increased risk of recurrent myocardial infarction in patients presenting with ST 
elevation myocardial infarction (Bjerre, Pedersen et al. 2013). The role of 
osteopontin in mediating plaque activity is noted by the beneficial effect of statins in 
reducing osteopontin levels and thereby reduce the risk of plaque rupture 
(Kadoglou, Kottas et al. 2014). The relationship between 18F-fluoride uptake and 
osteopontin therefore supports its role as a marker of early calcification activity and 
adverse plaque. However, ultimately data are required to investigate whether 18F-
fluoride predicts future myocardial infarction and therefore might provide important 
clinical information. In this regard, to determine whether coronary 18F-fluoride has 
clinical utility, prognostic observation studies in patients with recent myocardial 
infarction are ongoing (NCT02278211).  
 
5.5.1 Limitations 
There are some limitations to this study. Legislation regarding the regulation of 
tissue in victims of sudden death meant that only left main and proximal left anterior 
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descending coronary artery specimens could be obtained for detailed research 
analysis. These specimens did not include sections of culprit coronary plaque 
rupture with thrombus formation and therefore extrapolation of these findings to 
ruptured atherosclerotic plaques cannot be made. Ante-mortem demographics 
regarding risk factors such as diabetes mellitus and renal disease which influence 
atherosclerotic calcification were unavailable. However, the majority of cases in this 
study were adjudicated by a forensic pathologist who determined a cause of death 
attributed to ischemic heart disease independent from the study investigators. This 
provides further evidence of the high prevalence of 18F-fluoride binding in coronary 
arteries in a high-risk cohort. Although the significance of the high frequency of 
sudden cardiac death (77%) in this study population is uncertain, further studies 
exploring the utility of coronary 18F-fluoride imaging in victims of sudden death are 
worth pursuing. 
  




In this ex vivo study of coronary atherosclerotic plaques, 18F-fluoride binding was 
highly selective for unbound hydroxyapatite deposition. High 18F-fluoride intensity 
was associated with intimal microcalcification in regions of osteopontin and Runx-2 
expression. This study provides further evidence to support the use of 18F-fluoride 
positron emission tomography as a marker of plaque vulnerability in patients with 
coronary artery disease. 
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with high-risk coronary artery plaque 
 
 
Moss AJ, Dweck MR, Doris MK, Andrews JPM, Bing R, Forsythe RO, Cartlidge TR, Pawade TA, 
Daghem M, Raftis JB, Williams MC, van Beek EJR, Forsyth L, 
Lewis SC, Lee RJ, Shah ASV, Mills NL, Newby DE, Adamson PD. 
Ticagrelor to reduce myocardial injury in patients 
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High-risk coronary atherosclerotic plaque is associated with higher plasma troponin 
concentrations suggesting ongoing myocardial injury that may be a target for dual 
antiplatelet therapy. To determine whether ticagrelor reduces high-sensitivity 
troponin I concentrations in patients with established coronary artery disease and 
high-risk coronary plaque. 
 
Methods 
In a randomised double-blind placebo-controlled trial, patients with multivessel 
coronary artery disease underwent coronary 18F-fluoride positron emission 
tomography-computed tomography and measurement of high-sensitivity cardiac 
troponin I and were randomized (1:1) to ticagrelor 90 mg twice daily or matched 
placebo. The primary endpoint was troponin I concentration at 30 days in patients 
with increased coronary 18F-fluoride uptake. 
 
Results 
In total, 202 patients were randomised and 191 met the pre-specified criteria for 
inclusion in the primary analysis. In patients with increased coronary 18F-fluoride 
uptake (n=120/191) there was no evidence that ticagrelor had an effect on plasma 
troponin concentrations at 30 days (ratio of geometric means for ticagrelor versus 
placebo, 1.11, [95% confidence interval 0.90 to 1.36], p=0.32). Over 1 year, 
ticagrelor had no effect on troponin concentrations in patients with increased 
coronary 18F-fluoride uptake (ratio of geometric means, 0.86, 95% confidence 
interval 0.63 to 1.17, p=0.33).  




Dual antiplatelet therapy with ticagrelor does not reduce plasma troponin 
concentrations in patients with high-risk coronary plaque, suggesting that subclinical 
plaque thrombosis does not contribute to ongoing myocardial injury in this setting. 
 
Clinical Trial Registration Information 
Clinical Trials.gov Study ID: NCT02110303  




Coronary plaque rupture is the commonest cause of acute coronary thrombosis and 
myocardial infarction (Libby, 2013). Patients who have an increased risk of recurrent 
plaque rupture events may benefit from intensification of secondary prevention 
therapy (Fox, Carruthers et al. 2010). In this regard, the addition of a P2Y12 receptor 
antagonist to low-dose aspirin reduces the risk of cardiovascular death, myocardial 
infarction and stroke in patients with recent (Wallentin, Becker et al. 2009) or prior 
(Bonaca, Bhatt et al. 2015) myocardial infarction. Ticagrelor is an oral reversible 
antagonist of the platelet adenosine diphosphate P2Y12 receptor. It provides faster, 
more potent and more consistent P2Y12 inhibition than clopidogrel (Gurbel, Bliden et 
al. 2009). In the PLATelet inhibition and patients Outcomes (PLATO) trial of 18,624 
patients presenting with acute coronary syndrome, ticagrelor was superior to 
clopidogrel for the prevention of cardiovascular events and death (3) (Wallentin, 
Becker et al. 2009). Moreover, the prolonged use of dual antiplatelet therapy 
following myocardial infarction continues to reduce cardiovascular events, albeit at 
the expense of increased rates of major bleeding (Bonaca, Bhatt et al. 2015). Thus, 
there is a clinical need to improve the risk stratification of patients to enable 
physicians to better select ‘vulnerable’ patients who may benefit from extended 
duration of dual antiplatelet therapy.  
 
A novel approach for assessing patients at high-risk of coronary plaque rupture is 
using positron emission tomography and coronary computed tomography 
angiography (PET-CCTA). This technique uses the radiotracer 18F-fluoride to 
identify regions of increased disease activity in coronary artery plaques. Previous 
studies have demonstrated that coronary 18F-fluoride uptake correlates with a high-
risk cardiovascular profile and identifies ruptured coronary plaques in patients with 
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recent myocardial infarction (Dweck, Chow et al. 2012, Joshi, Vesey et al. 2014). 
Importantly, we have previously reported an association between increased 
coronary 18F-fluoride uptake and higher plasma high-sensitivity cardiac troponin I 
concentrations in patients with stable coronary artery disease (Joshi, Vesey et al. 
2014). Silent plaque rupture is common and subclinical plaque thrombus formation 
is a frequent incidental post-mortem finding in patients with multivessel coronary 
artery disease who have died from non-cardiovascular causes (Mann, Davies, 
1999). This suggests that coronary 18F-fluoride uptake may identify high-risk plaque 
that is associated with thrombus formation and subclinical myocardial injury from 
microemboli. If correct, this would potentially be modifiable with intensive dual 
antiplatelet therapy. 
 
In this study, coronary 18F-fluoride activity was used to identify patients with stable 
multivessel coronary artery disease who respond favorably to ticagrelor as 
assessed by a reduction in high-sensitivity cardiac troponin I concentrations. 
  





6.3.1 Study Design 
This was an investigator-initiated double-blind randomised parallel-group placebo-
controlled trial conducted at a single centre in Edinburgh, UK. The study was 
approved by the local institutional review board, the Scottish Research Ethics 
Committee (REC reference: 14/SS/0089), Medicines and Healthcare products 
Regulatory Agency, and the United Kingdom (UK) Administration of Radiation 
Substances Advisory Committee. It was performed in accordance with the 
Declaration of Helsinki. All patients provided written informed consent prior to any 
study procedures. 
 
6.3.2 Study Population 
Patients were recruited between March 2015 and March 2017. Patients were 
included if they met the following criteria: age ≥40 years and already receiving 
aspirin therapy with angiographically proven multivessel coronary artery disease 
defined as at least two major epicardial vessels with any combination of either (a) 
>50% luminal stenosis, or (b) previous revascularization (percutaneous coronary 
intervention or coronary artery bypass graft surgery). Patients were excluded if they 
had any of the following criteria: an acute coronary syndrome within the last 12 
months, any ongoing indication for dual anti-platelet therapy, or concurrent 
thienopyridine (clopidogrel or prasugrel) or oral anticoagulant therapy, or 
percutaneous coronary intervention or coronary artery bypass graft surgery within 
the last 3 months.  
6.3.3 Study Procedures 
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All patients underwent a baseline assessment to confirm eligibility and 
measurement of plasma high-sensitivity cardiac troponin I concentration and 
platelet-monocyte aggregates. An electrocardiogram (ECG) gated 18F-fluoride PET-
CCTA was performed after patients had received 50-100 mg of oral metoprolol if 
their resting heart rate was >65 beats/min prior to the intravenous administration of 
250 MBq 18F-fluoride. After 60 min, patients were imaged with a hybrid PET-CT 
scanner (64-multidetector Biograph mCT, Siemens Medical Systems, Erlangen, 
Germany). Attenuation correction CT scans were performed prior to the acquisition 
of ECG-gated list-mode PET data using a single 30-min bed position centred on the 
heart. Finally, an ECG-gated CCTA was performed in mid-diastole during held 
expiration following sublingual glyceryl trinitrate.  
 
6.3.4 Statistical Analysis 
Categorical data are presented using counts and percentages, whilst continuous 
variables are presented using mean, standard deviation (SD), median, interquartile 
range, minimum, maximum, and number of patients. Participants were removed 
from formal statistical analysis where data were missing for that outcome variable. 
All (except safety) analyses were performed on a per-protocol population that 
excluded participants without a blood sample, or whose compliance was <80% for 
the study medication, at the 30-day visit. For the primary analysis, the change in 
troponin I concentration from baseline to 30 days was compared between the two 
treatment groups (ticagrelor and placebo) using linear regression, adjusting for the 
minimisation variables in patients with increased coronary 18F-fluoride uptake. Prior 
to analysis, tests for normality were undertaken and, where data were skewed, 
logarithmic transformation was performed. Central estimates and 95% confidence 
intervals (CI) were calculated. Similar analyses were performed for secondary 
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outcomes. In post-hoc testing, comparison was made of baseline troponin 
concentrations between patients with and without evidence of coronary 18F-fluoride 
activity and also confirmed treatment efficacy by comparison of ADP-stimulated 
platelet activation between the two trial intervention groups (ticagrelor versus 
placebo). For 1-year evaluation of changes in cardiac troponin I concentrations, an 
adjusted linear regression model (adjusted for the minimisation variables) was 
generated and descriptive statistics were presented for the area under the curve. 
Where there were missing values, the value was imputed linearly from adjacent 
measurements. Adjustment for age was performed as a linear term. To determine 
whether there was efficacy of ticagrelor using a baseline troponin I concentration ≥5 
ng/L, a post-hoc comparison was made between groups using the method 
described in the primary analysis. For all analyses, a two-sided p<0.05 was taken as 
statistically significant. Statistical analysis was performed using SAS (Software 9.4, 
North Carolina) with the primary analysis validated by a second statistician in 
Edinburgh Clinical Trials Unit. Post-hoc analyses were performed separately from 
the primary statistical analysis plan using R version 3.4.0 (R Foundation for 
Statistical Computing, Vienna, Austria).  





6.4.1 Study Population 
A total of 361 patients were screened and 202 patients were randomized following 
the baseline coronary 18F-fluoride PET-CCTA (Figure 6.1). Eleven patients 
discontinued the study early due to withdrawal of consent (n=1), a new diagnosis of 
malignancy on baseline PET-CCTA (n=1), <80% compliance with study medication 
at 30 days (n=8), and a sudden unexpected death prior to receiving study 
medication (n=1). The randomized groups were well matched for the presence of 
cardiovascular risk factors and represented a high-risk cohort with 70% having a 
history of acute coronary syndrome (median 2.25 years prior to study enrolment) 
(Table 6.1). A per-protocol population of 191 patients (mean age 65.9, SD 8.3 
years, 80% male) had both blood sampling at 30 days and ≥80% compliance with 
the study medication, comprising 94 patients in the ticagrelor group and 97 patients 
in the placebo group. One hundred and twenty (62.8%) patients had evidence of 
coronary 18F-fluoride activity in at least one epicardial vessel (Table 6.2, Figure 
6.2).  
 
The geometric mean troponin I concentration at baseline was 3.8 (Geometric SD 
2.9) ng/L in patients with increased coronary 18F-fluoride activity compared with 2.5 
(Geometric SD 2.6) ng/L in those without uptake (p=0.004; Table 6.3). 
  






Figure 6.1 CONSORT Diagram of DIAMOND trial. 
Flow diagram of the progress through the phases of the randomised trial between ticagrelor 
and placebo groups. 
  





Table 6.1 Baseline characteristics of the DIAMOND population. 
 






















Age, years 65.9±8.2 65.9±8.3 65.5±8.4 66.3±8.1 0.504 
Male  162 (80) 152 (80) 74 (79) 78 (80) 0.912 
Body Mass Index, kg/m2 29.8±5.2 29.7±5.0 30.0±5.2 
29.4±4.9 0.413 
Medical history      
History of acute coronary 
syndrome 143 (71) 134 (70) 65 (69) 
69 (71) 0.887 













Intervention 163 (81) 154 (81) 75 (80) 
79 (81) 0.915 
Coronary Artery Bypass 
Grafting 40 (20) 38 (20) 18 (19) 
20 (21) 0.942 
Hypertension  113 (56) 105 (55) 52 (55) 53 (55) 1.000 
Hypercholesterolaemia 195 (97) 185 (97) 93 (99) 92 (95) 0.228 
Diabetes Mellitus  39 (19) 36 (19) 19 (20) 17 (18) 0.772 
Prior Stroke/Transient 
Ischaemic Attack  4 (2) 4 (2) 2 (2) 
2 (2) 1.000 
History of Atrial Fibrillation  5 (2) 5 (3) 4 (4) 1 (1) 0.346 
Peripheral Vascular Disease  8 (4) 7 (4) 1 (1) 6 (6) 0.134 
Medications      
Aspirin  202 (100) 191 (100) 94 (100) 97 (100) NA 
Statin  192 (95) 182 (95) 92 (98) 90 (93) 0.188 




Receptor Blocker  
155 (77) 145 (76) 68 (72) 77 (79) 
0.333 




   
 0.547 
  31-60 23 (11) 22 (12) 9 (10) 13 (13)  
   >60 179 (89) 169 (88) 85 (90) 84 (87)  
Total Cholesterol, mg/dL 162±39 162±39 162±39 162±35 0.852 
High density lipoprotein, 
mg/dL 46±12 46±12 43±15 
46±12 0.128 
Low density lipoprotein, 
mg/dL 89 ±31 89±31 85±35 
89±27 0.377 
Triglycerides, mg/dL 159±97 151±97 159±106 151±80 0.556 















CORONARY 18F-FLUORIDE UPTAKE   
N 120 59 61  
BASELINE 3.8±2.9 4.2±2.9 3.5±3.0 0.197 
30 DAYS 3.6±2.7 4.1±2.5 3.2±2.9 0.072 
RATIO OF 30 
DAYS TO 
BASELINE 
0.95±1.87 0.97±2.13 0.93±1.59 0.907 
NO CORONARY 18F-FLUORIDE UPTAKE  
N 71 35 36  
BASELINE 2.5±2.6 2.5±2.8 2.4±2.4 0.872 
30 DAYS 2.4±2.7 2.4±2.8 2.3±2.6 0.877 
RATIO OF 30 
DAYS TO 
BASELINE 
0.97±1.68 0.97±1.77 0.96±1.59  
 
Table 6.2 Plasma high-sensitivity cardiac troponin I concentration (ng/L) in the per-protocol 
population. 
 
Geometric mean and geometric standard deviation, back transformed from log transformed 
values. 
  











Figure 6.2 Intracoronary thrombus and coronary 18F-fluoride activity. 
 
A 72-year-old female with intracoronary thrombus in the left main stem (A, B arrow). Axial 
reconstructions demonstrate a non-obstructive intracoronary thrombus at 11 o’clock with 
coronary calcification at 2 o’clock and 7 o’clock (C and D, schematic). 18F-Fluoride activity 
was present in the coronary plaque (E and F, schematic).  
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6.4.2 Effect of ticagrelor on platelet function 
Baseline platelet and monocyte reactivities were well balanced between treatment 
arms. Consistent with its known pharmacological action, ticagrelor markedly 
inhibited platelet P-selectin expression and reduced the formation of platelet-
monocyte aggregates following ex vivo stimulation with ADP (Figure 6.3, p<0.001 
for all). Ticagrelor had no effect on 30-day unstimulated platelet activation (p>0.05 
for all). These results were derived from post-hoc analysis. 
  







Table 6.3 Plasma high-sensitivity cardiac troponin I concentration (ng/L) at 30 days for the 
per-protocol population. 
 
Estimates are back transformed estimates from analysis of log transformed values at 30 
days adjusting for age, sex and log transformed baseline troponin. Ratio of geometric means 
is Ticagrelor divided by Placebo. GSE, geometric standard error   
 Adjusted Geometric 
Mean (GSE) 
Ratio of Geometric 
Means 
 
 Ticagrelor Placebo (95% CI) p-valve 
Cardiac troponin I, 
ng/L 
(18F-fluoride activity) 
3.8 (1.1) 3.4 (1.1) 1.11 (0.90 to 1.36) 0.32 
Cardiac Troponin I, ng/L 
(No 18F-fluoride activity) 
2.4 (1.1) 2.3 (1.1) 1.02 (0.80 to 1.31) 0.87 






Figure 6.3 Flow cytometry assessment of platelet activation at baseline and 30 days. 
 
Unstimulated (upper panels) and adenosine diphosphate (20 µmol/L) stimulated (lower 
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6.4.3 Effect of ticagrelor on high-sensitivity troponin I at 30 
days 
For the primary endpoint, there was no effect of ticagrelor on troponin I at 30 days in 
patients who had increased coronary 18F-fluoride activity (ratio of geometric means 
ticagrelor versus placebo 1.11, 95% CI 0.90 to 1.36; p=0.32) (Table 6.3). Similarly, 
amongst the 71 (37.2%) patients without discernible coronary 18F-fluoride activity, 
there was no difference in the 30-day troponin I concentration between ticagrelor 
and placebo (ratio of geometric means 1.02, 95% CI 0.80 to 1.31; p=0.87) (Table 
6.3). 
 
Secondary endpoints explored whether a reduction in cardiac troponin I could be 
demonstrated over twelve months. Twelve-month troponin I concentrations were 
measured in 183 (95.8%) patients, comprising of 91 (96.8%) patients in the 
ticagrelor group and 92 (94.8%) patients in the placebo group. There was no 
difference in area under the concentration curve of troponin I over twelve months 
between the ticagrelor and placebo groups (ratio of geometric means 0.92, 95% CI 
0.74 to 1.13; p=0.42) (Figure 6.4) (Table 6.4). Post-hoc analysis of the subset of 
patients with a baseline troponin I concentration ≥5 ng/L (ticagrelor n=34, baseline 
geometric mean 10.3 ng/L; placebo n=33, baseline geometric mean 8.7 ng/L), found 
there was no change in troponin I concentration at 30 days (p=0.89) or twelve 
months (p=0.86). (Figure 6.5, Table 6.5). 
  





Figure 6.4 Plasma high-sensitivity cardiac troponin I concentration over 1 year. 
 
Box-whisker plot of individual patient-level plasma high-sensitivity troponin I concentration 
(ng/L) in ticagrelor (blue) and placebo (red) groups at baseline, 1, 3, 6, 9 and 12 months. 
Median and interquartile range for each time point. 
  




 Adjusted Geometric 
Mean (GSE) 
Ratio of Geometric 
Means 
 
 Ticagrelor Placebo (95% CI) p-valve 
AUC from 30 days to 
1 year 
(18F-fluoride activity) 
3.7 (1.1) 4.4 (1.1) 0.86 (0.63 to 1.17) 0.33 
AUC from 30 days to 
1 year 
(No 18F-fluoride activity) 
2.4 (1.1) 2.3 (1.1) 1.04 (0.84 to 1.28) 0.70 
 
Table 6.4 Plasma high-sensitivity cardiac troponin I concentration over 1 year for 
participants in per-protocol population. 
 
Estimates are back transformed estimates from analysis of log transformed values area 
under curve from 30 days to 1 year adjusting for age, sex and log transformed baseline 
troponin. Ratio of geometric means is Ticagrelor divided by Placebo. AUC, area under curve, 
ng/L, GSE, geometric standard error. 
  





Figure 6.5 Plasma high-sensitivity cardiac troponin I concentration (stratified population with 
troponin I >5ng/L at baseline) over 1 year. 
 
Box-whisker plot of individual patient-level plasma high-sensitivity troponin I concentration 
(ng/L) in ticagrelor (blue) and placebo (red) groups at baseline, 1, 3, 6, 9 and 12 months 
(p=ns for all values). Median and interquartile range for each time point. 
  




PLACEBO Baseline 18F-fluoride uptake on PET-CT 


















(1.4 to 2.3) 
7.7 
(5.9 to 10.1) 
1.8 
(1.4 to 2.3) 
9.3 
(7.2 to 12.1) 




(1.3 to 2.3) 
7.1 
(4.1 to 12.1) 
1.8 
(1.4 to 2.3) 
8.3 
(6.1 to 11.2) 
 
TICAGRELOR Baseline 18F-fluoride uptake on PET-CT 


















(1.4 to 2.3) 
8.7 
(4.7 to 16.3) 
2.3 
(1.9 to 2.9) 
10.3 
(7.6 to 15.8) 




(1.3 to 2.2) 
10.2 
(5.2 to 20.1) 
2.7 
(2.1 to 3.4) 
8.3 
(6.1 to 11.2) 
 
Table 6.5 Efficacy of Ticagrelor in patients with troponin I concentration ≥ 5 ng/L. 
  




6.4.4 Safety outcomes 
There were no suspected unexpected serious adverse reactions over the course of 
this study. Serious adverse events occurred in 7/100 (7%) patients who received at 
least one single dose of ticagrelor and 15/101 (11.9%) patients who were 
administered placebo (Table 6.6). There were no reported major life-threatening or 
other major bleeding events over the course of this study. Minimal bleeding events 
(bruising) were reported in 64 (64.0%) patients in the ticagrelor group and 12 
(11.9%) patients in the placebo group (Table 6.7). Dyspnoea episodes occurred in 
24 (24%) patients in the ticagrelor group compared with 8 (7.9%) patients in the 
placebo group at one year. 
  

































 10 7 (7%) 15 12 
(11.9%) 
25 19 (9.5%) 
Outcome Resolved 10 7 (7%) 15 12 
(11.9%) 
25 19 (9.5%) 
Causality Unrelated to 
IMP & NIMP 
9 7 (7%) 14 11 
(10.9%) 
23 18 (9%) 
Unrelated to 
IMP 
1 1 (1%) 1 1 (1%) 2 2 (1%) 
Expectedne
ss 
Expected 0 0 (0%) 0 0 (%) 0 0 (0%) 
Unexpected 10 7 (7%) 15 12 
(11.9%) 
25 19 (9.5%) 
Severity Mild 5 5 (5%) 5 4 (4%) 10 9 (4.5%) 
Moderate 5 3 (3%) 9 9 (8.9%) 14 12 (6%) 
Severe 0 0 (0%) 1 1 (1%) 1 1 (0.5%) 
 
Table 6.6 Serious adverse events for safety population. 
 
 
Table 6.7 Bleeding and dyspnoea events for safety population.  


































Minor 1 1 (1%) 0 0 (0%) 1 1 (0.5%) 
Major 0 0 (0%) 0 0 (0%) 0 0 (0%) 
Major life 
threatening 
0 0 (0%) 0 0 (0%) 0 0 (0%) 
Dyspnoea At 1 year 27 24 (24%) 8 8 (7.9%) 35 32 
(15.9%) 




In this randomised placebo-controlled trial, this study found no evidence that 
ticagrelor 90 mg twice daily reduces plasma high-sensitivity cardiac troponin I 
concentrations in patients with high-risk plaque and established multivessel 
coronary artery disease. This suggests that, in patients with high-risk coronary 
plaque, plasma cardiac troponin I concentrations are not attributable to subclinical 
myocardial injury from thrombotic microembolic injury.  
 
This study has several important strengths. This is the first trial to use PET-CCTA 
imaging with 18F-fluoride to identify patients with high-risk coronary plaque who 
may be at heightened risk of future coronary events and thereby have the most to 
gain from potent dual antiplatelet therapies. It is also the largest trial to date 
employing coronary plaque PET imaging. Whilst previous PET studies have used 
18F-fluorodeoxyglucose to visualise inflammation within the carotid arteries as a 
surrogate to guide intensification of atherosclerotic therapy (Tawakol, Fayad et al. 
2013, Fayad, Mani et al. 2011), the coronary and cerebral vascular beds differ both 
with respect to their underlying molecular pathophysiology and also in response to 
the treatment effect using ticagrelor (Wallentin, Becker et al. 2009, Johnston, 
Amarenco et al. 2016). Second, the study design enabled high-risk patients with 
multivessel coronary disease and in vivo evidence of disease activity to be precisely 
phenotyped prior to randomization in a manner that can seldom be achieved in 
larger clinical outcome trials (Wallentin, Becker et al. 2009, Vranckx, Valgimigli et al. 
2018). Finally, this is the first prospective randomised controlled trial to use high-
sensitivity cardiac troponin I concentrations as a surrogate outcome measure for 
assessing future cardiovascular risk. 
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In trying to understand why P2Y12 inhibition did not reduce cardiac troponin in this 
study, it is worth addressing some of the underlying assumptions in the trial design. 
Does coronary 18F-fluoride activity identify patients with high-risk plaque? Recent 
studies have found that 18F-fluoride holds potential in identifying culprit plaques in 
the coronary circulation by classifying patients who have a high-risk cardiovascular 
phenotype and culprit plaque rupture following type 1 myocardial infarction (Dweck, 
Chow et al. 2012, Joshi, Vesey et al. 2014). Histological validation indicates that 
18F-fluoride preferentially binds to microcalcification in regions of plaque 
mineralisation, a key component of high-risk plaque (Irkle, Vesey et al 2015). 
Hydroxyapatite, the most common form of atherosclerotic microcalcification, is 
extruded from apoptotic macrophages, and accumulates within necrotic cores where 
it may destabilise the structural integrity of the fibrous cap (New, Goettsch et al. 
2013, Hutcheson, Goettsch et al. 2016). The identification of abnormal material 
composition of the arterial wall has clinical relevance, as these regions may lead to 
atherosclerotic plaque rupture manifesting as myocardial infarction, stroke or 
aneurysm rupture (Joshi, Vesey et al. 2014, Vesey, Jenkins et al. 2017, Forsythe, 
Dweck et al. 2018). In this cohort, the frequency of 18F-fluoride activity (>60%) in 
stable coronary artery disease is similar to previous estimates in patients with a high 
burden of coronary artery disease and prior myocardial infarction (Dweck, Chow et 
al. 2012). This work confirms the high prevalence of coronary 18F-fluoride activity in 
stable patients with multivessel coronary artery disease in whom intensification of 
antiplatelet therapy may be considered. 
 
A key question is whether troponin measurement below the 99th centile reflects 
subclinical plaque rupture with accompanying distal microvascular embolisation as 
has previously been posited (Oemraswingh, Cheng et al. 2017). In this regard, 
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some therapies directed at reducing the risk of atherosclerotic plaque rupture, such 
as pravastatin, both modify troponin concentrations and reduce the risk of 
myocardial infarction (Ford, Shah et al. 2016, Januzzi, Hahn et al. 2000). In 
contrast, strategies that have failed to demonstrate a reduction in cardiovascular 
events in the context of stable coronary artery disease, such as coronary 
revascularisation, attenuation of plaque inflammation and inhaled therapies for 
respiratory disease, have not correlated with a reduction in serial troponin 
concentration (Welsh, Tuckwell et al. 2016, Everett, Brooks et al. 2015, Adamson, 
Anderson et al. 2018). If subclinical plaque thrombosis is the dominant mechanism 
underlying detectable troponin I concentrations in patients with stable coronary 
artery disease, a reduction in troponin I concentration would be expected following 
the administration of potent antiplatelet therapy. The lack of response to ticagrelor in 
this study would suggest that other contributing mechanisms to myocardial injury 
should be considered. The emergence of newer therapies (such as sodium/glucose 
cotransporter 2 inhibition) that lower blood pressure may reduce troponin 
concentrations through an improvement in myocardial remodelling, further raising 
doubts over the subclinical plaque rupture hypothesis (Januzzi, Suchindran et al. 
2018, Lohrke, Sibeneicher et al. 2017, McEnvoy, Chen et al. 2016). In this study, 
high-sensitivity cardiac troponin I concentrations were higher in patients with 18F-
fluoride activity, albeit the differences were small and below the established risk 
stratification threshold of 5 ng/L (Shah, Anand et al. 2015, Ford, Shah et al. 2016, 
Januzzi, Suchindran et al. 2018). Therefore, it seems unlikely that troponin at these 
concentrations reflects subclinical plaque rupture and it is perhaps unsurprising that 
ticagrelor treatment did not result in an early or late reduction in troponin 
concentration. 
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Previous reports have suggested that there is a high incidence of subclinical 
intracoronary thrombus in patients with apparently stable coronary artery disease. 
Indeed, some have suggested that this occurs in as many as one in seven patients 
(Mann, Davies, 1999). If this is the case, it would appear that intracoronary 
thrombus does not track with troponin. This suggests we require better non-invasive 
markers of coronary thrombosis, such as novel PET tracers (Lohrke, Siebeneicher 
et al. 2017) or non-invasive imaging (Jansen, Perera et al. 2011), to use as 
biomarkers of cardiovascular risk and anti-thrombotic therapeutic efficacy. 
 
6.5.1 Limitations 
There are some study limitations that should be acknowledged. This study had a 
modest sample size to assess the impact of ticagrelor on a readily available plasma 
biomarker, and a larger study would be required to assess clinical outcomes of 
ticagrelor use in patients with stable coronary artery disease and coronary 18F-
fluoride activity. The low baseline troponin I concentrations observed in this study 
may have limited power to demonstrate the benefit of ticagrelor in this population. 
Enrichment of the population by selecting patients with higher troponin I 
concentrations prior to study entry may need to be considered for future trials. It 
should also be acknowledged that this study was undertaken in a single centre with 
expertise in coronary 18F-fluoride imaging and the methods for analysing coronary 
18F-fluoride activity are subject to a number of operator and scan-dependent 
variables. Whilst recent reports have suggested that coronary 18F-fluoride activity 
may hold prognostic value in stratifying high-risk populations (Kitagawa, Yamamoto, 
et al. 2018), larger prospective studies evaluating the prognostic utility of coronary 
18F-fluoride activity in patients with cardiovascular disease are ongoing 
(NCT02278211).  





In patients with multivessel coronary artery disease and in vivo coronary 18F-
fluoride activity, this study found no evidence that intensification of antiplatelet 
therapy using ticagrelor 90 mg twice daily reduces plasma high-sensitivity cardiac 
troponin I concentration at 30 days or 1 year. These findings suggest that in this 
group of patients plasma high-sensitivity cardiac troponin I concentrations may not 
be a suitable marker to predict efficacy of P2Y12 inhibition.  
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7.1 Summary of thesis findings 
Clinicians routinely make intuitive decisions that aim to ‘personalise’ an individual’s 
treatment. This is far from an exact science, and often results in clinicians 
oversimplifying the complexity of the underlying pathophysiology. In a time-
pressured clinical environment, clinicians use intuitive decision-making to make fast 
and impulsive judgments that often attribute a patient’s complaint to a single 
common phenotype leading to a “one size fits all” approach to treatment. This 
population-approach to the management of human coronary atherosclerosis has 
yielded better use of evidence-based therapies and promotion of lifestyle 
modifications to dramatically reduce early deaths from myocardial infarction over the 
past two decades. However, many patients fail to benefit from the widely advocated 
successes of a “one size fits all” approach either by sustaining harm from treatment 
or by remaining at increased risk of recurrent cardiovascular events despite optimal 
therapeutic interventions. 
 
To influence long-term outcomes, a more considered approach is required. 
Precision medicine requires taking account of the heterogeneity of disease and an 
individual’s variable response to treatment. A detailed insight into the biological 
continuum of disease will help unravel the complexity of why some individuals gain 
significant benefits from interventions whereas others do not. Whereas current 
strategies in coronary artery disease have focused on population-derived evidence-
based therapies, precision imaging seeks to understand an individual’s unique 
biological network to better stratify treatment. 
 
The core aims of this thesis were to investigate whether the identification of 
vulnerable coronary plaques could refine the assessment of residual risk in 
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individual’s with stable and unstable coronary artery disease and test it’s use in 
stratifying high-risk individuals to intensified medical therapy. 
 
7.1.1 Adverse plaque characterisation using coronary 
computed tomography angiography 
In a sub-study of the Scottish Computed Tomography of the HEART (SCOT-
HEART) trial, patients who were randomised to coronary computed tomography 
angiography for the assessment of stable chest pain underwent coronary plaque 
analysis to identify high-risk plaque features (positive remodelling, low attenuation 
plaque, spotty calcification, ‘napkin ring’ sign). For the purpose of this analysis, 
1,769 patients had an interpretable coronary computed tomography angiography, of 
whom 608 (34%) patients had one of more features high-risk coronary plaque 
features. The primary outcome for this observational sub-study was a composite of 
fatal and non-fatal myocardial infarction at 5 years. 
 
Patients with high-risk coronary plaque were at a three-fold increased risk of fatal 
and non-fatal myocardial infarction at 5 years compared to those without high-risk 
plaque features. When compared to patients with normal coronary arteries, the 
group at highest risk of fatal and non-fatal myocardial infarction included patients 
with a combination of both obstructive coronary artery disease and high-risk plaque 
(Figure 7.1). However, these associations were not independent of coronary plaque 
burden measured using the coronary artery calcium score. More specific methods of 











Figure 7.1 Adverse plaque features on coronary computed tomography angiography 
identifies patients at an increased risk of subsequent events. 
 
(A) Bar graph of the frequency of coronary heart disease or nonfatal myocardial infarction at 
2 and 5 years for patients with normal coronary arteries and non-obstructive or obstructive 
with and without adverse plaque. (B) Coronary computed tomography angiography and 
invasive coronary angiography images from a patient with non-obstructive coronary artery 
disease who had a subsequent non-ST segment elevation myocardial infarction. The 
red/yellow dotted lines and arrows correspond to the location of the plaques in the red/yellow 
boxes. 
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7.1.2 Reproducibility and optimisation of coronary 18F-
Fluoride positron emission tomography imaging 
Coronary positron emission tomography is a non-invasive imaging modality which 
has been used to detect high-risk coronary plaque. Microcalcification is a key 
feature of vulnerable plaques and can be readily identified with 18F-Fluoride. This 
radiotracer has been used to highlight regions of microcalcification in large vessel 
vascular beds, however technical challenges have limited the clinical translation of 
this technique to accurately identify plaque activity in coronary arteries.  To establish 
the optimal methodology for quantifying and categorising 18F-fluoride uptake in the 
coronary vasculature, a prospective observational study was performed recruiting 
patients with stable and unstable multi-vessel coronary artery disease. Thirty 
patients with stable or recent acute coronary syndrome underwent scan-rescan 
imaging with coronary 18F-fluoride positron emission tomography within a two-week 
interval. 
 
Twenty patients with stable coronary artery disease and ten patients with recent 
acute coronary syndrome had serial 250 MBq 18F-fluoride positron emission 
tomography scans. There was good agreement in the quantification and 
categorisation of plaque activity between observers and between scans. Coronary 
18F-fluoride uptake is therefore a precise and reproducible metric in the coronary 
arteries and the analytic performance is sufficient to use this imaging biomarker in 
clinical trials. 
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7.1.3 Histological confirmation of 18F-fluoride binding in 
coronary artery specimens 
The pathophysiological processes governing the deposition of microcalcification in 
coronary arteries are complex. In skeletal bone, 18F-fluoride binds to the exposed 
surface of hydroxyapatite to form fluoroapatite, however no previous study has 
demonstrated hydroxyapatite to be the substrate for 18F-fluoride binding in coronary 
arteries. In an ex vivo study using sections of human coronary arteries, regions of 
18F-fluoride binding were evaluated for hydroxyapatite deposition using a selective 
immunofluorescence bisphosphonate probe and Raman spectroscopy. The 
expression of proteins and transcription factors associated with plaque 
mineralisation were analysed in regions of increased 18F-fluoride binding. 
 
18F-Fluoride was highly selective for unbound hydroxyapatite deposition in coronary 
atherosclerotic plaques. In advanced atherosclerotic plaques, intimal hydroxyapatite 
identified using 18F-fluoride was associated with increased expression of 
osteopontin and Runt-related transcription factor 2 (Figure 7.2). These findings 
suggest that 18F-fluoride highlights regions of active atherosclerosis and may be 
used as a biomarker of disease activity. 
 
  












Figure 7.2 Histological analysis of 18F-fluoride binding in coronary artery specimens 
 
Coronary 18F-fluoride uptake identifies regions of microscopic hydroxyapatite deposition in 
intimal atherosclerotic plaque. Intense 18F-fluoride uptake is associated with the intimal 
expression of osteopontin and Runt-related transcription factor 2, markers of plaque 
mineralization. 
FBP, Fluorescein-Bisphosphonate, OPN, osteopontin, Runx-2, Runt-related transcription 
factor 2.  
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7.1.4 Identification of patients with high-risk plaque features 
to stratify treatment 
Whilst high-risk plaque features are associated with an increased risk of 
cardiovascular events, it remains unknown whether intensified medical therapy 
should be used in these patients. To address whether patients with increased 
coronary 18F-fluoride uptake may benefit from the addition of P2Y12 inhibition with 
ticagrelor, a randomised, double-blind, placebo-controlled trial was performed. 
Patients with multi-vessel coronary artery disease were randomised (1:1) to either 
ticagrelor 90 mg twice daily or matched placebo and serial measurement of high-
sensitivity cardiac troponin I was performed at 30 days and at 3-month intervals up 
to 1 year. The primary endpoint was a change in plasma troponin I concentration at 
30 days in patients with increased coronary 18F-fluoride uptake. 
 
Dual antiplatelet therapy using Ticagrelor did not reduce plasma troponin I 
concentration in patients with high-risk plaque features identified using coronary 
18F-fluoride uptake (Figure 7.3). Despite a significant reduction in platelet reactivity 
in patients receiving ticagrelor, plasma troponin I concentration remained 
unchanged suggesting that subclinical coronary thrombosis does not contribute to 

















Figure 7.3 Using coronary 18F-fluoride to identify patients who may benefit from intensified 
dual antiplatelet therapy. 
 
Coronary 18F-fluoride positron emission tomography was used to identify high-risk coronary 
plaque in patients with stable multivessel coronary artery disease. Randomisation to 
intensified dual antiplatelet therapy with ticagrelor did not reduce plasma high-sensitivity 
cardiac troponin I concentrations at 30-days in patients with high-risk plaque.  
(Moss, Doris et al. 2019) 
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7.2 Future Directions 
The findings of this thesis raise important issues relevant to the application of 
vulnerable plaque detection in human coronary atherosclerosis. There is an unmet 
clinical need to improve clinical risk stratification in patients with coronary artery 
disease. As novel therapies targeting key components of the atherosclerotic 
pathway become more widely available for clinical use, selecting the appropriate 
patient for the appropriate treatment will remain a clinical priority. In this regard, 
cardiovascular imaging using hybrid positron emission tomography is an attractive 
tool, as it enables clinicians to phenotype coronary artery disease and monitor 
plaque activity. Ongoing clinical trials are exploring whether positron emission 
tomography may have prognostic clinical utility in the context of human coronary 
atherosclerosis.  
 
7.2.1 Using 18F-fluoride imaging to predict future 
cardiovascular events 
Following an acute myocardial infarction, one in five patients will have a recurrent 
event despite optimal medical therapy (Mills et al, 2011). Half of these recurrent 
myocardial infarctions occur at a site that was not deemed to be of clinical 
importance at the time of their initial presentation (Stone et al, 2011). The central 
hypothesis of the Prediction of Recurrent Events with 18F-Fluoride to Identify 
Ruptured and High-risk Coronary Artery Plaques in Patients with Myocardial 
Infarction, the PRE18FFIR trial (NCT02278211), is that coronary 18F-fluoride uptake 
can identify high-risk and ruptured atherosclerotic plaque in patients with recent 
myocardial infarction and thereby assist in the diagnosis, risk stratification and 
management of patients with acute myocardial infarction. More targeted and 
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focused investigations and interventions have the potential to shorten hospital stay, 
to avoid the indiscriminate application of expensive therapies, and to focus and to 
maximize the impact of our current successful therapies to reduce recurrent major 
adverse cardiac events. The study rationale aims to confirm preliminary findings 
presented in this thesis in a broad range of patients across different centres 
throughout the United Kingdom. Specifically, this study is intended to confirm 
whether coronary 18F-fluoride uptake identifies high-risk or ruptured coronary 
atherosclerotic plaque, and to determine if coronary 18F-fluoride uptake is predictive 
of disease progression and clinical outcome. 
 
7.2.2 Natural history of 18F-fluoride uptake in stable coronary 
artery disease and following recent myocardial infarction 
Numerous studies have determined the predictive utility of features of vulnerability 
as determined by a variety of invasive and non-invasive imaging modalities.  The 
majority of these investigations have focused on clinical endpoints following a single 
measurement rather than using serial imaging to detect temporal changes in plaque 
vulnerability. In this thesis, investigations using 18F-fluoride plaque characterisation 
have determined tracer uptake on a single positron emission tomography scan or 
within a two-week interval. In order to support more widespread adoption of this 
imaging method and better understand the natural history of plaque vulnerability, it 
is necessary to assess the temporal changes in 18F-fluoride radiotracer uptake by 
performing repeated imaging studies. A sub-study of the PRE18FFIR trial, 
PRE18FFIR-TIME – The Investigation of teMporal changE, will recruit 80 patients 
from the main study who will undergo an additional coronary 18F-fluoride positron 
emission tomography scan at 6 weeks, 12 weeks, 26 weeks and 52 weeks after 
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their baseline scan to determine how the pattern of coronary 18F-fluoride uptake 
change over the period of one year. 
 
7.2.3 Correlation of 18F-fluoride with invasive imaging 
characteristics 
The most comprehensively investigated diagnostic tools for assessing plaque 
vulnerability are invasive intravascular imaging using ultrasound (IVUS) and Fourier 
domain optical coherence tomography (OCT). In a pilot study, plaques with 
increased 18F-fluoride uptake correlated with high-risk features on intravascular 
imaging (Joshi, Vesey et al. 2014). Similar to findings that were observed in the 
adverse plaque sub-study of SCOT-HEART, necrotic core and positive remodelling 
identified using IVUS were the two plaque features which closely resembled plaques 
with increased 18F-fluoride uptake. 
 
A recent development in intravascular imaging catheters has combined IVUS with 
near-infrared spectroscopy (NIRS) which allows the differing tissue characteristics of 
coronary plaques to be quantitatively measured with regards to light scatter and 
absorption, in particular, to detect cholesterol deposits. Accurate co-registration of 
invasive and non-invasive imaging datasets will provide more detailed information of 
plaque composition. By identifying individual culprit plaque rupture using 
intravascular imaging, the aim of the PRE18FFIR – IMAGE sub-study is to determine 
whether coronary 18F-fluoride uptake is associated with culprit plaque rupture, 
luminal thrombosis and an increased lipid burden of cholesterol deposits. 
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7.2.4 Clinical trials using novel radiotracers to assess plaque 
rupture in coronary artery disease 
Coronary plaque positron emission tomography imaging has focused on re-
purposing oncological tracers for identifying plaque, however the potential exists to 
generate radiotracers which have specific ligands directly involved in atherosclerotic 
pathways. In this regard, the 18F-glycoprotein I (18F-GP1) is a novel fiban class 
ligand that binds with high affinity to the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor on 
activated platelets. Following the activation of GPIIb/IIIa, the incorporation of 
fibrinogen results in cross-linking and thrombus formation. As a result, GPIIb/IIIa has 
been a therapeutic target in cardiology for many years, with inhibitors (tirofiban, 
abciximab and eptifibatide) commonly used in high-risk acute coronary syndromes 
upstream of, or during, percutaneous coronary intervention. 
 
Kim et al performed a first-in-human investigational study of 18F-GP1 in patients 
with acute deep vein thrombosis or pulmonary embolism (Kim, Lee et al. 2018). The 
radiotracer was well tolerated with initial high uptake followed by rapid clearance in 
the spleen, kidneys and blood pool. 18F-GP1 PET-CT detected 89% of vessels with 
deep vein thrombosis and 60% with pulmonary embolism, and interestingly 
demonstrated increased uptake in 32 vessels that were not detected by 
conventional imaging (Lohrke, Sibeneicher et al. 2017). The mean standardised 
uptake value of thromboemboli to blood pool ratio was 4.9±1.4 and 3.7±1.5 for deep 
vein thrombosis and pulmonary embolism respectively; a signal to background ratio 
that is superior to 18F-fluoride. Recently, the first-in-human study of 18F-GP1 in 
arterial thrombosis (6 endovascular repair of abdominal aortic aneurysm, 1 bypass 
surgery and stent placement, 1 endarterectomy, 1 arterial dissection, and 1 acute 
cerebral infarction) has been reported (Chae, Kwon et al. 2019). The investigators 
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found uptake in arterial thrombus in all patients, again demonstrating a high mean 
standardised uptake value of thrombus to blood pool ratio. The favourable safety 
and radiation dosimetry profile of 18F-GP1 has been demonstrated and is 
comparable to other PET radiotracers (Lee, Chae et al. 2019). In light of these 
preliminary data, 18F-GP1 is a novel, highly promising radiotracer for coronary 
atherosclerosis imaging. The clinical applications of this specific thrombus tracer 
would be particularly useful in detecting subclinical plaque rupture events and 
distinguish type 1 from type 2 myocardial infarction. This will be addressed in the in-
vivo Thrombus imaging with 18F-GP1 study, iThrombus (NCT03943966) which will 
determine whether the expression of GPIIb/IIIa receptor within thrombus can be 
detected in the arterial and venous circulation.  
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7.3 Clinical Perspective 
Accurate risk prediction of future cardiovascular events in patients with coronary 
artery disease is a pertinent problem for frontline clinicians. Specifically in the 
current era of high-sensitivity troponin measurement, diagnosing the different types 
of myocardial infarction in patients in order to select the right treatment for the right 
individual is a vexing problem. The increasing prevalence of myocardial injury 
identified using high-sensitivity troponin assays in patients who present to the 
emergency department or outpatient clinic has made it more difficult to identify with 
sufficient certainty which patients are actually having a plaque rupture event. By 
using non-invasive imaging to unravel the complexity of the in vivo 
pathophysiological mechanisms at play in an individual, a more precise phenotype 
of coronary artery disease can be characterised. 
 
There are number of clinical scenarios in which the identification of plaque rupture 
may have major clinical utility, for example, in populations where identifying high-risk 
individuals is a clinical priority. This would be the case for patients undergoing major 
non-cardiac surgery where the inappropriate initiation of medical therapy may confer 
more harm than benefit. This would also apply to individuals with a systemic 
inflammatory response due to a non-cardiac illness who are often diagnosed with a 
persistent troponin elevation attributed to chronic myocardial injury or type 2 
myocardial infarction. Additionally, as targeted therapies using monoclonal 
antibodies and ribonucleic acid interference become more widely available, non-
invasive imaging tools may be able to better stratify treatment in high-risk 
individuals. Moving away from a “one size fits all” approach in patients with coronary 
artery disease towards bespoke treatment algorithms based on the residual risk of a 
cardiac event is an important and necessary step. 




In this thesis, the use of hybrid positron emission tomography computed 
tomography imaging to detect vulnerable plaques and stratify therapy has been 
shown to be both feasible and can be applied in the clinical trial setting. Whilst 
vulnerable plaque detection using coronary computed tomography angiography 
alone can be readily performed in clinical practice, coronary computed tomography 
angiography may lack the specificity needed to identify individuals who may benefit 
from intensified treatment to reduce their residual risk of future cardiovascular 
events. In this regard, coronary 18F-fluoride positron emission tomography has 
been shown to be a quantitative reproducible metric of plaque activity in the 
coronary vasculature. At the cellular level, it represents active mineralisation within 
coronary plaques and may serve to highlight coronary plaques at increased risk of 
rupture. The clinical utility of coronary 18F-fluoride positron emission tomography in 
identifying vulnerable plaques which contribute to future cardiovascular events will 
be more fully explored in the PRE18FFIR study. 
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